
<html lang="en"     class="pb-page"  data-request-id="eae3d99b-3dff-4e78-8f87-38c04f751e09"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01886"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative" /></meta><meta name="dc.Creator" content="Bruce D.  Hammock" /></meta><meta name="dc.Creator" content="Cindy B.  McReynolds" /></meta><meta name="dc.Creator" content="Karen  Wagner" /></meta><meta name="dc.Creator" content="Alan  Buckpitt" /></meta><meta name="dc.Creator" content="Irene  Cortes-Puch" /></meta><meta name="dc.Creator" content="Glenn  Croston" /></meta><meta name="dc.Creator" content="Kin Sing Stephen  Lee" /></meta><meta name="dc.Creator" content="Jun  Yang" /></meta><meta name="dc.Creator" content="William K.  Schmidt" /></meta><meta name="dc.Creator" content="Sung Hee  Hwang" /></meta><meta name="dc.Description" content="This report describes the development of an orally active analgesic that resolves inflammation and neuropathic pain without the addictive potential of opioids. EC5026 acts on the cytochrome P450 br..." /></meta><meta name="Description" content="This report describes the development of an orally active analgesic that resolves inflammation and neuropathic pain without the addictive potential of opioids. EC5026 acts on the cytochrome P450 br..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 7, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01886" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01886" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01886" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01886" /></link>
        
    
    

<title>Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01886" /></meta><meta property="og:title" content="Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0013.jpeg" /></meta><meta property="og:description" content="This report describes the development of an orally active analgesic that resolves inflammation and neuropathic pain without the addictive potential of opioids. EC5026 acts on the cytochrome P450 branch of the arachidonate cascade to stabilize epoxides of polyunsaturated fatty acids (EpFA), which are natural mediators that reduce pain, resolve inflammation, and maintain normal blood pressure. EC5026 is a slow-tight binding transition-state mimic that inhibits the soluble epoxide hydrolase (sEH) at picomolar concentrations. The sEH rapidly degrades EpFA; thus, inhibiting sEH increases EpFA in vivo and confers beneficial effects. This mechanism addresses disease states by shifting endoplasmic reticulum stress from promoting cellular senescence and inflammation toward cell survival and homeostasis. We describe the synthesis and optimization of EC5026 and its development through human Phase 1a trials with no drug-related adverse events. Additionally, we outline fundamental work leading to discovery of the analgesic and inflammation-resolving CYP450 branch of the arachidonate cascade." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01886"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01886">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01886&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01886&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01886&amp;href=/doi/10.1021/acs.jmedchem.0c01886" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1856-1872</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01863" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c01917" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Bruce D. Hammock</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bruce D. Hammock</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+D.++Hammock">Bruce D. Hammock</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1408-8317" title="Orcid link">http://orcid.org/0000-0003-1408-8317</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cindy B. McReynolds</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cindy B. McReynolds</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cindy+B.++McReynolds">Cindy B. McReynolds</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3309-1773" title="Orcid link">http://orcid.org/0000-0003-3309-1773</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen Wagner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen Wagner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Wagner">Karen Wagner</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5238-7847" title="Orcid link">http://orcid.org/0000-0002-5238-7847</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alan Buckpitt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alan Buckpitt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Buckpitt">Alan Buckpitt</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6643-5208" title="Orcid link">http://orcid.org/0000-0001-6643-5208</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Irene Cortes-Puch</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Irene Cortes-Puch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Irene++Cortes-Puch">Irene Cortes-Puch</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3639-5046" title="Orcid link">http://orcid.org/0000-0002-3639-5046</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Glenn Croston</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Glenn Croston</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Glenn++Croston">Glenn Croston</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6352-0922" title="Orcid link">http://orcid.org/0000-0002-6352-0922</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kin Sing Stephen Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kin Sing Stephen Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Synthia LLC, P.O. Box 1238, Gualala, California 95445, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kin+Sing+Stephen++Lee">Kin Sing Stephen Lee</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4541-3063" title="Orcid link">http://orcid.org/0000-0003-4541-3063</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jun Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jun Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Yang">Jun Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8126-1728" title="Orcid link">http://orcid.org/0000-0001-8126-1728</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">William K. Schmidt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">William K. Schmidt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=William+K.++Schmidt">William K. Schmidt</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5841-4810" title="Orcid link">http://orcid.org/0000-0001-5841-4810</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sung Hee Hwang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sung Hee Hwang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">EicOsis Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#4132292936202f26012428222e3228326f222e2c"><span class="__cf_email__" data-cfemail="36455e5e4157585176535f5559455f451855595b">[email protected]</span></a>. Phone: (530) 338-0070.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sung+Hee++Hwang">Sung Hee Hwang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9891-928X" title="Orcid link">http://orcid.org/0000-0002-9891-928X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01886&amp;href=/doi/10.1021%2Facs.jmedchem.0c01886" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1856–1872</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 7, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 October 2020</li><li><span class="item_label"><b>Published</b> online</span>7 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01886" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01886</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ec-1612971054143.svg" alt="ACS Editors’ Choice" /></img><span>ACS Editors’ Choice</span></a><span class="article_header-cc-by-nc"><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_nc-1612971093307.svg" alt="NC: Only noncommercial uses of the work are permitted" /></img><span><strong>NC: </strong>Only noncommercial uses of the work are permitted</span></a><a href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_nd-1612971093637.svg" alt="ND: No derivatives or adaptations of the work are permitted" /></img><span><strong>ND: </strong>No derivatives or adaptations of the work are permitted</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01886"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8891</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01886" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;D. Hammock&quot;},{&quot;first_name&quot;:&quot;Cindy&quot;,&quot;last_name&quot;:&quot;B. McReynolds&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Wagner&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Buckpitt&quot;},{&quot;first_name&quot;:&quot;Irene&quot;,&quot;last_name&quot;:&quot;Cortes-Puch&quot;},{&quot;first_name&quot;:&quot;Glenn&quot;,&quot;last_name&quot;:&quot;Croston&quot;},{&quot;first_name&quot;:&quot;Kin&quot;,&quot;last_name&quot;:&quot;Sing Stephen Lee&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;K. Schmidt&quot;},{&quot;first_name&quot;:&quot;Sung&quot;,&quot;last_name&quot;:&quot;Hee Hwang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;1856-1872&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01886&quot;},&quot;abstract&quot;:&quot;This report describes the development of an orally active analgesic that resolves inflammation and neuropathic pain without the addictive potential of opioids. EC5026 acts on the cytochrome P450 branch of the arachidonate cascade to stabilize epoxides of polyunsaturated fatty acids (EpFA), which are natural mediators that reduce pain, resolve inflammation, and maintain normal blood pressure. EC5026 is a slow-tight binding transition-state mimic that inhibits the soluble epoxide hydrolase (sEH) at picomolar concentrations. The sEH rapidly degrades EpFA; thus, inhibiting sEH increases EpFA in vivo and confers beneficial effects. This mechanism addresses disease states by shifting endoplasmic reticulum stress from promoting cellular senescence and inflammation toward cell survival and homeostasis. We describe the synthesis and optimization of EC5026 and its development through human Phase 1a trials with no drug-related adverse events. Additionally, we outline fundamental work leading to discovery of the analgesi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01886&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01886" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01886&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01886" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01886&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01886" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01886&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01886&amp;href=/doi/10.1021/acs.jmedchem.0c01886" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01886" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01886" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01886%26sid%3Dliteratum%253Aachs%26pmid%3D33550801%26genre%3Darticle%26aulast%3DHammock%26date%3D2021%26atitle%3DMovement%2Bto%2Bthe%2BClinic%2Bof%2BSoluble%2BEpoxide%2BHydrolase%2BInhibitor%2BEC5026%2Bas%2Ban%2BAnalgesic%2Bfor%2BNeuropathic%2BPain%2Band%2Bfor%2BUse%2Bas%2Ba%2BNonaddictive%2BOpioid%2BAlternative%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D4%26spage%3D1856%26epage%3D1872%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292461" title="Neurophysiology">Neurophysiology</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/jmcmar.2021.64.issue-4/20210225/jmcmar.2021.64.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">This report describes the development of an orally active analgesic that resolves inflammation and neuropathic pain without the addictive potential of opioids. EC5026 acts on the cytochrome P450 branch of the arachidonate cascade to stabilize epoxides of polyunsaturated fatty acids (EpFA), which are natural mediators that reduce pain, resolve inflammation, and maintain normal blood pressure. EC5026 is a slow-tight binding transition-state mimic that inhibits the soluble epoxide hydrolase (sEH) at picomolar concentrations. The sEH rapidly degrades EpFA; thus, inhibiting sEH increases EpFA <i>in vivo</i> and confers beneficial effects. This mechanism addresses disease states by shifting endoplasmic reticulum stress from promoting cellular senescence and inflammation toward cell survival and homeostasis. We describe the synthesis and optimization of EC5026 and its development through human Phase 1a trials with no drug-related adverse events. Additionally, we outline fundamental work leading to discovery of the analgesic and inflammation-resolving CYP450 branch of the arachidonate cascade.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76270" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76270" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There is a pressing need for new pharmaceuticals to treat pain in general and neuropathic pain specifically in view of the opioid epidemic discussed below. Here we provide an overview of the discovery and development of a new class of nonopioid analgesics that appear devoid of addictive potential, resolve inflammation, and reduce endoplasmic reticulum (ER) stress. EC5026, a small molecule drug candidate disclosed in this study, is an exceptionally potent transition-state mimic inhibitor of the soluble epoxide hydrolase (sEH) enzyme which is widely distributed in mammalian tissues.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Interestingly, the sEH was found while studying fundamental insect developmental biology where the hydration of epoxides of juvenile hormones is a key reaction in metamorphosis. This biology was exploited for the rational development of a class of green pesticides termed insect growth regulators (IGRs), and the mammalian sEH was discovered while studying the metabolism of one of these IGRs in mammals. Following the first report of the sEH in 1972, the full metabolism of the terpene epoxide developed as a vector control and agricultural chemical was described in 1974, and the properties of the sEH in mammals were investigated.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Over the past several decades, a primary role of this enzyme was found to be the rapid conversion of anti-inflammatory, antihypertensive, and analgesic chemical mediators, the fatty acid epoxides also named epoxy-fatty acids (EpFA), into their respective 1,2-diols.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Therefore, several classes of sEH inhibitors (sEHI) have been developed over the past several decades and were useful in establishing EpFA as key chemical mediators. In contrast to the cyclooxygenase (COX) and lipoxygenase (LOX) branches that are predominately but not exclusively pro-inflammatory, it is generally accepted that a third branch (cytochrome P450s or CYP450s) of the arachidonic acid cascade is largely anti-inflammatory and pro-resolving.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The discovery that ureas, amides, carbamates, and various heterocycles could act, as not only epoxide mimics but also transition-state mimics, started the field down a path to several exceptionally potent sEHI including EC5026 described here.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> The physical, pharmacokinetic (PK), and biological properties of sEHI yielded a unique set of advantages and challenges in their development to the clinic as described below. In addition, EC5026 has been successfully moved to the clinic through a unique and largely publicly funded clinical development path.</div><div class="NLM_p last">In the following paragraphs, we cover the early chemistry and structure–activity relationship studies of sEHI, and the path to drug candidates for human, equine, and companion animals. We also present the synthetic pathway to EC5026 and its full characterization (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>). In parallel to the medicinal chemistry, advances were made in understanding the action of sEHI with the target enzyme and on mammalian physiology. Although there are a variety of possible indications and clinical paths for sEHI, neuropathic pain has been selected for multiple reasons including lack of effective therapies for this pressing need, the reluctance of large pharmaceutical companies to enter the field, and the possibility that a small company could take a new product through trials demonstrating efficacy. We present an update on the Phase 1a clinical trial and our plans for the immediate future. We conclude with a brief discussion of moving the compounds to the clinic largely with the support of the NIH.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65083" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65083" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Early sEH Chemistry</h3><div class="NLM_p">Early substrate mimics and irreversible inhibitors of the sEH were useful biochemical probes but too metabolically unstable to be useful as pharmaceuticals.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> A series of fundamental studies in enzymology discovered that the sEH belongs to the α/β-fold hydrolase class of enzymes and that the key catalytic residue is a nucleophilic aspartic acid.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> This class of enzymes has been inhibited by carbodiimides, which initially appeared to be the case with sEH as well. However, Morisseau et al.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> found the actual compound that acts as a potent, time-dependent inhibitor against sEH is dicyclohexyl urea (DCU, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a hydrated form of dicyclohexyl carbodiimide (DCC). DCU is a byproduct from amide coupling reactions with DCC. This urea was our initial lead compound, and throughout the chemical history of this series, the goal has been to maximize potency and other pharmacological properties while dealing with these high melting, poorly soluble lipophilic molecules. The redeeming features of these transition-state mimics were their exceptionally high potency on the target enzyme and their high selectivity. A variety of structures have been used as mimics of epoxides at putative receptors including ureas, amides, and carbamates, so these functional groups were examined as central pharmacophores of the inhibitors. Since epoxides of long chain polyunsaturated fatty acids were the hypothetical natural substrates of sEH, many early compounds were designed to mimic these substrates while incorporating a pharmacophore that mimics the epoxide group of the substrate or the putative transition-state(s) of the epoxide ring opening. This resulted in a series of compounds such as 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), which were exceptionally potent enzyme inhibitors but also suffered from being good mimics of the biological active EpFA at their putative receptors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition, they were rapidly metabolized to inactive degradation products,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and, as expected based on their physical properties such as high lipophilicity and high melting points as well as difficulty in formulation to obtain high bioavailability. Despite these difficulties, a number of biologists used these compounds to demonstrate multiple roles of EpFA in reducing hypertension and vascular inflammation.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In early stages of the development of sEHI, the adamantyl group used in AUDA and AEPU (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) yielded exceptionally high detection sensitivity on an LC-MS as well as high potency on the target sEH. This detection sensitivity afforded by the adamantyl group allowed rapid PK studies of these sEHI in rodents where PK-absorption, distribution, metabolism, and excretion (ADME) could be rapidly determined using just a few microliters of blood.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The ease of determining oral bioavailability and PK parameters as well as availability of rapid quantitative enzyme assays resulted in rapid filters to select progressively more potent orally bioavailable sEHI. Kim et al.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> found that the presence of a polar group approximately 7 Å from the carbonyl of the central pharmacophore dramatically increased solubility without loss of potency as in AEPU shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of early stage sEHI. A commonly used four-letter abbreviation and a University of California (UC) number are provided. Our lead compound in this series was DCU. The presence of an adamantyl group made the sEHI more potent and easier to detect by LC-MS in blood. They also tended to mimic EpFA, which were the presumptive substrates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These leads were exploited aggressively in both industrial and academic laboratories.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Among these, an excellent compound was GSK2256294 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> A major success was the discovery of ureas that are constructed with simple cyclicalkyl groups on a nitrogen atom of the urea combined with conformationally restricted substituents on the other nitrogen atom of the urea. This approach resulted in compounds such as APAU (AR9281) and <i>t</i>-AUCB (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) possessing drug-like properties, high potency, and improved PK profiles.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> These series of compounds were further optimized by replacing the metabolically unstable cyclicalkyl group such as the adamantyl group by more stable aryl groups such as the <i>p</i>-trifluoromethoxyphenyl group as in TPPU and <i>t</i>-TUCB (UC1770, EC1728, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> One compound from the conformationally restricted ureas was AR9281 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) that was proven to be safe even at high doses in a Phase 2a clinical trial but failed to show adequate efficacy for further development. Although it is surprisingly water-soluble, it contained an adamantyl group that resulted in complex metabolites and a short half-life due to rapid hydroxylation of the adamantyl group.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> One of its human metabolites was only found in primates requiring expensive primate safety studies. This, coupled with mediocre potency on the human recombinant sEH and a short drug-target residence time on the human enzyme, probably contributed to its clinical failure. Because once or twice a day dosing is the norm for hypertension and diabetes drugs, exceptionally high levels of AR9281 were required to maintain adequate blood levels.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Interestingly, it has never been clear why AR9281 was selected for development when the related TPPU which demonstrated much greater potency on the recombinant human enzyme and a 100-fold higher PK-AUC in mice was already reported.<a onclick="showRef(event, 'ref17 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref19">(17,19)</a> In pain assays in rodents, TPPU was of similar potency to AR9281 on the recombinant murine enzyme but was more potent than morphine.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As mentioned above, AR9281 is quite potent on the recombinant mouse sEH, but it is quite a weak inhibitor with a rapid off rate on the recombinant human enzyme as discussed below. TPPU has emerged as the standard in the field used in many biological studies to inhibit the sEH due to its good PK and high potency on both primate and rodent sEH enzymes.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of late stage sEH inhibitors. A commonly used four-letter abbreviation and University of California numbers are provided.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Polypharmacy with sEHI</h3><div class="NLM_p last">sEHI have been found to synergize with several other pharmaceuticals. In several cases, the mechanism of this synergism is quite well understood often based on monitoring the profiles of blood regulatory lipids and key regulatory pathways. The best studied to date are structures combining pharmacophores that inhibit COX-2. This synergism was predicted when lipid profiles in murine sepsis models showed that EpFA were increased and diols decreased in the blood as expected with sEHI, but the sEHI quickly and dramatically resolved the high levels of PGE<sub>2</sub> and other inflammatory mediators. The effect on products the COX branch of the arachidonate cascade was far more dramatic than on the CYP450 branch in plasma analysis. Even in the early study, this was shown to be via transcriptional down regulation of COX-2 induced in the sepsis model.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> There is now evidence that this is due to reduction of ER stress and inflammatory pathways leading to prostaglandin synthases and COX-2.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This synergism of COX and sEHI when combined is fortunate since in addition to synergism many of the cardiovascular and gastrointestinal side effects of COX inhibitors are blocked by sEHI.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> sEHI have been found to synergize with PPAR agonists, FLAP and FAAH inhibitors, phosphodiesterase inhibitors, and others which can be exploited by drug combinations or integrated molecules.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> A summary of this class of dual inhibitors/modulators is listed in <a class="ref internalNav" href="#notes1" aria-label="Table S4">Table S4</a>.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> SAR Leading to IND Candidate EC5026</h3><div class="NLM_p">On the basis of investigations of compounds such as TPPU, it became clear that the drug-target residence time with sEHI was a better indicator of inhibitor’s <i>in vivo</i> efficacy than its potency in enzyme assays (IC<sub>50</sub> or <i>K</i><sub>i</sub>).<a onclick="showRef(event, 'ref19 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref24">(19,24)</a> The drug-target residence time and potency were correlated but not tightly correlated, especially for very tight-binding sEHI (IC<sub>50</sub> or <i>K</i><sub>i</sub> ≤ 5 nM).<a onclick="showRef(event, 'ref19 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref24">(19,24)</a> sEHI with a urea pharmacophore like TPPU work well <i>in vivo,</i> but a careful formulation is critical for reproducible results, particularly for experiments requiring high doses due to the high lipophilicity, high melting point, and poor water-solubility of some sEHI. Formulation of either high melting or lipophilic compounds can normally be addressed particularly with highly potent compounds. However, high melting lipophilic compounds such as some of the potent sEHI present a challenge for the field (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Although replacing the central urea pharmacophore by an amide group lowered the melting point and increased the water solubility in general, such replacement also reduced the potency of the inhibitors by an order of magnitude (EC5026 vs EC5049 in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Within EicOsis, the goal was to find sEHI that were more potent with a lower melting point, and/or more water-soluble. A new series of compounds was designed based on the scaffold shown in TPPU.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a><named-content content-type="anchor" rid="fig3" type="simple"></named-content></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical properties impact ease of formulation. Generally, the more potent the compound the more facile the formulation. There are relatively routine procedures to formulate high melting or poorly water-soluble materials, but high melting poorly soluble crystals are a challenge. This problem was addressed by synthesis to increase potency on the human target enzyme, increase water solubility, and reduce the stability of the crystal structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Physical Properties, Potency, and Target Occupancy of AR9281, TPPU, EC5023, EC5024, and EC5026</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0011.gif" alt="" id="gr4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Solubility was measured with sodium phosphate buffer (0.1 M, pH 7.4).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">LogP was measured by HPLC.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last"><i>K</i><sub>i</sub> and <i>t</i><sub>R</sub> (which is a reciprocal of <i>k</i><sub>off</sub>) were determined against the affinity purified recombinant human sEH (hsEH) by a FRET-displacement assay.</p></div></div><div></div></div><div class="NLM_p">Within the series of inhibitors synthesized by EicOsis, the incorporation of a fluorine atom in the <i>meta-</i>position of the <i>p</i>-trifluoromethoxyphenyl group of sEHI (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) not only increased the potency against human sEH (dramatically in some cases) but also reduced the melting point significantly while maintaining the drug-target residence time (e.g., TPPU vs EC5023 in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). This came with the cost of reduced water solubility and increased LogP. It was assumed that an addition of a <i>meta-</i>fluoro substituent on the phenyl group of the inhibitors broke the overall symmetry of the chemical structure of the inhibitors and thus destabilized the crystalline state resulting in a drop in the melting point.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In addition, a previous SAR study<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> suggested that introduction of an extra methyl group at the α-carbon of the amide group of the inhibitor could significantly improve the potency of the inhibitor. Therefore, a significant improvement of potency was expected with EC5019 when we introduced an extra methyl group on the α-carbon of the amide group of EC5023. As expected, EC5019 improved the potency but showed poor water solubility due probably to the increased melting points. Therefore, we further modified EC5019 by performing another SAR study<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and found that introduction of another extra methyl group at the β-carbon of EC5019 could lower melting points, which in turn improve water solubility (EC5019 vs EC5026 in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and also further improve potency. To further test whether we could improve the potency and water solubility of EC5026 by reducing its size, we replaced the 4-trifluoromethoxy group on the phenyl of EC5026 by 4-trifluoromethyl group (EC5034). However, this attempt failed, resulting in lower potency and poorer water solubility compared to EC5026. Therefore, EC5026 was selected as a drug candidate for further development. The increase in potency coupled with a low melting point reduces the likelihood of off-target toxicity and makes the compounds a remarkably simple formulate for oral administration (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a><named-content content-type="anchor" rid="tbl2" type="simple"></named-content></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. PK Profiles of EC5023, EC5024, and EC5026 in Rats</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0012.gif" alt="" id="gr5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Sprague–Dawley rats (male, <i>n</i> = 6) received the compounds by oral gavage with a single dose at 0.1 mg/kg (inhibitors were dissolved in PEG 300). PK parameters of inhibitors were calculated by WinNonlin based on the best fitted one compartment model. Note that the driver was a lower AUC and shorter half-life for a first-in-class drug.</p></div></div><div></div></div><div class="NLM_p last">The selection of an IND candidate is based on multiple factors ranging from the potency to the cost of synthesis. Unique drivers in this series included long drug-target residence time (reciprocal of <i>k</i><sub>off</sub> of the inhibitor from the enzyme),<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> the moderate <i>in vivo</i> half-life needed for a first-in-class compound, and sometimes a compromise between reduced melting point and potency in favor of ease of formulation.  With many highly potent compounds in hand, plasma protein binding was considered as an asset to facilitate a rapid drug distribution of inhibitors. Among the most potent inhibitors possessing the <i>meta-</i>fluoro substituent on the phenyl ring, the PK profiles in mice were found to vary dramatically. In some cases, the compounds such as EC5023 and EC5024 and even TPPU were considered too stable following oral administration in preclinical species for development for use in humans (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Thus, the slow, tight-binding EC5026 was selected as a leading candidate for the clinic because it had a significantly shorter <i>in vivo</i> half-life than other analogues, yet a sufficient half-life to avoid break-through pain should a patient miss a daily dose.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Formulation for Human Phase 1a</h3><div class="NLM_p">The EC5026 drug product was initially developed as an immediate-release oral dosage form in a gelatin capsule using liquid formulation by considering the following attributes. First, EC5026 is an uncharged molecule with a low pH-independent solubility of <0.1 mg/mL in aqueous systems. Therefore, the equilibrium solubility of EC5026 in various media was screened to aid the development of preclinical formulations and a dissolution method (<a class="ref internalNav" href="#notes1" aria-label="Table S1">Table S1</a>). Second, the permeability (<i>P</i><sub>app</sub>) of EC5026 using a colorectal adenocarcinoma cell line (Caco-2) is 26.4 × 10<sup>–6</sup> cm/s indicated that the compound is well absorbed (<a class="ref internalNav" href="#notes1" aria-label="Table S2">Table S2</a>). Therefore, per the Biopharmaceutics Classification System (BCS), EC5026 is classified as a BCS Class 2 compound (high permeability and poor solubility over the physiologic pH range), and its absorption rate is limited by either solubility or dissolution or both.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">Poor solubility of BCS Class 2 compounds limits the formulation choices and drug product dosage forms that can deliver the drug to the systemic circulation. Prior experience with structurally similar compounds to EC5026 indicated the drugs need to be in solution when dosed otherwise they will not be absorbed, which is directly related to poor solubility. This directed a formulation effort seeking a fully solubilized drug substance in a dosage form for both preclinical toxicology studies and use in the clinic. If dissolution is too fast, the compounds can also be recrystallized in the stomach. Therefore, liquid-filled hard capsules were the initial target for development. Since EC5026 has good solubility in PEG 400 (<a class="ref internalNav" href="#notes1" aria-label="Table S1">Table S1</a>), efforts focused on capsules filled with the drug substance EC5026 dissolved in PEG 400. Several different capsules were evaluated, but all of the ones acceptable to the contract laboratory were affected by long-term exposure to PEG 400. The most prevalent incompatibility was leaking, with capsule deformation as a distant second problem. Overall, the output from these studies showed that none of the capsules tested were compatible with PEG 400. To address leaking of PEG 400 from capsules, we investigated novel PEG-based formulation using combinations of various PEG compounds based our prior experience and that of others which suggested that PEG 400 in combination with even very low concentrations of PEG 3350 produces a semisolid matrix which is hard and not easily deformed.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The semisolid matrix forms after a heated solution of the two PEGs cools to room temperature. The combination of PEG compounds in a ratio of 80% PEG 400 and 20% PEG 3350 was chosen for the semisolid matrix formulation because the ratio of the two PEG compounds provides the physical rigidity to prevent leaking, analysis showed no crystal formation, EC5026 remained in solution in the dosage form, and the process was suitable for transfer to a compounding pharmacy where the clinical drug product was to be made for Phase 1a clinical trials. Therefore, the EC5026 drug product for use in initial clinical studies was an extemporaneously compounded immediate-release capsule for oral administration. Briefly, EC5026 capsules were prepared by filling a solution heated at 70 °C consisting of EC5026 drug substance dissolved in 80% PEG 400/20% PEG 3350 (w/w) into size 0, white opaque/white opaque, hard-gelatin capsules. The capsules were hand filled by volume with the heated solution and allowed to cool prior to capping. On the basis of an in-use stability study at both accelerated (40 °C/75% RH) and long-term (25 °C/60% RH) conditions for 4 weeks, these EC5026 drug products were found to be stable, but capsules were stored at 15–30 °C at the clinical site until dosing following preparation at the clinical pharmacy in accordance with pharmacy compounding procedures. Compositions of the EC5026 capsules, as well as the function and quality standard for each component of the dosage forms, are given in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> (the detailed preparation of EC5026 is described in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>). This procedure could be considered a low technology hot melt where, even if the compound were not soluble in the PEG matrix, its glass-like consistency precludes crystal formation.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Compositions of 0.5 mg and 8 mg EC5026 Product</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">quantity per capsule</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">component</th><th class="colsep0 rowsep0" align="center">0.5 mg strength</th><th class="colsep0 rowsep0" align="center">8 mg strength</th><th class="colsep0 rowsep0" align="center">function</th><th class="colsep0 rowsep0" align="center">quality standard</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EC5026</td><td class="colsep0 rowsep0" align="left">0.50 mg</td><td class="colsep0 rowsep0" align="left">8.0 mg</td><td class="colsep0 rowsep0" align="left">API</td><td class="colsep0 rowsep0" align="left">in house</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PEG 400</td><td class="colsep0 rowsep0" align="left">435.6 mg</td><td class="colsep0 rowsep0" align="left">429.6 mg</td><td class="colsep0 rowsep0" align="left">solubilizer</td><td class="colsep0 rowsep0" align="left">Ph Eur, JP</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PEG 3350</td><td class="colsep0 rowsep0" align="left">108.9 mg</td><td class="colsep0 rowsep0" align="left">107.4 mg</td><td class="colsep0 rowsep0" align="left">matrix former</td><td class="colsep0 rowsep0" align="left">USP</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Licaps capsules white opaque, size 0<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1 each</td><td class="colsep0 rowsep0" align="left">1 each</td><td class="colsep0 rowsep0" align="left">dosage form encapsulation</td><td class="colsep0 rowsep0" align="left">in house</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">total capsule fill weight</td><td class="colsep0 rowsep0" align="left">545.0 mg</td><td class="colsep0 rowsep0" align="left">545.0 mg</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Manufactured by Capsugel (Greenwood, SC). Abbreviations: API = active pharmaceutical ingredient, JP = Japanese pharmacopeia; PEG = polyethylene glycol; Ph Eur = European Pharmacopeia; USP = United States Pharmacopeia</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Biochemcal Mechanism of Action</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Degradation of Fatty Acid Epoxides (EpFA)</h3><div class="NLM_p">By weight, well over 50% of the world’s drugs act on the arachidonic acid cascade; only the COX and LOX pathways of the cascade have been exploited, and these drugs act by blocking the production or action of predominantly inflammatory chemical mediators. Of these, the COX branch has been the most studied and predominantly exploited by NSAIDs and COXIBs. In contrast, the sEHI work on the more recently discovered and largely analgesic and inflammation-resolving CYP450 branch of the cascade. Of these, the epoxides of arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid, abbreviated EETs, EEQs, and EDPs, respectively, are generally analgesic and anti-inflammatory mediators known collectively as EpFA. One could alter the pathway by increasing precursor polyunsaturated fatty acids, by stimulating the biosynthesis of EpFA or the release of EpFA from phospholipids, by using mimic natural bioactive EpFA, or by stabilizing the biologically active EpFA as reported here with sEHI.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The sEH is a very active enzyme with a high <i>k</i><sub>cat</sub>, a low <i>K</i><sub>m</sub>, and in some tissues of higher abundance than its putative EpFA substrates, and thus a powerful inhibitor with high target occupancy is needed. The sEHI discussed here fit these criteria resulting in inhibition of the target sEH and the resulting increase in EpFA (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Roles of EETs and sEH in the arachidonic acid cascade. Similar products arise from other polyunsaturated fatty acids. EETs are epoxides of arachidonic acid, and DHETs are the corresponding diols.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Thus, the sEHI are increasing tissue levels of the natural EpFA resulting in a variety of generally positive effects. Among these positive effects are a reduction in both inflammatory and neuropathic pain.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Structure and Inhibitor Binding to Enzyme</h3><div class="NLM_p">Several X-ray crystal structures of human sEH complexed with urea-based sEHI have been determined.<a onclick="showRef(event, 'ref19 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref19 ref28 ref29">(19,28,29)</a> The human sEH structures revealed that the epoxide hydrolase domain is located at C-terminus, while the phosphatase domain is located at N-terminus.</div><div class="NLM_p">In addition, the urea of the inhibitors mimics the transition state of the epoxide hydration in sEH (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The oxygen of the urea forms two tight hydrogen bonds with tyrosine 383 and tyrosine 466. In addition, both urea hydrogens strongly interact with aspartate 336 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). The resulting polarization of the urea may lead to an aspartate–urea salt bridge stabilized by the two hydrogen bonds with the urea. The binding pocket of sEH resembles a long hydrophobic channel (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B); therefore, the binding pocket generally cannot tolerate the polar or charged substituent, such as a pyridyl group, on 1,3-disubstituted urea.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Interestingly, the recent crystal structure of human sEH with TPPU also showed an extra binding pocket next to the α position of the piperidinyl amide of the TPPU as predicted earlier by Kim.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> This observation was further supported from SAR studies (EC5019 vs EC5023 in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref5 ref19'); return false;" href="javascript:void(0);" class="ref ref5 ref19">(5,19)</a> Also, Lee et al. revealed that the binding pocket of sEH is promiscuous,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and the left side of the pocket can tolerate chemical structures of various sizes.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The tunnel appears to breathe or even open to accept bulky groups. Therefore, EicOsis synthesized a new series of sEHI with a methyl substituent at the alpha-carbon of the piperidinyl amide of EC5023, resulting in a very potent EC5026 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) The crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OD0">4OD0</a>) of human sEH bound with TPPU (cyan, stick) showed that Tyr383 and Tyr466 formed tight hydrogen bonding with the carbonyl oxygen of the urea and Asp336 formed a tight hydrogen bonding with the urea hydrogens. (B) The crystal structure revived the long hydrophobic binding channel at the C-terminus domain of human sEH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Catalytic Enzyme Assays</h3><div class="NLM_p last">Multiple assays have been developed to determine the potency of the sEHI, which includes early radiolabel assays, high-throughput colorimetric and fluorescent substrate assays, an LC-MS/MS assay with natural substrates, and FRET<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> displacement assays. These and other assays have been discussed in reviews.<a onclick="showRef(event, 'ref4 ref33'); return false;" href="javascript:void(0);" class="ref ref4 ref33">(4,33)</a> In EicOsis, the fluorescent substrate assay was used as a primary screening assay because of the robustness and throughput of the assay. However, the fluorescent substrate screening assay has limits in distinguishing extremely potent compounds (IC<sub>50</sub> ≤ 5 nM) effectively.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Therefore, the potencies of the identified sEHI were further validated with a FRET displacement assay, radiometric assay, and LC-MS/MS based assay with natural substrates. Recent studies revealed that drug-target residence time is a better predictor of the <i>in vivo</i> activity of sEHI. This is particularly important when natural substrates have a very high apparent affinity for the enzyme. Therefore, the drug-target residence time of the sEHI which can be determined by the FRET displacement assay was also included in our inhibitor selection criteria.<a onclick="showRef(event, 'ref19 ref32'); return false;" href="javascript:void(0);" class="ref ref19 ref32">(19,32)</a> The availability of recombinant sEH of human and other preclinical species and the robust high-throughput assays allowed rapid SAR study of sEHI. Combining these data with a rapid determination of PK/ADME identified a promising candidate for efficacy testing <i>in vivo</i>.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Physiological Mechanism of Action</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20823" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20823" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> History of EpFA Action</h3><div class="NLM_p last">sEHI allowed for the elucidation of the biological activity of the transient EpFA, and it was discovered that EpFA are anti-inflammatory, pro-resolving, antihypertensive, and analgesic. Although the receptor for EpFA has not been identified, preclinical models of disease have identified multiple biological actions that contribute to the efficacious properties of EpFA. These actions include preventing or reversing endothelial cell dysfunction, altering the immune response, and reducing ER stress. These activities result in the regulation of cellular stress by stabilizing mitochondrial function, reducing reactive oxygen species, and shifting the ER response toward maintenance of homeostasis and away from severe activation of inflammatory pathways and cell death.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> ER Stress and Mitochondrial Dysfunction as a Unifying Mechanism</h3><div class="NLM_p last">This mechanism explains why there are so many possible indications for sEHI. We predict when ER stress and/or mitochondrial dysfunction is involved, sEHI administration will be beneficial. The original biological activity found for sEHI was the reduction of blood pressure.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Considering that a search for endothelium derived hyperpolarizing factors had been in progress for years, EETs appeared to fit the criteria for an endothelium-derived hyperpolarizing factor (EDHF). However, with the ability to block the rapid hydrolysis of EpFA with sEHI, new roles for both were quickly found including attenuating inflammation, and beneficial effects in treating COPD, sepsis, stroke, cardiac contractile function, cardiac hypertrophy, and others, which is summarized in a recent review paper.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> This of course raised the concern among critics if there was any disease where the sEHI were ineffective. Since neuropathic pain remains largely an unmet medical need, and we needed to demonstrate there was a disease where the sEHI had no efficacy, we evaluated them on neuropathic pain rodent models and were surprised to find that they were exceptionally potent.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> We have since observed a lack of efficacy in preclinical models with high reactive oxygen species. Later studies resulted in the discovery that stabilization of EpFA by sEHI moves the ER stress response back toward cell survival and homeostasis and away from acute inflammation and cell death.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Thus, a unifying mechanism was found for the combined action of EpFA and sEHI. ER stress has been found to be an underlying contributor to every disease state where EpFA are effective to date, and therefore, the presence of ER stress in a disease suggests that sEHI should be effective.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Selecting a Clinical Path</h3><div class="NLM_p">The sEHI stabilize whatever EpFA are released and biosynthesized at the time they are administered. Since various EpFA have slightly different biological action and potencies, the effects of sEHI are anticipated to vary somewhat with the individual treated, their diet, and their physiological state. However, reversing the shift of the ER stress pathway away from initiation of inflammation, pain, and other disease states and toward resolution seems a common effect of stabilizing and increasing EpFA. As indicated by <a class="ref internalNav" href="#notes1" aria-label="Table S6">Table S6</a> and in several review articles, this fundamental mechanism underlies many disease states ranging from hepatic steatosis to senescence and aging, and more possible clinical targets are being found as the role of ER stress in disease becomes better understood. Thus, each of the companies involved in the development of sEHI or mimics of EpFA has the “problems of the rich” in selecting a good commercial target and a viable clinical path from among many possibilities. For example, Arête Therapeutics initially selected hypertension for a short acting drug candidate, although the standard at the time in the field of hypertension was once or twice a day dosing. Numerous published studies demonstrated the efficacy of sEHI in treating hypertension driven by the renin–angiotensin system.<a onclick="showRef(event, 'ref10 ref36'); return false;" href="javascript:void(0);" class="ref ref10 ref36">(10,36)</a> However, for many patients, hypertension can be effectively controlled by several combination therapies delivered by drugs that appear quite safe and often inexpensive. Thus, this type of hypertension is a very hard target to address commercially with new chemistries. Since sEHI control many of the comorbidities of diabetes, Arête Therapeutics thought diabetes may be a good target and tried in their Phase 2a clinical trial to pick up efficacy on both diabetes and hypertension but failed to get clinically and economically relevant efficacy in either indication. In retrospect, we now know that ER stress is stimulated by high glucose. Diabetes is an attractive target as a growing and massive market, and certainly sEHI can address many of the comorbidities of diabetes, but diabetes itself is a difficult clinical path and comes with expensive and long-term clinical trials.</div><div class="NLM_p last">Problems caused by cardiac ischemia have long been considered potential targets. EicOsis initially considered COPD and asthma as indications as well, but GSK was already moving down this path. Atrial fibrillation also was considered since it is common, and one can envision relatively short and well-defined clinical trials.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Atrial fibrillation also is a precursor to atrial fibrosis and cardiac hypertrophy, which are both major markets but involve expensive and long clinical trials.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> However, we were swayed toward pain by the observation that sEHI not only were powerful analgesics in inflammatory pain models where they synergized with and reduced the gastrointestinal toxicity of NSAIDs and COXIBs, but they also were analgesic in neuropathic pain models. Neuropathic pain remains an unmet medical need, and it is poorly handled by existing medications. There is a long history of pharma failures with the neuropathic pain indication. However, we were encouraged by the evidence that we could successfully treat severe equine laminitis, a neuropathic pain condition, with sEHI. This gave us confidence in moving from models into patients and from rodents into humans. Some neuropathic pain conditions also lend themselves to relatively short-term trials. With both in-house expertise and strong collaborators in the neuropathic pain area, we selected this indication. Because of the increasing appreciation that the opioid crisis in the United States is devastating both on a personal basis and economically, EicOsis was lucky in finding nondilutive resources to follow the neuropathic pain indication.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Clinical Path to Treating Inflammatory and Neuropathic Pain</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Importance of Pain Drugs</h3><div class="NLM_p">We chose diabetic peripheral neuropathy (DPN) for our initial neuropathic pain trials due to the prevalence and growing incidence in the U.S. population, but also because DPN is a serious condition that causes substantial disability and often leads patients to use opioid analgesics when they fail to get adequate pain relief from currently approved neuropathic pain drugs. We are following this with several other pain indications selected based on the efficacy of sEHI in rodent and nonrodent species and where the indications seem to lead to opioid dependence. Our biological data support the hypothesis that the sEHI can control both inflammatory and neuropathic pain by acting peripherally.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Therefore, our conclusion is that central nervous system penetration is not necessary for analgesic action, which also explains why sEHI work topically. However, it does not exclude action at the dorsal root ganglia or the CNS. Recently, it was reported that TPPU and EC5026 prevent neuroinflammation in the CNS of an LPS-induced mouse model, where TPPU has shown brain-to-plasma ratio of 17.2–21.7% in mice.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">The available treatments for neuropathic pain have, at most, modest efficacy, and dose-limiting and/or serious side effects, including somnolence, decreased cognition, dizziness, and, in some cases, respiratory depression. The commonly prescribed drugs, such as gabapentin and pregabalin, can produce significant CNS side effects.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In addition, 50% or more of patients with neuropathic pain and painful diabetic peripheral neuropathy, in particular, are prescribed opioids to manage their symptoms, with the associated risk of opioid misuse and addiction.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Patients requiring more than one drug class are at a higher risk for these central effects and for respiratory depression, especially with opioids. CNS adverse effects are common to most currently available neuropathic pain drugs and because of their impact on the day-to-day functioning of patients often result in discontinuation of treatment. Even NSAIDs, often prescribed for inflammatory pain including osteoarthritis, present a significant risk of GI-associated adverse events. Novel drugs able to demonstrate efficacy in inflammatory and neuropathic pain without these side effects would provide an important advance for patients.</div><div class="NLM_p">sEHI in general and EC5026, in particular, are devoid of the side effects produced by other drugs used for this therapeutic indication.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> sEHI have a unique mechanism, blocking ER stress and inflammation in the diseased state to shift responses toward resolution and repair, providing efficacy without the side effects seen with other mechanisms. On the basis of data from preclinical studies, EC5026 has the potential to provide efficacy comparable to available treatments while avoiding serious side effects observed with other pain drugs, including CNS-related adverse events (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Previous sEHI, including AR9281 and GSK2256294, that were tested in clinical trials showed minor adverse events.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Unlike opioid analgesics, sEH inhibition has shown no evidence thus far of tolerance, dependence, or additional liability with chronic exposure in animals, avoiding the risk of addiction. sEHI do not disturb cognition, or produce sedation preclinically, and they do not produce the GI side effects of NSAIDs, and synergize with NSAIDs to block their side effects, further supporting their unique potential as pain drugs.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) In a chronic constriction injury model of neuropathy in male SD rats, EC5026 blocked pain measured with a von Frey assay (mechanical withdrawal thresholds). The efficacy of EC5026 was superior to pregabalin at 10–20 fold lower doses over the time course represented as area under the response curve (AUC) over 6 h post dose. The AUC was calculated with the trapezoidal method for each animal and the average of the group reported ± SEM (<i>n</i> = 6–8/group). Kruskal–Wallis one way analysis of variance on ranks, <i>H</i> = 21.011 with 3 degrees of freedom with Dunn’s Method post hoc. EC5026 vs PEG 300 (<i>p</i> ≤ 0.001), EC5026 vs pregabalin (30 mg/kg) (<i>p</i> = 0.039). (B) The same effective dose of 3 mg/kg EC5026 was able to block withdrawal pain in morphine dependent rats (male SD rats, <i>n</i> = 4/group). Rats were made morphine tolerant with twice daily 10 mg/kg subcutaneous injections of morphine for 10 days. Morphine was stopped and after 18 h of withdrawal the rats were assessed and administered EC5026 or vehicle by oral gavage and tested at 30 min and 1 h post treatment. Painful withdrawal baseline scores (von Frey assay) were normalized to zero (zero is the painful state). EC5026 relieved opioid withdrawal pain compared to vehicle controls. For both graphs scores are calculated as the percent improvement over the painful baseline: the score per time point/painful baseline score *100 calculated for each animal and averaged ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Other important aspects of drug safety include the selectivity of drugs for the target and the avoidance of drug–drug interactions. Several of the available therapies for neuropathic pain have been shown to cause drug–drug interactions, and patients with neuropathic pain often require more than one drug class.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> EC5026 has proven selective for sEH when screened against a large receptor panel <i>in vitro</i>, and additional <i>in vitro</i> data described below suggest that the potential of drug–drug interactions for EC5026 is low, further supporting the safety of EC5026 and its unique profile as a therapeutic for neuropathic pain.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> IND-Enabling Studies</h4><div class="NLM_p">Species selection for dose-range finding toxicology studies is generally determined based on species comparisons of rates of metabolism and on whether unique metabolites are generated in humans. These studies involve the use of microsomal enzymes and/or hepatocytes from rodents, canine, and primates. Rat and dog were selected as the toxicological species due to similarities in PK and metabolite formation. Studies to identify clinically relevant toxicological species based on metabolism profiles and to predict human equivalent doses based on clearance rates are described below.</div><div class="NLM_p"><i>In vitro</i> metabolism studies were conducted in mouse, rat, dog, monkey, and human hepatocyte incubations at SEKISUI XenoTech and demonstrated the formation of seven putative metabolites (hydroxylated EC5026 and their corresponding dehydrated products) that were separated by HPLC and detected by mass spectrometry. All seven metabolites were detected in the mouse, rat, monkey, and human hepatocyte incubations, while only six metabolites were observed in dog hepatocytes. On the basis of the <i>in vitro</i> metabolite profiles, it is likely that EC5026 is mainly metabolized by CYP450 enzymes.</div><div class="NLM_p">Considering the main route of metabolism is likely through CYP450s, inhibition and induction of CYP450s were measured after incubation of 7 μM EC5026. Of seven major CYP450 isoforms assessed for inhibition, EC5026 had little to no inhibitory effects except for CYP2C9 and CYP2C19. At 7 μM, EC5026-mediated inhibition was about 25% and 34% for CYP2C9 and CYP2C19, respectively. An <i>in vitro</i> study was conducted to assess the inductive effects of EC5026 on CYP1A2, CYP2B6, and CYP3A4 by using three different batches of cryopreserved human hepatocytes. CYP1A2, CYP2B6, and CYP3A4 are known to be induced via three mechanistically distinct mechanisms. Treatment of cultured human hepatocytes with EC5026 up to 30 μM had little or no effect (i.e., < 2-fold change and/or <20% of the positive control) on CYP1A2, CYP2B6, and CYP3A4 mRNA levels. These results strongly suggest that EC5026 is not a potent CYP inhibitor or inducer. Clinically effective concentrations measured at the highest dose tested (24 mg) in human clinical trials achieved 301 ng/mL, or 9.4× lower than the concentrations used in this study. Therefore, potential CYP-mediated drug interactions caused by EC5026 are not expected.</div><div class="NLM_p last">Excretion: Distribution studies were contracted with QPS (Newark, DE) to characterize the rate and extent of excretion of EC5026 after a single oral dose of [<sup>14</sup>C]EC5026 at 3 mg/kg in male and 1.5 mg/kg in female Sprague–Dawley rats. 96.5% of the dose was recovered in the urine and feces through 168 h postdose. On the basis of these data, it is believed that the elimination of EC5026 is mainly attributed to hepatic metabolism, likely through CYP450 metabolism.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Safety Studies</h3><div class="NLM_p">EC5026 has been assessed in a series of nonclinical toxicology studies consistent with ICH M3(R2): <i>Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals</i> (January 2010) including in vitro metabolism, genotoxicity studies, CNS effects in a modified Irwin assay, and single and multiple repeat dose studies in the most sensitive species in male and female rats and dogs. Twenty-eight day repeat-dose GLP toxicity studies were also conducted to estimate safety in humans.</div><div class="NLM_p">Three dose levels of EC5026 were tested via oral gavage were tested in GLP toxicity studies conducted in rat and dog for 28 consecutive days in independent groups of male and female Beagle dogs and Sprague–Dawley rats (6 dogs and 15 rats/sex). A control group was administered the vehicle (PEG 400) at an equivalent volume. Animals were sacrificed on Days 29 and 57 (4 dogs and 10 rats/sex each at “Main” and 2 dogs and 5 rats/sex each at “Recovery” necropsies). The following potential toxicities were evaluated: plasma drug levels and toxicokinetics, mortality/morbidity, clinical observations including electrocardiograms (dog only) and ophthalmologic exams, functional observational battery (male rats only), body weights, micronucleus evaluation for genetic toxicity (rats only), food consumption, clinical pathology (hematology, clinical chemistry, and coagulation), urinalysis, gross necropsy observations, organ weights, and microscopic evaluation of tissues.</div><div class="NLM_p">With the available animal data via the 28 Day GLP toxicity studies and efficacy studies in preclinical species, a therapeutic index (TI) was estimated based blood level exposures to EC5026. For this estimation there was no toxic dose in 50% of the population (TD50) observed so the dose for the No Observed Adverse Effect Level (NOAEL) was used. To correlate to this level the minimum dose with observed efficacy was used rather than the efficacious dose in 50% of subjects (ED<sub>50</sub>). The Area Under the Curve after the last dose (AUC<sub>last</sub>) in ng*h/mL exposure for the NOAEL was divided by the AUC<sub>last</sub> of the minimum efficacious dose previously determined in a rat chronic constriction injury model of neuropathic pain.<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_m001.gif" alt="" id="_i23" /></img></span></div><div class="NLM_p">This resulted in a 37–111× therapeutic index based on rat and dog exposures, respectively.</div><div class="NLM_p">In addition, Panigrahy et al. reported that EETs promote tumor growth. In particular, EETs can stimulate multiorgan metastasis and escape from tumor dormancy in several tumor mouse models.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> EETs promoted metastasis by triggering secretion of VEGF by the endothelium, which was critical for EETs’ cancer-stimulating activity. The stimulation of metastasis by EETs is due to their action at the secondary (metastasis) site and not due to their effect on the cells of the primary tumor. The authors failed to show EETs-promoted growth of the primary tumor and at the site of metastasis using sEH-null mice while exogenously administrated EETs promote them where systemic EET level is twice than the sEH-null mice. However, such high EET level in the sEH-null mice cannot be achieved by sEHI.</div><div class="NLM_p last">More importantly, GSK was also aware of this issue and concerned about the role of EETs and sEH in VEGF signaling and expression. Therefore, GSK measured VEGF concentrations to ensure human safety in their Phase 1 clinical trial and found no significant changes in VEGF concentrations from baseline to day 15 in the repeat dose subjects. Overall, serum VEGF concentrations were not increased and actually trended lower in subjects who received the higher dose. Meanwhile, near maximal sEH inhibition (98–99%) was observed for the doses following two-week repeated dosing.<a onclick="showRef(event, 'cit14b'); return false;" href="javascript:void(0);" class="ref cit14b">(14b)</a> Considering the reasons listed above, the results from using mouse models of cancer are not likely to translate to human cancers, and no such concern was raised by the FDA when EC5026 moved on in the IND application process to Phase 1a clinical trial. Despite this, long-term studies are still necessary to fully assess the potential effects.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Fast Track</h3><div class="NLM_p">In April 2020, the FDA granted Fast Track designation to EC5026 for the treatment of neuropathic pain. The FDA’s Fast Track process is intended to facilitate the development and expedite the review of new therapies to address an unmet medical need in the treatment of a serious condition. Neuropathic pain is estimated to affect 7–10% of the general population, substantially affecting day-to-day functioning and quality of life of patients. Currently available treatments for neuropathic pain remain ineffective and are associated with frequent adverse effects and poor tolerability. The FDA’s Fast Track designation recognizes the potential of EC5026 to address the pressing need for effective, nonaddictive alternative drugs for pain management, decrease the use of prescription opioids, and reduce the opioid abuse epidemic. The Fast Track program enables drug companies to have early and frequent communication with the FDA throughout the drug development and review process, and confers important benefits, including the potential eligibility for Priority Review of a New Drug Application.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Phase 1a Clinical Trial</h4><div class="NLM_p">A Phase 1a single ascending dose study to investigate the safety, tolerability, and PK of EC5026 in healthy volunteers was recently completed at PPD in Austin, TX (ClinicalTrials.gov Identifier: NCT04228302). Oral EC5026 was administered in five escalating single dose regimens (0.5–24 mg) in 40 healthy male and female subjects, eight subjects in each cohort, equal male and female with six subjects randomly assigned to receive EC5026 and two subjects the placebo. Dose escalation was done in a stepwise fashion following acceptable safety and tolerability of the preceding dose(s), as determined by the safety review committee. EC5026 was monitored in urine and plasma over 14 days. The study was completed with no drug-related safety concerns or adverse effects, and all doses were very well tolerated. EC5026 was well absorbed with linear dose-proportionality (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Safety was demonstrated at ∼12× the predicted efficacious dose, and concentrations were 600× higher than the predicted efficacious concentrations determined from preclinical pain studies. The mean terminal half-life of EC5026 in plasma was between 42 and 59 h at doses of 8–24 mg, consistent with predictions based on IND-enabling toxicity studies, and suitable for once daily dosing. These results are reassuring for the advancement of EC5026 into multiple ascending dose (MAD) Phase 1b studies. EicOsis is planning to start a Phase 1b MAD clinical trial in healthy volunteers in the second half of 2021, followed by two nested Phase 1b MAD studies in patients with two chronic pain conditions that are anticipated to start in 2021. These MAD Phase 1b studies will evaluate the safety and tolerability of three escalating dose regimens of EC5026, administered as a single oral dose daily, for 7 consecutive days. Each dose regimen will be tested first in the healthy volunteer population before being tested in the two chronic pain populations.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) <i>C</i><sub>max</sub> and (B) area under the curve (AUC) of EC5026 after single oral dose administration in humans. Following single oral administration of EC5026 in healthy male and female subjects, plasma concentrations peaked rapidly with <i>T</i><sub>max</sub> observed at 1.25 h across all dose groups and declined slowly through the end of sampling (14 days, data not shown). Plasma concentrations following 0.5 mg EC5026 were below the limit of quantification for all subjects at all time. Linear exposure was observed in the highest concentration measured at a specific time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Rationale for the Anticipated Therapeutic Index</h3><div class="NLM_p last">With the assumption that the <i>in vivo</i> IC<sub>90</sub> of EC5026 in humans is similar to the <i>in vitro</i> IC<sub>90</sub> (0.62 nM), the effective plasma AUC required to maintain target inhibition over 24 h is estimated to be ≥892 nM·min (362 ng·min/mL). For a daily dosing regimen, the effective total AUC of EC5026 can then be calculated to be 6 ng h/mL. After a single oral dose, administration of 2 mg EC5026 exceeded these concentrations; therefore, we predict that the efficacious dose level will be <2 mg administered once daily and the therapeutic index >12x based on the highest concentration tested to date in human, 24 mg.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Metabolism</h3><div class="NLM_p">The abundant metabolites found in human blood after a single oral dose of EC5026 in Phase 1a trial were hydroxylated products on carbons that are susceptible to oxidation by CYPs as predicted from a previous metabolism study of the related sEHI compound TPPU<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and previous microsomal and hepatocyte metabolism studies prepared from rat, dog and monkey with EC5026 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Of note, there were no detectable cleavage products of the urea moiety or deacylation products of the hindered amide. Neither glucuronides formed from conjugation of the oxidative metabolites nor the <i>N</i>,<i>N’</i>, or diglucuronides formed from <i>N</i>-glucuronidation of the ureas as seen with the urea triclocarban<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> were detected in human blood.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> These glucuronide metabolites would be predicted to be rapidly excreted into the urine where they are found.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of metabolites of EC5026 identified from human blood in Phase 1a clinical trial. Amide or urea cleavage was not observed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Future Plans</h3><div class="NLM_p last">As a small company, EicOsis must focus on a path to the clinic targeting neuropathic and inflammatory pain. However, stabilization of EpFA regulates a homeostatic mechanism of ER stress and has the potential for treating multiple disease states as mentioned above. Hopefully, given the extensive library of highly potent compounds held by EicOsis, other promising indications can be followed. In addition to the conditions discussed previously, additional indications could include reduction of postsurgical pain, chemotherapy, and CAR-T induced tumor growth and metastasis due to cell debris,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> modulation of cytokine storms associated with sepsis and COVID-19,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and inflammation of the central nervous system.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Equine laminitis and Treating Companion Animals</h3><div class="NLM_p">The purpose of the ACS symposium this report is associated with was to highlight “First-Time Disclosures of Clinical Candidates” specifically for new human health drugs; however, EicOsis is also pursuing a second sEHI in a different patent class, <i>t</i>-TUCB or EC1728 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), for efficacy in horses and companion animals with neuropathic and arthritic pain. Animal health represents a major market, but more relevant to human health, demonstration of efficacy in these studies validates the ability to translate preclinical efficacy studies to a heterogeneous human patient population with diverse disease ideologies. Translating success in rodent pain models to humans has proven difficult in the past. This may be due to vast genetic differences in species, or possibly the use of models where pain is generated mechanically, genetically, or clinically. At EicOsis, we have had the advantage of close collaboration with a veterinary school where we can evaluate sEHI on veterinary patients with real disease states rather than models, patients presenting with complex comorbidities, and patients of four significantly different mammalian orders. The sEHI successfully relieving neuropathic and inflammatory pain certainly raises confidence that translation of this work to pain patients in another mammalian orders will be successful.</div><div class="NLM_p">Possibly the most visual demonstration of the use of sEHI in animals resulted from research by Guedes<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> in horses with laminitis. Laminitis is a painful inflammatory condition that shifts to a neuropathic pain resulting from initial inflammation of the hoof laminae. It is often of idiopathic origin and presents as both chronic and acute duration, either of which often ends in euthanasia of the horse due to pain and inability to stand. After discovering that sEH is upregulated in laminitic joints, Guedes<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> implemented emergency measures to treat a laminitic horse scheduled for euthanasia with <i>t</i>-TUCB after all available treatments failed. After 5 days of treatment, this horse made a complete recovery with no recurrent laminitis (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Since this initial case, seven other laminitic horses showed improvement in disease after having been treated with <i>t</i>-TUCB when all other treatments failed.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Hulahalla (4-year old female thoroughbred), shown above, before (left) and after (right) a five-day treatment of once daily <i>t</i>-TUCB at 0.1 mg/kg. Hulahalla presented with acute laminitis and was treated with standard of care for 3 days with little effect. Her condition became extremely painful, and given the lack of response to the medications and worsening of the condition, humane euthanasia was being considered as the last resort to relieve pain and suffering. At this point, daily <i>t</i>-TUCB was administered in addition to her standard of care treatment. Over the course of the five-day treatment, her pain level decreased, and no signs of adverse effects were observed both from clinical exams and evaluation of blood work. Hulahalla continued to do well, and laminitis has not reoccurred.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In another example, dogs with naturally occurring osteoarthritis were treated with sEHI for 5 days and had significant  reduction in pain, as determined by a questionnaire quantifying pain behaviors and recorded by a blinded technician, compared to placebo-treated animals.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><i>t</i>-TUCB was selected for use in animals over EC5026 due to potency on companion animal enzymes.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Fundamental Concepts Advanced by This sEHI Project</h3><div class="NLM_p last">The mammalian sEH was discovered investigating the rodent metabolism chemistry of an agricultural chemical. Although it was discovered in an applied project, the enzyme research was driven by fundamental curiosity primarily in the academic sector with inhibitors of sEH and mimics of EpFA initially prepared as research tools. However, with translating the sEHI to the clinic, the scientists involved have made a number of fundamental advances. Since the sEH is so efficient at hydrolyzing most EpFA, the first application of this work was in allowing researchers to evaluate the role of EpFA in a number of physiological systems where previously the metabolism was so fast the biological results were not reproducible. As the sEHI were increasingly used <i>in vivo</i>, they illustrated new and often unexpected involvement of EpFA in biological systems. These discoveries continue a broad front. For example, in nutrition they illustrate that many of the attributes of dietary omega-3 fatty acids may be through their epoxide metabolites. The most recent example of unexpected activities comes from the observation that sEHI prevent and ameliorate several CNS diseases in rodent models. They were also valuable in dissection of the crosstalk between predominantly inflammatory pathways such as those driven by the COX and the LOX enzymes. Using dual inhibitors and inhibitor combinations, this has been extended to the interaction of sEHI with the PPARs. The sEHI are an excellent example of mimicking the transition state(s) along reaction coordinates to design inhibitors and the value of kinetic treatments to describe this interaction. The slow-tight-binding nature of sEHI and often their slow kinetic off rates illustrated the value of target occupancy in describing potent inhibitors. This slow off rate of sEHI from the target enzyme has been used to illustrate the role of target mediated drug disposition (TMDD) in explaining both efficacy and PK.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Recent work illustrates a key role of lipid chemical mediators in regulating endoplasmic reticulum stress, resolving inflammation and controlling pain in general. Hopefully, there will be more fundamental insights as EC5026 and other sEHI move toward the clinic.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Research by numerous academic scientists around the world discovered a plethora of biological effects mediated by the CYP450 branch of the arachidonate cascade due, in part, to the availability of high-quality EpFA and sEH inhibitors to stabilize them. A variety of technologies ranging from cloning and expressing the relevant enzymes to antibodies and enzyme assays for monitoring them supported this biological work. Demonstration of the <i>in vivo</i> efficacy of sEHI by a variety of international scientists demonstrated their potential roles as pharmaceuticals. As indicated by the patent literature, numerous companies followed these leads with both classical SAR driven and very innovative high-throughput approaches, leading to potent sEHI. The extensive information on the biology and chemistry of the EpFA came largely from government support through competitive funding and a spirit of openness and collaboration among academic and government scientists.</div><div class="NLM_p last">The development of the sEHI class was based on knowledge of enzymology and a methodical stepwise synthesis and screening approach over many years enabling the discovery of the initial lead sEHI. Parallel tracks were taken in the academic and industrial paths toward structural optimization. Key to the success of the academic path in medicinal chemistry was simple synthesis, rapid feedback from quantitative enzyme assays, rapid analysis of parent molecules in the blood following oral administration, technology to monitor blood eicosanoids as indicators of efficacy and target engagement, and, of course, a rigorous filter to only move the most promising compounds forward into animal pain models. The resulting university use patents were supplemented by later composition of matter patents allowing EicOsis to spin out of the University of California. With several SBIR grants from NIEHS, then the NINDS Blueprint Development Grant, and now a NIDA Heal Grant and NCI SBIR, EicOsis was able to develop the independent composition of matter IP described here, obtain an IND and FDA Fast Track Status, and complete human Phase 1a human trials. This example of sEHI development is among the first successful examples to date of the NIH-academic collaborative approach to drug development. The NIH-academic-industry collaboration illustrated here will add to the range of current approaches in drug development and to the diversity of new therapeutics that are so desperately needed.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Synthetic Procedures</h3><div class="NLM_p last">This synthesis was performed by Adesis, Inc. All reagents and solvents were obtained from commercial suppliers and were used without further purification. All reactions, unless otherwise described, were performed under an inert atmosphere of dry nitrogen. Melting points were determined on an OptiMelt melting point apparatus and are uncorrected. <sup>1</sup>H NMR, <sup>13</sup>C NMR, and <sup>19</sup>F NMR spectra were recorded at 600 or 400, 150, and 376 MHz, respectively. <sup>1</sup>H–<sup>1</sup>H<sup>2</sup>D NMR was recorded at 400 MHz. ATR FT-IR, UV–vis, and elemental analyses were determined at Robertson Microlit laboratories, Ledgewood, NJ. Ultraviolet absorbance spectrum was obtained on a PerkinElmer Lambda 35 UV–vis spectrometer. Mass spectra were measured by an Agilent Infinity 1290 LC with Agilent 6150 Quadrupole MS using electrospray (+) ionization. All final products synthesized to >93% purity as determined by HPLC or LC/MS. HPLC analysis was performed using Agilent 1100 LC. HPLC conditions; wavelength 210 nm, bandwidth 4, column: SorbTech C18AQ, 2.1 × 50 mm, 3 μm; gradient method from 95:5 to 5:95 water/MeCN (0.1% formic acid in both) in 14 min with a 4 min hold at 95% acetonitrile, 0.7 mL/min (retention time 6.81 min). LC-MS analysis was performed using Agilent 1260 with Bruker timeTOF instrument. HPLC conditions; column: Phenomenex Kinetex C18, 21. X150 m, 1.7 μm; gradient method from 98:2 to2:98 water/MeCN (0.1% formic acid in both) in 10 min. EC5026 was synthesized to >99% ee as determined by chiral HPLC Analysis (Agilent 1100 LC with a Chiralpak OD column, 25 cm x 4.6 mm, 10 μm). Optical rotation was measured using PerkinElmer polarimeter 343. Experimental details for the synthesis and characterization of standards of EC5026 metabolites <b>1</b> and <b>2</b> are available in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Scale-Up Synthesis of EC5026</h3><div class="NLM_p">The scale-up non-GMP synthesis of EC5026 is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a><named-content content-type="anchor" rid="sch1" type="simple"></named-content></div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0010.jpeg" id="GRAPHIC-d7e1219-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Scale-up Non-GMP Synthesis of EC5026</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) triphosgene, <i>tert</i>-butyl 4-amino-piperidine-1-carboxylate, Et<sub>3</sub>N, DCM, −78 °C to rt, overnight; (b) 4 N HCl in MeOH, rt, overnight; (c) <b>7</b>, Jones reagent, acetone, 0 °C to rt, 2.4 h; (d) EDCI, Et<sub>3</sub>N, DCM, rt, overnight.</p></p></figure><div id="sec7_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>tert</i>-Butyl 4-(3-(3-fluoro-4-(trifluoromethoxy)phenyl)ureido)piperidine-1-carboxylate (<b>4</b>)</h4><div class="NLM_p last">A solution of 3-fluoro-4-(trifluoromethoxy)aniline (<b>3</b>) (250 g, 1.28 mol) and Et<sub>3</sub>N (260 mL, 1.86 mol) in DCM (500 mL) was added dropwise over 4 h to a thick slurry of triphosgene (171 g, 0.576 mol) in DCM (500 mL) in a dry ice/acetone bath while maintaining the temperature below −64 °C. The cold bath was removed, and the mixture was warmed to rt and stirred for 30 min. The reaction was cooled to −78 °C, and a slurry of <i>tert</i>-butyl 4-amino-piperidine-1-carboxylate (386.4 g, 1.92 mol) and Et<sub>3</sub>N (260 mL, 1.86 mol) in DCM (1.2 L) was added in small portions over 3 h while maintaining the temperature below −65 °C. The reaction was warmed to rt and stirred overnight, at which point LCMS indicated a mixture of compound <b>3</b> (major), as well as both symmetrical ureas. The reaction mixture was washed with 10% aq HCl (4 × 1 L) The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to give a crude compound <b>4</b> as a viscous yellow oil (800 g) which was used in the next step without further purification.</div></div><div id="sec7_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-3-(piperidin-4-yl)urea (<b>5</b>)</h4><div class="NLM_p last">to a solution crude compound <b>4</b> (800 g) in MeOH (1.5 L) was added a solution of 4 N HCl in MeOH (1.8 L), which was prepared with 600 mL of conc. HCl and 1.2 L of MeOH. The reaction mixture was stirred at room temperature overnight at which point LC-MS indicated the reaction was complete. The MeOH was removed under reduced pressure and the residue was slurried in a mixture of water (500 mL) and DCM (250 mL) and filtered. The filtrate was transferred to a separatory funnel and the layers were separated. The aqueous layer was transferred to a 5 L 4-neck flask and basified to pH 12 by adding 300 mL of 50% aq NaOH solution dropwise. After stirring for 10 min, the precipitates were filtered and washed with water (500 mL) followed by heptanes (500 mL). The product was initially dried in a convection oven overnight at 40 °C. The material from two reactions of similar size was combined and triturated with 15% DCM in heptanes (2 L). The solid was dried overnight in a convection oven at 40 °C to give compound <b>5</b> (778 g, 96% yield over 2 steps) as a white powder. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43 (dd, <i>J</i> = 12.1, 2.6 Hz, 1H), 7.17 (t, <i>J</i> = 8.6 Hz, 1H), 6.97 (ddd, <i>J</i> = 8.8, 2.5, 1.5 Hz, 1H), 6.69 (br s, 1H), 4.77 (br s, 1H), 3.81–3.70 (m, 1H), 3.07 (td, <i>J</i> = 12.6, 3.3 Hz, 2H), 2.73–2.65 (m, 2H), 1.98 (br dd, <i>J</i> = 12.3, 2.8 Hz, 2H), 1.38–1.28 (m, 2H).</div></div><div id="sec7_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>S</i>)-2-Methylbutanoic acid (<b>7</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-2-methylbutan-1-ol <b>6</b> (140 g, Sigma 65980-100 ML, ≥ 95%<i>ee</i>, 1.59 mol, 1 equiv) in 1.4 L of acetone was added dropwise Jones reagent (a solution of CrO<sub>3</sub> (263 g, 2.63 mol) in 500 mL of water and 250 mL of conc. H<sub>2</sub>SO<sub>4</sub>) while maintaining the temperature below 5 °C. During the addition, chromium salts began to precipitate out, either forming a gum on the bottom of the flask of a golf size ball. The addition was considered complete when an orange/brown color persisted (620 mL of Jones reagent)). After removal of the cooling bath, the reaction mixture was stirred for additional 2.5 h at ambient temperature. The reaction was quenched by adding 50 mL of IPA (50 mL), and the reaction mixture was stirred overnight. The solution was decanted and concentrated under reduced pressure. All solids were dissolved in water (1.3 L) and transferred to a separatory funnel. After <i>tert</i>-butyl methyl ether (750 mL) was added, the layers were separated. The remained organic layer was further washed with water (250 mL). The combined aqueous layer was extracted with <i>tert</i>-butyl methyl ether (750 mL), and the organic layer was washed with water (200 mL). All combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The material from two reactions of equal size was combined and distilled under reduced pressure (Teflon pump, 20 Torr, 80–85 °C) to give (<i>S</i>)-2-methylbutanoic acid (<b>7</b>, 234 g, 72% yield) as a colorless liquid, [∝]<sub class="stack">D</sub><sup class="stack">20</sup>= +19.2 (c = 1.671 g/100 mL chloroform).</div></div><div id="sec7_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>S</i>)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (EC5026)</h4><div class="NLM_p">A mixture of (<i>S</i>)-2-methylbutanoic acid <b>7</b> (175 g, 1.71 mol, 1.3 equiv). EDCI (327 g, 1.71 mol, 1.3 equiv), Et<sub>3</sub>N (260 mL, 1.86 mol, 1.4 equiv), and compound <b>5</b> (425 g, 1.32 mol, 1 equiv) in DCM (6 L) was stirred overnight at room temperature, at which point LC-MS indicated ∼75% conversion to the desired product. 10% aqueous HCl solution (2 L) was added to the reaction flask, and stirring was continued for 5 min. The mixture was transferred to a 22 L separatory funnel containing 4 L of 10% aq HCl solution. After stirring for 10 min, the layers were separated. The organic layer was washed with 10% HCl (4 L) followed by saturated aq. Na<sub>2</sub>CO<sub>3</sub> solution (2 × 6 L). The organic layer from two reactions of the same scale were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to dryness under reduced pressure. The residue was slurried in EtOAc (2 L) and reconcentrated. EtOAc (2 L) was added to the residue, the vacuum was stopped, and the bath temperature was raised to 60 °C. A clear yellow solution was obtained. The heat was turned off, and the solution was cooled with rotation to ambient temperature. After no visible solids were confirmed, EtOAc was removed in vacuo until solids began to form. The vacuum was terminated, and the mixture was stirred overnight at ambient temperature and pressure. The solids were collected by filtration and dried in a convection oven at 40 °C overnight to give EC5026 (526.6 g, 49% yield, > 99% purity) as a white solid. The filtrate was concentrated under reduced pressure to give a yellow waxy solid. After triturating with heptanes (400 mL), the resulting solid was recrystallized twice with EtOAc (250 and 150 mL) to give additional EC5026 (63.6 g, > 99% purity) for an overall yield of 55%.</div><div id="sec7_2_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Final Purification</h5><div class="NLM_p last">A 12 L 4-neck flask was rinsed with absolute EtOH before use. Absolute EtOH (1 L) was added to the flask, the heat was turned on, and EC5026 (1034 g) was added in portions with stirring. Once all the solid had been added, additional EtOH was added in portions until a clear solution was obtained (1.45 L). The heat was turned off and DIUF water was added dropwise until a cloudy solution was obtained (1.38 L). The mixture was then reheated to obtain a clear solution and left to cool gradually with stirring. Once the solution became cloudy, the mixture was seeded and stirring was continued for 2 h. The resulting solids were filtered and washed with water (500 mL). The solids were dried in a convection oven at 40 °C overnight to give EC5026 (854 g, 82.6% recovery, 99.7% purity, 97.5% ee) as a white solid. mp 148.8–150.0 °C, <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ 8.04 (d, <i>J</i> = 38.3 Hz, 1H), 7.53 (ddd, <i>J</i> = 12.4, 6.0, 2.5 Hz, 1H), 7.15 (t, <i>J</i> = 8.6 Hz, 1H), 7.04–7.00 (m, 1H), 5.42 (d, <i>J</i> = 8.1 Hz, 1H), 4.66–4.46 (m, 1H), 4.05–3.85 (m, 2H), 3.21 (td, <i>J</i> = 12.1, 2.7 Hz, 1H), 2.90–2.73 (m, 1H), 2.68 (p, <i>J</i> = 6.8 Hz, 1H), 2.33–2.17 (m, 1H), 2.04–1.88 (m, 1H), 1.71–1.58 (m, 1H), 1.47–1.37 (m, 1H), 1.24–1.15 (m, 2H), 1.11 (dd, <i>J</i> = 27.9, 6.7 Hz, 3H), 0.90 (t, <i>J</i> = 7.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.54, 154.01, 153.6 (d, <i>J</i> = 246.1 Hz), 141.24 (d, <i>J</i> = 10.4 Hz), 128.39 (d, <i>J</i> = 13.3 Hz), 120.12 (q, <i>J</i> = 256.8 Hz), 113.57, 113.55, 105.65 (d, <i>J</i> = 23.6 Hz), 46.36, 43.48, 35.60, 32.77, 31.86, 31.66, 26.59, 17.17, 11.54. <sup>19</sup>F NMR (CDCl3) δ −59.25 (d, <i>J</i> = 3.8 Hz), −127.19 (t, <i>J</i> = 7.5 Hz). MS (ESI) <i>m</i>/<i>z</i> = 406.2 (M + H<sup>+</sup>). Anal. (C<sub>18</sub>H<sub>23</sub>F<sub>4</sub>N<sub>3</sub>O<sub>3</sub><b>·</b>0.95H<sub>2</sub>O): cald. C, 51.17; H, 5.94; N, 9.95. found. C, 51.11; H, 5.80; N, 9.80. [∝]<sub class="stack">D</sub><sup class="stack">20</sup>= +10.4 (<i>c</i> = 0.506 g/100 mL EtOH).</div></div></div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> EC5026 Metabolite Standard Synthesis</h3><div id="sec7_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(3-hydroxy-2-methylbutanoyl)piperidin-4-yl)urea (<b>1</b>, Most Abundant EC5026 Metabolite)</h4><div class="NLM_p last">To a solution of the 1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(piperidin-4-yl)urea <b>5</b> (100 mg, 0.31 mmol) and 3-hydroxy-2-methylbutanoic acid (40 mg, 0.34 mmol) in DMF (3 mL) were added PyBOP (208 mg, 0.40 mmol) followed by Et<sub>3</sub>N (66 μL, 0.47 mmol) at 0 °C. The reaction mixture was allowed to slowly warm to room temperature and stirred overnight. The solvent was removed <i>in vacuo</i>, and the residue was purified by column chromatography (3:7 hexanes-EtOAc containing 5% MeOH) to give the title compound, 111 mg (85%, purity = 93.75%) as a white solid. mp 53.9–63.5 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.77 (d, <i>J</i> = 30.9 Hz, 1H), 7.67 (d, <i>J</i> = 13.3 Hz, 1H), 7.39 (t, <i>J</i> = 8.9 Hz, 1H), 7.11 (d, <i>J</i> = 8.9 Hz, 1H), 6.43–6.35 (m, 1H), 4.65–4.53 (m, 1H), 4.27–4.16 (m, 1H), 3.96–3.86 (m, 1H), 3.75–3.62 (m, 2H), 3.22–3.11 (m, 1H), 2.84–2.65 (m, 2H), 1.92–1.73 (m, 2H), 1.52–1.12 (m, 2H), 1.09–0.88 (m, 6H). MS (ESI) <i>m</i>/<i>z</i>: 420.1557 (M – H)<sup>−</sup>.</div></div><div id="sec7_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-hydroxy-2-methylbutanoyl)piperidin-4-yl)urea (<b>2</b>, Minor EC5026 Metabolite)</h4><div class="NLM_p last">To a solution of the 1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(piperidin-4-yl)urea <b>5</b> (100 mg, 0.31 mmol) and 2-hydroxy-2-methylbutanoic acid (40 mg, 0.34 mmol) in DMF (3 mL) was added PyBOP (208 mg, 0.40 mmol) followed by Et<sub>3</sub>N (66 μL, 0.47 mmol) at 0 °C. The reaction mixture was allowed to slowly warm to room temperature and stirred overnight. The solvent was removed <i>in vacuo</i> ,and the residue was purified by column chromatography (3:7 Hexanes-EtOAc containing 5% MeOH) to give the title compound, 107 mg (82%, purity = 98.92) as a white solid. mp 188.2–189.9 °C. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub><i>6</i></sub>): δ <sup>1</sup>H NMR (599 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.75 (s, 1H), 7.67 (dd, <i>J</i> = 13.3, 2.5 Hz, 1H), 7.39 (t, <i>J</i> = 9.0 Hz, 1H), 7.11 (d, <i>J</i> = 8.9 Hz, 1H), 6.38 (d, <i>J</i> = 7.6 Hz, 1H), 5.22 (s, 1H), 4.75–4.13 (m, 2H), 3.75–3.66 (m, 1H), 3.25–3.18 (m, 1H), 2.82 (br s, 1H), 1.91–1.77 (m, 3H), 1.74–1.53 (m, 2H), 1.35–1.22 (m, 4H), 0.80 (t, <i>J</i> = 7.3 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 420.1566 (M – H)<sup>−</sup>.</div></div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Chronic Constriction Injury Model of Neuropathy</h3><div class="NLM_p">All animal experiments were performed based on protocols approved by the Animal Use and Care Committee of Antibody, Inc. Sprague–Dawley rats (male, 250–300 g) were purchased from Charles River Laboratories.</div><div id="sec7_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Pain Attenuation in a Chronic Constriction Injury Model of Neuropathy</h4><div class="NLM_p last">Male SD rats underwent a chronic constriction injury surgery where 4 ligatures were loosely tied around the sciatic nerve. The rats were allowed to heal for 14 days and tested for allodynia in a von Frey assay. At 21 days post injury rats were treated via oral gavage with PEG 300 (vehicle), EC5026 or pregabalin as indicated and followed over a 6-h time course. The AUCs were calculated with the trapezoidal method for each animal and the average of the group reported ± SEM (<i>n</i> = 6–8/group). Kruskal–Wallis One Way Analysis of Variance on Ranks, <i>H</i> = 21.011 with three degrees of freedom with Dunn’s Method post hoc. EC5026 vs Peg300 (<i>p</i> ≤ 0.001), EC5026 vs pregabalin 30 (<i>p</i> = 0.039).</div></div><div id="sec7_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Blocking Withdrawal Pain in Morphine-Dependent Rats</h4><div class="NLM_p last">Male SD rats were made morphine tolerant with twice daily treatment of 10 mg/kg s.c. morphine. After 10 days the morphine was withheld, and opioid withdrawal pain was measured with a von Frey assay 18 h after the last morphine dose. The opioid withdrawal baselines decreased 49% from pain-free naïve baseline scores. Rats were then dosed with vehicle or EC5026 (<i>n</i> = 4/group) via oral gavage and assessed for mechanical withdrawal thresholds at 30 min and 1 h post dose. Mann–Whitney Rank Sum Test, U Statistic = 10.0, <i>T</i> = 90.0 n(small) = 8, <i>n</i>(big) = 8, <i>P</i>(exact) = 0.021.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01886" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01886?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01886</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Data for the full characterization of EC5026; EC5026 drug product preparation; P-gp inhibition and in vitro absorption of EC5026; CYP induction and inhibition by EC5026; Tables S1–S7 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_001.pdf">jm0c01886_si_001.pdf (1.0 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_002.csv">jm0c01886_si_002.csv (1.52 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01886" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40384" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40384" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sung Hee Hwang</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9891-928X" title="Orcid link">http://orcid.org/0000-0002-9891-928X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8dfee5e5faece3eacde8e4eee2fee4fea3eee2e0"><span class="__cf_email__" data-cfemail="8cffe4e4fbede2ebcce9e5efe3ffe5ffa2efe3e1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce D. Hammock</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1408-8317" title="Orcid link">http://orcid.org/0000-0003-1408-8317</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cindy B. McReynolds</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3309-1773" title="Orcid link">http://orcid.org/0000-0003-3309-1773</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Wagner</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5238-7847" title="Orcid link">http://orcid.org/0000-0002-5238-7847</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Buckpitt</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6643-5208" title="Orcid link">http://orcid.org/0000-0001-6643-5208</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Irene Cortes-Puch</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3639-5046" title="Orcid link">http://orcid.org/0000-0002-3639-5046</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Glenn Croston</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6352-0922" title="Orcid link">http://orcid.org/0000-0002-6352-0922</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kin Sing Stephen Lee</span> - <span class="hlFld-Affiliation affiliation">Synthia
LLC, P.O. Box 1238, Gualala, California 95445, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4541-3063" title="Orcid link">http://orcid.org/0000-0003-4541-3063</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Yang</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8126-1728" title="Orcid link">http://orcid.org/0000-0001-8126-1728</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William K. Schmidt</span> - <span class="hlFld-Affiliation affiliation">EicOsis
Human Health Inc., Subsidiary of EicOsis LLC, 1930 Fifth Street, Suite A, Davis, California 95616, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5841-4810" title="Orcid link">http://orcid.org/0000-0001-5841-4810</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">This work was presented as Paper MEDI 217 in the “First-Time Disclosure of Clinical Candidates” at the American Chemical Society Meeting in San Diego, CA, 2019. The authors declare no competing financial interest other than obvious association with EicOsis Human Health and the University of California in some cases.<br /></br>The authors declare the following competing financial interest(s): BDH, CBM, KW, AB, IC-P, GC, JY, WKS and SHH are employees of EicOsis LLC and KSSL is an employee of Synthia LLC.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24884" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24884" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Institute of Environmental Health Sciences (NIEHS) SBIR Program R43/R44 ES025598, National Institute of Neurological Disorders and Stroke (NINDS) Blueprint Neurotherapeutics Network UG3/UH3NS094258, National Cancer Institute (NCI) R43CA233371, and National Institute on Drug Abuse (NIDA) Award Number UG3DA048767.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AEPU</td><td class="NLM_def"><p class="first last">1-adamantanyl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl]}urea</p></td></tr><tr><td class="NLM_term"><i>t</i>-AUCB</td><td class="NLM_def"><p class="first last"><i>trans</i>-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid</p></td></tr><tr><td class="NLM_term">AUDA</td><td class="NLM_def"><p class="first last">12-(3-adamantan-1-yl-ureido)dodecanoic acid</p></td></tr><tr><td class="NLM_term">BCS</td><td class="NLM_def"><p class="first last">biopharmaceutics classification system</p></td></tr><tr><td class="NLM_term">sEH</td><td class="NLM_def"><p class="first last">soluble epoxide hydrolase</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">dicyclohexyl carbodiimide</p></td></tr><tr><td class="NLM_term">DCU</td><td class="NLM_def"><p class="first last">dicyclohexyl urea</p></td></tr><tr><td class="NLM_term">DPN</td><td class="NLM_def"><p class="first last">diabetic peripheral neuropathy</p></td></tr><tr><td class="NLM_term">ECD</td><td class="NLM_def"><p class="first last">endothelial cell dysfunction</p></td></tr><tr><td class="NLM_term">EDHF</td><td class="NLM_def"><p class="first last">endothelium-derived hyperpolarizing factor</p></td></tr><tr><td class="NLM_term">EETs</td><td class="NLM_def"><p class="first last"><i>cis</i>-epoxyeicosatrienoic acids</p></td></tr><tr><td class="NLM_term">EpFA</td><td class="NLM_def"><p class="first last">epoxy-fatty acids</p></td></tr><tr><td class="NLM_term">IGRs</td><td class="NLM_def"><p class="first last">insect growth regulators</p></td></tr><tr><td class="NLM_term">sEH inhibitors</td><td class="NLM_def"><p class="first last">sEHI</p></td></tr><tr><td class="NLM_term">TMDD</td><td class="NLM_def"><p class="first last">target mediated drug disposition</p></td></tr><tr><td class="NLM_term">TPPU</td><td class="NLM_def"><p class="first last">1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea</p></td></tr><tr><td class="NLM_term"><i>t</i>-TUCB</td><td class="NLM_def"><p class="first last"><i>trans</i>-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid</p></td></tr><tr><td class="NLM_term">UC</td><td class="NLM_def"><p class="first last">University of California.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31841" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31841" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodani, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">The 2014 Bernard B. Brodie Award Lecture Epoxide Hydrolases: Drug metabolism to therapeutics for chronic pain</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.063339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1124%2Fdmd.115.063339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=25762541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1artrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=788-802&issue=5&author=S.+D.+Kodaniauthor=B.+D.+Hammock&title=The+2014+Bernard+B.+Brodie+Award+Lecture+Epoxide+Hydrolases%3A+Drug+metabolism+to+therapeutics+for+chronic+pain&doi=10.1124%2Fdmd.115.063339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain</span></div><div class="casAuthors">Kodani, Sean D.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">788-802</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Dr.  Bernard Brodie's legacy is built on fundamental discoveries in pharmacol. and drug metab. that were then translated to the clinic to improve patient care.  Similarly, the development of a novel class of therapeutics termed the sol. epoxide hydrolase (sEH) inhibitors was originally spurred by fundamental research exploring the biochem. and physiol. of the sEH.  Here, we present an overview of the history and current state of research on epoxide hydrolases, specifically focusing on sEHs.  In doing so, we start with the translational project studying the metab. of the insect juvenile hormone mimic R-20458 [(E)-6,7-epoxy-1-(4-ethylphenoxy)-3,7-dimethyl-2-octene], which led to the identification of the mammalian sEH.  Further investigation of this enzyme and its substrates, including the epoxyeicosatrienoic acids, led to insight into mechanisms of inflammation, chronic and neuropathic pain, angiogenesis, and other physiol. processes.  This basic knowledge in turn led to the development of potent inhibitors of the sEH that are promising therapeutics for pain, hypertension, chronic obstructive pulmonary disorder, arthritis, and other disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnfbbEZsuMs7Vg90H21EOLACvtfcHk0lh5agCNp13DFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1artrs%253D&md5=128ca0de985be1c5e20b75ecd080fc75</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.063339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.063339%26sid%3Dliteratum%253Aachs%26aulast%3DKodani%26aufirst%3DS.%2BD.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DThe%25202014%2520Bernard%2520B.%2520Brodie%2520Award%2520Lecture%2520Epoxide%2520Hydrolases%253A%2520Drug%2520metabolism%2520to%2520therapeutics%2520for%2520chronic%2520pain%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26issue%3D5%26spage%3D788%26epage%3D802%26doi%3D10.1124%2Fdmd.115.063339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S. S.</span>; <span class="NLM_string-name">Hammock, B. D.</span>; <span class="NLM_string-name">Yamamoto, I.</span>; <span class="NLM_string-name">Casida, J. E.</span></span> <span> </span><span class="NLM_article-title">Preliminary Chromatographic Studies on the Metabolites and Photodecomposition Products of the Juvenoid 1-(4′-ethylphenoxy-6,7-epoxy-3,7- dimethyl-2-octene</span>. In  <i>Insect Juvenile Hormones: Chemistry and Action</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menn, J. J.</span>, <span class="NLM_string-name">Beroza, M.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1972</span>; pp  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">189</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2FB978-0-12-490950-2.50013-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1972&pages=177-189&author=S.+S.+Gill&author=B.+D.+Hammock&author=I.+Yamamoto&author=J.+E.+Casidaauthor=J.+J.+Menn&author=M.+Beroza&title=Insect+Juvenile+Hormones%3A+Chemistry+and+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-490950-2.50013-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-490950-2.50013-9%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DS.%2BS.%26atitle%3DPreliminary%2520Chromatographic%2520Studies%2520on%2520the%2520Metabolites%2520and%2520Photodecomposition%2520Products%2520of%2520the%2520Juvenoid%25201-%25284%25E2%2580%25B2-ethylphenoxy-6%252C7-epoxy-3%252C7-%2520dimethyl-2-octene%26btitle%3DInsect%2520Juvenile%2520Hormones%253A%2520Chemistry%2520and%2520Action%26aulast%3DMenn%26aufirst%3DJ.%2BJ.%26pub%3DAcademic%2520Press%26date%3D1972%26spage%3D177%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casida, J. E.</span></span> <span> </span><span class="NLM_article-title">Mammalian metabolism and environmental degradation of the juvenoid 1-(4’- ethylphenoxy)-3,7-dimethyl-6,7-epoxy-trans-2-octene and related compounds</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">386</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1021/jf60193a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf60193a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADyaE2c3lslartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1974&pages=386-395&issue=3&author=S.+S.+Gillauthor=B.+D.+Hammockauthor=J.+E.+Casida&title=Mammalian+metabolism+and+environmental+degradation+of+the+juvenoid+1-%284%E2%80%99-+ethylphenoxy%29-3%2C7-dimethyl-6%2C7-epoxy-trans-2-octene+and+related+compounds&doi=10.1021%2Fjf60193a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian metabolism and environmental degradation of the juvenoid 1-(4'-ethylphenoxy)-3,7-dimethyl-6,7-epoxy-trans-2-octene and related compounds</span></div><div class="casAuthors">Gill S S; Hammock B D; Casida J E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of agricultural and food chemistry</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">386-95</span>
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdeZUfMt0x_tHxxy173TfNfW6udTcc2ebtWSRsAQzC8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2c3lslartw%253D%253D&md5=1ec657a025cad465c8cb128adcc888de</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1021%2Fjf60193a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf60193a058%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DS.%2BS.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DCasida%26aufirst%3DJ.%2BE.%26atitle%3DMammalian%2520metabolism%2520and%2520environmental%2520degradation%2520of%2520the%2520juvenoid%25201-%25284%25E2%2580%2599-%2520ethylphenoxy%2529-3%252C7-dimethyl-6%252C7-epoxy-trans-2-octene%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D1974%26volume%3D22%26issue%3D3%26spage%3D386%26epage%3D395%26doi%3D10.1021%2Fjf60193a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span>; <span class="NLM_string-name">Gill, S. S.</span>; <span class="NLM_string-name">Mumby, S. M.</span>; <span class="NLM_string-name">Ota, K.</span></span> <span> </span><span class="NLM_article-title">Comparison of Epoxide Hydrases in the Soluble and Microsomal Fractions of Mammalian Liver</span>. In:  <i>Molecular Basis of Environmental Toxicity</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, R. S.</span></span>, Eds.; <span class="NLM_publisher-name">Ann Arbor Science Publishers</span>: <span class="NLM_publisher-loc">Ann Arbor, MI</span>, <span class="NLM_year">1980</span>; pp  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">272</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1980&pages=229-272&author=B.+D.+Hammock&author=S.+S.+Gill&author=S.+M.+Mumby&author=K.+Otaauthor=R.+S.+Bhatnagar&title=Molecular+Basis+of+Environmental+Toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DComparison%2520of%2520Epoxide%2520Hydrases%2520in%2520the%2520Soluble%2520and%2520Microsomal%2520Fractions%2520of%2520Mammalian%2520Liver%26btitle%3DMolecular%2520Basis%2520of%2520Environmental%2520Toxicity%26aulast%3DBhatnagar%26aufirst%3DR.%2BS.%26pub%3DAnn%2520Arbor%2520Science%2520Publishers%26date%3D1980%26spage%3D229%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spector, A. A.</span></span> <span> </span><span class="NLM_article-title">Arachidonic acid cytochrome P450 epoxygenase pathway</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">S52</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1194/jlr.R800038-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1194%2Fjlr.R800038-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=18952572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BD1MzltFGjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=S52-56&author=A.+A.+Spector&title=Arachidonic+acid+cytochrome+P450+epoxygenase+pathway&doi=10.1194%2Fjlr.R800038-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Arachidonic acid cytochrome P450 epoxygenase pathway</span></div><div class="casAuthors">Spector Arthur A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of lipid research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50 Suppl</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S52-6</span>
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    </div><div class="casAbstract">Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four epoxyeicosatrienoic acid (EET) regioisomers, 5,6-, 8,9-, 11,12-, and 14,15-EET, that function as autacrine and paracrine mediators.  EETs produce vascular relaxation by activating smooth muscle large-conductance Ca2+-activated K+ channels (BKCa).  In addition, they have anti-inflammatory effects on blood vessels and in the kidney, promote angiogenesis, and protect ischemic myocardium and brain.  CYP epoxygenases also convert eicosapentaenoic acid to vasoactive epoxy-derivatives, and endocannabinoids containing 11,12- and 14,15-EET are formed.  Many EET actions appear to be initiated by EET binding to a membrane receptor that activates ion channels and intracellular signal transduction pathways.  However, EETs also are taken up by cells, are incorporated into phospholipids, and bind to cytosolic proteins and nuclear receptors, suggesting that some functions may occur through direct interaction of the EET with intracellular effector systems.  Soluble epoxide hydrolase (sEH) converts EETs to dihydroxyeicosatrienoic acids (DHETs).  Because this attenuates many of the functional effects of EETs, sEH inhibition is being evaluated as a mechanism for increasing and prolonging the beneficial actions of EETs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRlmbUW5992b5oR8RchjrrfW6udTcc2ebtWSRsAQzC8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzltFGjtg%253D%253D&md5=95173f3b316afa04d960b93b6eb6d3db</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R800038-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R800038-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DSpector%26aufirst%3DA.%2BA.%26atitle%3DArachidonic%2520acid%2520cytochrome%2520P450%2520epoxygenase%2520pathway%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2009%26volume%3D50%26spage%3DS52%26epage%3D56%26doi%3D10.1194%2Fjlr.R800038-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.095920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1146%2Fannurev.pharmtox.45.120403.095920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=15822179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVWjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=311-333&author=C.+Morisseauauthor=B.+D.+Hammock&title=Epoxide+hydrolases%3A+mechanisms%2C+inhibitor+designs%2C+and+biological+roles&doi=10.1146%2Fannurev.pharmtox.45.120403.095920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles</span></div><div class="casAuthors">Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-333, 3 plates</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Organisms are exposed to epoxide-contg. compds. from both exogenous and endogenous sources.  In mammals, the hydration of these compds. by various epoxide hydrolases (EHs) can not only regulate their genotoxicity but also, for lipid-derived epoxides, their endogenous roles as chem. mediators.  Recent findings suggest that the EHs as a family represent novel drug discovery targets for regulation of blood pressure, inflammation, cancer progression, and the onset of several other diseases.  Knowledge of the EH reaction mechanism provides a solid foundation for the rational design of inhibitors, and this review summarizes the current understanding of the catalytic mechanism of EHs.  Although the overall EH reaction mechanism is now known, the mol. basis of substrate selectivity, possible allosteric regulation, and many fine details of the catalytic mechanism remain to be solved.  Finally, recent development in the design of EH inhibitors and the biol. roles of EHs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgu-XChp4zKbVg90H21EOLACvtfcHk0licjhJZQvj9Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVWjt7k%253D&md5=faf96336e9373dd089c5eae29804f1bb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.095920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.095920%26sid%3Dliteratum%253Aachs%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DEpoxide%2520hydrolases%253A%2520mechanisms%252C%2520inhibitor%2520designs%252C%2520and%2520biological%2520roles%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D45%26spage%3D311%26epage%3D333%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.095920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">115735</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bmc.2020.115735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=33007552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVCjsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115735&issue=22&author=K.+S.+S.+Leeauthor=J.+C.+Ngauthor=J.+Yangauthor=S.+H.+Hwangauthor=C.+Morisseauauthor=K.+Wagnerauthor=B.+D.+Hammock&title=Preparation+and+evaluation+of+soluble+epoxide+hydrolase+inhibitors+with+improved+physical+properties+and+potencies+for+treating+diabetic+neuropathic+pain&doi=10.1016%2Fj.bmc.2020.115735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Ng, Jen C.; Yang, Jun; Hwang, Sung-Hee; Morisseau, Christophe; Wagner, Karen; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">115735</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH), a novel therapeutic target for neuropathic pain, is a largely cytosolic enzyme that degrades epoxy-fatty acids (EpFAs), an important class of lipid signaling mols.  Many inhibitors of sEH have been reported, and to date, the 1,3-disubstituted urea has the highest affinity reported for the sEH among the central pharmacophores evaluated.  An earlier somewhat water sol. sEH inhibitor taken to the clinic for blood pressure control had mediocre potency (both affinity and kinetics) and a short in vivo half-life.  We undertook a study to overcome these difficulties, but the sEH inhibitors carrying a 1,3-disubstituted urea often suffer poor phys. properties that hinder their formulation.  In this report, we described new strategies to improve the phys. properties of sEH inhibitors with a 1,3-disubstituted urea while maintaining their potency and drug-target residence time (a complementary in vitro parameter) against sEH.  To our surprise, we identified two structural modifications that substantially improve the potency and phys. properties of sEH inhibitors carrying a 1,3-disubstituted urea pharmacophore.  Such improvements will greatly facilitate the movement of sEH inhibitors to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrX3Srm06vvLVg90H21EOLACvtfcHk0licjhJZQvj9Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVCjsr%252FE&md5=abddbd9b05827074a7b93b3bcd58fde2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115735%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DNg%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DPreparation%2520and%2520evaluation%2520of%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%2520with%2520improved%2520physical%2520properties%2520and%2520potencies%2520for%2520treating%2520diabetic%2520neuropathic%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26issue%3D22%26spage%3D115735%26doi%3D10.1016%2Fj.bmc.2020.115735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beetham, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Molecular and biochemical evidence for the involvement of the Asp333-His523 pair in the catalytic mechanism of soluble epoxide hydrolase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">7968</span>– <span class="NLM_lpage">7974</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.14.7968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1074%2Fjbc.270.14.7968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=7713895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADyaK2MXltVShtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=7968-7974&issue=14&author=F.+Pinotauthor=D.+F.+Grantauthor=J.+K.+Beethamauthor=A.+G.+Parkerauthor=B.+Borhanauthor=S.+Landtauthor=A.+D.+Jonesauthor=B.+D.+Hammock&title=Molecular+and+biochemical+evidence+for+the+involvement+of+the+Asp333-His523+pair+in+the+catalytic+mechanism+of+soluble+epoxide+hydrolase&doi=10.1074%2Fjbc.270.14.7968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and biochemical evidence for the involvement of the Asp-333-His-523 pair in the catalytic mechanism of soluble epoxide hydrolase</span></div><div class="casAuthors">Pinot, Franck; Grant, David F.; Beetham, Jeffrey K.; Parker, Anthony G.; Borhan, Babak; Landt, Steve; Jones, Arthur D.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7968-74</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">To investigate the involvement of amino acids in the catalytic mechanism of the sol. epoxide hydrolase, different mutants of the murine enzyme were produced using the baculovirus expression system.  The results are consistent with the involvement of Asp-333 and His-523 in a catalytic mechanism similar to that of other α/β hydrolase fold enzymes.  Mutation of His-263 to asparagine led to the loss of approx. half the specific activity compared to wild-type enzyme.  When His-332 was replaced by asparagine, 96.7% of the specific activity was lost and mutation of the conserved His-523 to glutamine led to a more dramatic loss of 99.9% of the specific activity.  No activity was detectable after the replacement of Asp-333 by serine.  However, more than 20% of the wild-type activity was retained in an Asp-333 → Asn mutant produced in Spodoptera frugiperda cells.  The authors purified, by affinity chromatog., the wild-type and the Asp-333 → Asn mutant enzymes produced in Trichoplusia ni cells.  The authors labeled these enzymes by incubating them with the epoxide contg. radiolabeled substrate juvenile hormone III (JH III).  The purified Asp-333 → Asn mutant bound 6% of the substrate compared to the wild-type sol. epoxide hydrolase.  The mutant also showed 8% of the specific activity of the wild-type.  Preincubation of the purified Asp-333 → Asn mutant at 37° (pH 8), however, led to a complete recovery of activity and to a change of isoelec. point (pI), both of which are consistent with hydrolysis of Asn-333 to aspartic acid.  This intramol. hydrolysis of asparagine to aspartic acid may explain the activity obsd. in this mutant.  Wild-type enzyme that had been radiolabeled with the substrate was digested with trypsin.  Using reverse phase-high pressure liq. chromatog., the authors isolated four radiolabeled peptides of similar polarity.  These peptides were not radiolabeled if the enzyme was preincubated with a selective competitive inhibitor of sol. epoxide hydrolase 4-fluorochalcone oxide.  This strongly suggested that these peptides contained a catalytic amino acid.  Each peptide was characterized with N-terminal amino acid sequencing and electrospray mass spectrometry.  All four radiolabeled peptides contained overlapping sequences.  The only aspartic acid present in all four peptides and conserved in all epoxide hydrolases was Asp-333.  These peptides resulted from cleavage as different trypsin sites and the mass of each was consistent with the covalent linkage of Asp-333 to the substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr8f5a-BiDnLVg90H21EOLACvtfcHk0licjhJZQvj9Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltVShtLg%253D&md5=037a6bfb1933d5d1c5a744a5ee210db8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.14.7968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.14.7968%26sid%3Dliteratum%253Aachs%26aulast%3DPinot%26aufirst%3DF.%26aulast%3DGrant%26aufirst%3DD.%2BF.%26aulast%3DBeetham%26aufirst%3DJ.%2BK.%26aulast%3DParker%26aufirst%3DA.%2BG.%26aulast%3DBorhan%26aufirst%3DB.%26aulast%3DLandt%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DA.%2BD.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DMolecular%2520and%2520biochemical%2520evidence%2520for%2520the%2520involvement%2520of%2520the%2520Asp333-His523%2520pair%2520in%2520the%2520catalytic%2520mechanism%2520of%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26issue%3D14%26spage%3D7968%26epage%3D7974%26doi%3D10.1074%2Fjbc.270.14.7968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrow, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Potent urea and carbamate inhibitors of soluble epoxide hydrolases</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">8849</span>– <span class="NLM_lpage">8854</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.16.8849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1073%2Fpnas.96.16.8849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10430859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADyaK1MXltVeqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=8849-8854&issue=16&author=C.+Morisseauauthor=M.+H.+Goodrowauthor=D.+Dowdyauthor=J.+Zhengauthor=J.+F.+Greeneauthor=J.+R.+Sanbornauthor=B.+D.+Hammock&title=Potent+urea+and+carbamate+inhibitors+of+soluble+epoxide+hydrolases&doi=10.1073%2Fpnas.96.16.8849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Potent urea and carbamate inhibitors of soluble epoxide hydrolases</span></div><div class="casAuthors">Morisseau, Christophe; Goodrow, Marvin H.; Dowdy, Deanna; Zheng, Jiang; Greene, Jessica F.; Sanborn, James R.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8849-8854</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The sol. epoxide hydrolase (sEH) plays a significant role in the biosynthesis of inflammation mediators as well as xenobiotic transformations.  Herein, the authors report the discovery of substituted ureas and carbamates as potent inhibitors of sEH.  Some of these selective, competitive tight-binding inhibitors with nanomolar Ki values interacted stoichiometrically with the homogeneous recombinant murine and human sEHs.  These inhibitors enhance cytotoxicity of trans-stilbene oxide, which is active as the epoxide, but reduce cytotoxicity of leukotoxin, which is activated by epoxide hydrolase to its toxic diol.  They also reduce toxicity of leukotoxin in vivo in mice and prevent symptoms suggestive of acute respiratory distress syndrome.  These potent inhibitors may be valuable tools for testing hypotheses of involvement of diol and epoxide lipids in chem. mediation in vitro or in vivo systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobOIwuI01SYLVg90H21EOLACvtfcHk0licjhJZQvj9Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVeqsL8%253D&md5=eeff85f27c1a33e2da6fb7f8f2ae91de</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.16.8849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.16.8849%26sid%3Dliteratum%253Aachs%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DGoodrow%26aufirst%3DM.%2BH.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DGreene%26aufirst%3DJ.%2BF.%26aulast%3DSanborn%26aufirst%3DJ.%2BR.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DPotent%2520urea%2520and%2520carbamate%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26issue%3D16%26spage%3D8849%26epage%3D8854%26doi%3D10.1073%2Fpnas.96.16.8849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olearczyk, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imig, J. D.</span></span> <span> </span><span class="NLM_article-title">Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>318</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1307</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.103556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1124%2Fjpet.106.103556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=16772540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XovFygtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2006&pages=1307-1314&issue=3&author=J.+J.+Olearczykauthor=M.+B.+Fieldauthor=I.-H.+Kimauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=J.+D.+Imig&title=Substituted+adamantyl-urea+inhibitors+of+the+soluble+epoxide+hydrolase+dilate+mesenteric+resistance+vessels&doi=10.1124%2Fjpet.106.103556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels</span></div><div class="casAuthors">Olearczyk, Jeffrey J.; Field, Mary B.; Kim, In-Hae; Morisseau, Christophe; Hammock, Bruce D.; Imig, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1307-1314</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The epoxyeicosatrienoic acids (EETs) have been identified as endothelium-derived hyperpolarizing factors.  Metab. of the EETs to the dihydroxyeicosatrienoic acids is catalyzed by sol. epoxide hydrolase (sEH).  Administration of urea-based sEH inhibitors provides protection from hypertension-induced renal injury at least in part by lowering blood pressure.  Here, we investigated the hypothesis that a mechanism by which sEH inhibitors elicit their cardiovascular protective effects is via their action on the vasculature.  Mesenteric resistance arteries were isolated from Sprague-Dawley rats, pressurized, and constricted with the thromboxane A2 agonist U46619 (9,11-dideoxy-11,9-epoxymethano-prostaglandin F2α).  Mesenteric arteries were then incubated with increasing concns. of the sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA).  AUDA resulted in a concn.-dependent relaxation of mesenteric arteries, with 10 μM resulting in a 48±7% relaxation.  Chain-shortened analogs of AUDA had an attenuated vasodilatory response.  Interestingly, at 10 μM, the sEH inhibitors 1-cyclohexyl-3-dodecylurea, 12-(3-cyclohexyl-ureido)dodecanoic acid, and 950 [adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea] were significantly less active, resulting in a 25±8%, 10±9%, and -8±3% relaxation, resp.  Treatment of mesenteric arteries with tetraethyl-ammonium, iberiotoxin, ouabain, or glibenclamide did not alter AUDA-induced relaxation.  The AUDA-induced relaxation was completely inhibited when constricted with KCl.  In sep. expts., denuding mesenteric resistance vessels did not alter AUDA-induced relaxation.  Taken together, these data demonstrate that adamantyl-urea inhibitors have unique dilator actions on vascular smooth muscle compared with other sEH inhibitors and that these dilator actions depend on the adamantyl group and carbon chain length.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8pVo1uopB3rVg90H21EOLACvtfcHk0ljclq6rle4ifg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovFygtL4%253D&md5=27971d1365be872385e45ea04d3cb3ec</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.103556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.103556%26sid%3Dliteratum%253Aachs%26aulast%3DOlearczyk%26aufirst%3DJ.%2BJ.%26aulast%3DField%26aufirst%3DM.%2BB.%26aulast%3DKim%26aufirst%3DI.-H.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DImig%26aufirst%3DJ.%2BD.%26atitle%3DSubstituted%2520adamantyl-urea%2520inhibitors%2520of%2520the%2520soluble%2520epoxide%2520hydrolase%2520dilate%2520mesenteric%2520resistance%2520vessels%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D318%26issue%3D3%26spage%3D1307%26epage%3D1314%26doi%3D10.1124%2Fjpet.106.103556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lango, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bcp.2015.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=26494425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2015&pages=718-731&issue=4&author=J.+Y.+Liuauthor=H.+J.+Tsaiauthor=C.+Morisseauauthor=J.+Langoauthor=S.+H.+Hwangauthor=T.+Watanabeauthor=I.+H.+Kimauthor=B.+D.+Hammock&title=In+vitro+and+in+vivo+metabolism+of+N-adamantyl+substituted+urea-based+soluble+epoxide+hydrolase+inhibitors&doi=10.1016%2Fj.bcp.2015.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors</span></div><div class="casAuthors">Liu, Jun-Yan; Tsai, Hsing-Ju; Morisseau, Christophe; Lango, Jozsef; Hwang, Sung Hee; Watanabe, Takaho; Kim, In-Hae; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">718-731</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N,N'-disubstituted urea-based sol. epoxide hydrolase (sEH) inhibitors are promising therapeutics for hypertension, inflammation, and pain in multiple animal models.  The drug absorption and pharmacol. efficacy of these inhibitors have been reported extensively.  However, the drug metab. of these inhibitors is not well described.  Here we reported the metabolic profile and assocd. biochem. studies of an N-adamantyl urea-based sEH inhibitor 1-adamantan-1-yl-3-(5-(2-(2-ethoxyethoxy)ethoxy)pentyl)urea (AEPU) in vitro and in vivo.  The metabolites of AEPU were identified by interpretation of liq. chromatog.-mass spectrometry (LC-MS), liq. chromatog.-tandem mass spectrometry (LC-MS/MS) and/or NMR.  In vitro, AEPU had three major positions for phase I metab. including oxidns. on the adamantyl moiety, urea nitrogen atoms, and cleavage of the polyethylene glycol chain.  In a rodent model, the metabolites from the hydroxylation on the adamantyl group and nitrogen atom were existed in blood while the metabolites from cleavage of polyethylene glycol chain were not found in urine.  The major metabolite found in rodent urine was 3-(3-adamantyl-ureido)-propanoic acid, a presumably from cleavage and oxidn. of the polyethylene glycol moiety.  All the metabolites found were active but less potent than AEPU at inhibiting human sEH.  Furthermore, cytochrome P 450 (CYP) 3A4 was found to be a major enzyme mediating AEPU metab.  In conclusion, the metab. of AEPU resulted from oxidn. by CYP could be shared with other N-adamantyl-urea-based compds.  These findings suggest possible therapeutic roles for AEPU and new strategies for drug design in this series of possible drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoamH_ZDSrfurVg90H21EOLACvtfcHk0ljclq6rle4ifg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb7M&md5=dd67c79fac41ef5bfb3bc1c3b494c266</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DTsai%26aufirst%3DH.%2BJ.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLango%26aufirst%3DJ.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DI.%2BH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520metabolism%2520of%2520N-adamantyl%2520substituted%2520urea-based%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D98%26issue%3D4%26spage%3D718%26epage%3D731%26doi%3D10.1016%2Fj.bcp.2015.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imig, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdevila, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1161/hy0202.103788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1161%2Fhy0202.103788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=11882632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD38Xhs1WqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2002&pages=690-694&issue=2&author=J.+D.+Imigauthor=X.+Zhaoauthor=J.+H.+Capdevilaauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+inhibition+lowers+arterial+blood+pressure+in+angiotensin+II+hypertension&doi=10.1161%2Fhy0202.103788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension</span></div><div class="casAuthors">Imig, John D.; Zhao, Xueying; Capdevila, Jorge H.; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">690-694</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Epoxyeicosatrienoic acids (EETs) have antihypertensive properties and play a part in the maintenance of renal microvascular function.  A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conversion of biol. active EETs to dihydroxyeicosatrienoic acids (DHETs) that are void of effects on the preglomerular vasculature.  We hypothesized that inhibition of sol. epoxide hydrolase (sEH) would lower blood pressure in angiotensin II (Ang II) hypertension.  Rat renal cortical tissue was harvested and urine collected 2 wk following implantation of an osmotic minipump contg. Ang II (60 ng/min).  Renal cortical sEH protein expression was significantly higher in Ang II hypertension compared with normotensive animals.  Likewise, urinary 14,15-DHET levels were significantly increased in hypertensive compared with normotensive animals and averaged 8.1±1.3 and 2.7±1.1 ng/d; resp.  In addnl. expts., the sEH inhibitor N-cyclohexyl-N-dodecyl urea (NCND; 3 mg/d) or vehicle (corn oil, 0.5 mL) was administered daily by i.p. injection starting on day 10.  Administration of NCND for 4 days lowered systolic blood pressure by 30 mm Hg in Ang II hypertensive animals, whereas the corn oil vehicle had no effect on blood pressure in normotensive or Ang II hypertensive animals.  Measurement of blood pressure by indwelling arterial catheters in conscious animals with free movement in their cages confirmed that NCND had antihypertensive properties.  Arterial blood pressure averaged 119±5 mm Hg in normotensive, 170±3 mm Hg in hypertensive and 149±10 mm Hg in NCND-treated, Ang II-infused animals.  Administration of the potential metabolite of NCND, N-cyclohexylformamide to Ang II hypertensive rats did not lower the systolic blood pressure.  These studies demonstrate that increased sEH expression in the Ang II hypertensive kidney leads to increased EET hydration.  Moreover, sEH plays a role in the regulation of blood pressure, and inhibition of sEH during Ang II hypertension is antihypertensive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou360SDFrqPrVg90H21EOLACvtfcHk0liKa65HkQgrGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xhs1WqurY%253D&md5=859488f03618128f22a259863526f658</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1161%2Fhy0202.103788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fhy0202.103788%26sid%3Dliteratum%253Aachs%26aulast%3DImig%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DCapdevila%26aufirst%3DJ.%2BH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520inhibition%2520lowers%2520arterial%2520blood%2520pressure%2520in%2520angiotensin%2520II%2520hypertension%26jtitle%3DHypertension%26date%3D2002%26volume%3D39%26issue%3D2%26spage%3D690%26epage%3D694%26doi%3D10.1161%2Fhy0202.103788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis</span>. <i>Anal. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.aca.2005.11.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.aca.2005.11.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=16636700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFyhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2006&pages=37-44&author=T.+Watanabeauthor=D.+Schulzauthor=C.+Morisseauauthor=B.+D.+Hammock&title=High-throughput+pharmacokinetic+method%3A+cassette+dosing+in+mice+associated+with+minuscule+serial+bleedings+and+LC%2FMS%2FMS+analysis&doi=10.1016%2Fj.aca.2005.11.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis</span></div><div class="casAuthors">Watanabe, Takaho; Schulz, Daniela; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Analytica Chimica Acta</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-44</span>CODEN:
                <span class="NLM_cas:coden">ACACAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2670</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A method for pharmacokinetic studies using cassette dosing assocd. with serial bleeding in mice is described.  PK profiles of four sol. epoxide hydrolase inhibitors were detd. following oral, s.c. or i.p. administration individually or in cassette dosing.  Parent analyses were performed on only 5 μL of whole blood from serial bleeds (up to 10 per animal), by LC/MS/MS.  An accuracy (88-100%) and precision (<10% RSD) were obsd., leading to reliable datum points for PK calcn.  PK profiles, T max, C max and half-life values after cassette dosing were si similar to the individual PK results.  This method dramatically increases speed of data collection while dramatically reducing cost and animal usage.  The results presented here clearly indicate that this proposed method could be applicable to high-throughput PK studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEleltRqF1pbVg90H21EOLACvtfcHk0liKa65HkQgrGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFyhsrw%253D&md5=af8f278fc2c7de69a655416067a99437</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.aca.2005.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.aca.2005.11.049%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DSchulz%26aufirst%3DD.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DHigh-throughput%2520pharmacokinetic%2520method%253A%2520cassette%2520dosing%2520in%2520mice%2520associated%2520with%2520minuscule%2520serial%2520bleedings%2520and%2520LC%252FMS%252FMS%2520analysis%26jtitle%3DAnal.%2520Chim.%2520Acta%26date%3D2006%26volume%3D559%26spage%3D37%26epage%3D44%26doi%3D10.1016%2Fj.aca.2005.11.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2110</span>– <span class="NLM_lpage">2122</span>, <span class="refDoi"> DOI: 10.1021/jm030514j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030514j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2qtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2110-2122&author=I.+Kimauthor=C.+Morisseauauthor=T.+Watanabeauthor=B.+D.+Hammock&title=Design%2C+synthesis%2C+and+biological+activity+of+1%2C3-disubstituted+ureas+as+potent+inhibitors+of+the+soluble+epoxide+hydrolase+of+increased+water+solubility&doi=10.1021%2Fjm030514j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Activity of 1,3-Disubstituted Ureas as Potent Inhibitors of the Soluble Epoxide Hydrolase of Increased Water Solubility</span></div><div class="casAuthors">Kim, In-Hae; Morisseau, Christophe; Watanabe, Takaho; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2110-2122</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The sol. epoxide hydrolase (sEH) is involved in the metab. of endogenous chem. mediators that play an important role in blood pressure regulation and inflammation.  1,3-Disubstituted ureas are potent inhibitors of sEH that are active both in vitro and in vivo.  However, their poor soly. in either water or lipid reduces their in vivo efficacy and makes them difficult to formulate.  To improve these phys. properties, the effect of incorporating polar functional groups into one of the alkyl chains was evaluated on their inhibitor potencies, water soly., octanol/water partition coeffs. (log P), and m.ps.  No loss of inhibition potency was obsd. when a polar functional group was incorporated at least five atoms (∼7.5 Å) from the central urea carbonyl.  In addn., the presence of a polar group at least 11 atoms away from the urea carbonyl group for the mouse and human sEHs, resp., did not alter the inhibitor potency.  The resulting compds. have better water soly. and generally lower log P values and m.ps. than nonfunctionalized lipophilic ureas.  These properties will make the compds. more bioavailable and more sol. in either water- or oil-based formulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMDG4_y35pKLVg90H21EOLACvtfcHk0liKa65HkQgrGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2qtrs%253D&md5=d80753310c34a3374ad7e6c61e721e19</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm030514j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030514j%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activity%2520of%25201%252C3-disubstituted%2520ureas%2520as%2520potent%2520inhibitors%2520of%2520the%2520soluble%2520epoxide%2520hydrolase%2520of%2520increased%2520water%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2110%26epage%3D2122%26doi%3D10.1021%2Fjm030514j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1021/jm201468j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201468j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ajtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1789-1808&issue=5&author=H.+Shenauthor=B.+D.+Hammock&title=Discovery+of+inhibitors+of+soluble+epoxide+hydrolase%3A+a+target+with+multiple+potential+therapeutic+indications&doi=10.1021%2Fjm201468j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications</span></div><div class="casAuthors">Shen, Hong C.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1789-1808</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The inhibition of sol. epoxide hydrolase (sEH) by small mols. has been shown to increase the levels of fatty acid epoxides such as epoxyeicosatrienoic acids (EETs), and decrease the levels of the corresponding fatty acid diols including dihydroxyeicosatrienoic acids (DHETs).  Due to numerous beneficial effects of EETs, the elevation of their levels, as a result of sEH inhibition, may eventually lead to new therapeutic approaches for multiple diseases.  Specifically, it has been shown, largely in rodent models, that sEH inhibitors can be used to treat heart failure, hypertension, diabetes, stroke, dyslipidemia, inflammatory and neuropathic pain, immunol. disorders, eye diseases, neurol. diseases, and other indications.  Medicinal chem. strategies, key biol. data of benchmark compds., and possible paths for sEH inhibitors to reach the clinic will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBjFZ7QGkOVbVg90H21EOLACvtfcHk0liKa65HkQgrGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ajtrzK&md5=1a2ba726f26b7e207df467f67685cf2d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm201468j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201468j%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%253A%2520a%2520target%2520with%2520multiple%2520potential%2520therapeutic%2520indications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D5%26spage%3D1789%26epage%3D1808%26doi%3D10.1021%2Fjm201468j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Podolin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognese, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, E.,  3rd.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umbrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweitzer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galop, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyanskaya, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israel, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurali, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnette, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth-Genthe, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, J. F.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor</span>. <i>Prostaglandins Other Lipid Mediators</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104–105</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.prostaglandins.2013.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.prostaglandins.2013.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23434473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFCgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104%E2%80%93105&publication_year=2013&pages=25-31&author=P.+L.+Podolinauthor=B.+J.+Bologneseauthor=J.+F.+Foleyauthor=E.+Longauthor=B.+Peckauthor=S.+Umbrechtauthor=X.+Zhangauthor=P.+Zhuauthor=B.+Schwartzauthor=W.+Xieauthor=C.+Quinnauthor=H.+Qiauthor=S.+Sweitzerauthor=S.+Chenauthor=M.+Galopauthor=Y.+Dingauthor=S.+L.+Belyanskayaauthor=D.+I.+Israelauthor=B.+A.+Morganauthor=D.+J.+Behmauthor=J.+P.+Marinoauthor=E.+Kuraliauthor=M.+S.+Barnetteauthor=R.+J.+Mayerauthor=C.+L.+Booth-Gentheauthor=J.+F.+Callahan&title=In+vitro+and+in+vivo+characterization+of+a+novel+soluble+epoxide+hydrolase+inhibitor&doi=10.1016%2Fj.prostaglandins.2013.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor</span></div><div class="casAuthors">Podolin, Patricia L.; Bolognese, Brian J.; Foley, Joseph F.; Long, Edward; Peck, Brian; Umbrecht, Sandra; Zhang, Xiaojun; Zhu, Penny; Schwartz, Benjamin; Xie, Wensheng; Quinn, Chad; Qi, Hongwei; Sweitzer, Sharon; Chen, Stephanie; Galop, Marc; Ding, Yun; Belyanskaya, Svetlana L.; Israel, David I.; Morgan, Barry A.; Behm, David J.; Marino, Joseph P.; Kurali, Edit; Barnette, Mary S.; Mayer, Ruth J.; Booth-Genthe, Catherine L.; Callahan, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Prostaglandins and Other Lipid Mediators</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104-105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25-31</span>CODEN:
                <span class="NLM_cas:coden">POLMFL</span>;
        ISSN:<span class="NLM_cas:issn">1098-8823</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH, EPHX2) metabolizes eicosanoid epoxides, including epoxyeicosatrienoic acids (EETs) to the corresponding dihydroxyeicosatrienoic acids (DHETs), and leukotoxin (LTX) to leukotoxin diol (LTX diol).  EETs, endothelium-derived hyperpolarizing factors, exhibit potentially beneficial properties, including anti-inflammatory effects and vasodilation.  A novel, potent, selective inhibitor of recombinant human, rat and mouse sEH, GSK2256294A, exhibited potent cell-based activity, a concn.-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET in human, rat and mouse whole blood in vitro, and a dose-dependent increase in the LTX/LTX diol ratio in rat plasma following oral administration.  Mice receiving 10 days of cigarette smoke exposure concomitant with oral administration of GSK2256294A exhibited significant, dose-dependent redns. in pulmonary leukocytes and keratinocyte chemoattractant (KC, CXCL1) levels.  Mice receiving oral administration of GSK2256294A following 10 days of cigarette smoke exposure exhibited significant redns. in pulmonary leukocytes compared to vehicle-treated mice.  These data indicate that GSK2256294A attenuates cigarette smoke-induced inflammation by both inhibiting its initiation and/or maintenance and promoting its resoln.  Collectively, these data indicate that GSK2256294A would be an appropriate agent to evaluate the role of sEH in clin. studies, for example in diseases where cigarette smoke is a risk factor, such as chronic obstructive pulmonary disease (COPD) and cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXL0W8Yob67Vg90H21EOLACvtfcHk0lhMIlDS0_gshQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFCgu7s%253D&md5=e7842bc2d88795ef4a7fae1b0988454b</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2Fj.prostaglandins.2013.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prostaglandins.2013.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DPodolin%26aufirst%3DP.%2BL.%26aulast%3DBolognese%26aufirst%3DB.%2BJ.%26aulast%3DFoley%26aufirst%3DJ.%2BF.%26aulast%3DLong%26aufirst%3DE.%26aulast%3DPeck%26aufirst%3DB.%26aulast%3DUmbrecht%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DSweitzer%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGalop%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DBelyanskaya%26aufirst%3DS.%2BL.%26aulast%3DIsrael%26aufirst%3DD.%2BI.%26aulast%3DMorgan%26aufirst%3DB.%2BA.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DKurali%26aufirst%3DE.%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26aulast%3DMayer%26aufirst%3DR.%2BJ.%26aulast%3DBooth-Genthe%26aufirst%3DC.%2BL.%26aulast%3DCallahan%26aufirst%3DJ.%2BF.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520a%2520novel%2520soluble%2520epoxide%2520hydrolase%2520inhibitor%26jtitle%3DProstaglandins%2520Other%2520Lipid%2520Mediators%26date%3D2013%26volume%3D104%25E2%2580%2593105%26spage%3D25%26epage%3D31%26doi%3D10.1016%2Fj.prostaglandins.2013.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boardley, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newby, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">cheriyan, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.1111/bcp.12855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1111%2Fbcp.12855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=26620151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtF2ls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=971-979&author=A.+L.+Lazaarauthor=L.+Yangauthor=R.+L.+Boardleyauthor=N.+S.+Goyalauthor=J.+Robertsonauthor=S.+J.+Baldwinauthor=D.+E.+Newbyauthor=I.+B.+Wilkinsonauthor=R.+Tal-Singerauthor=R.+J.+Mayerauthor=J.+cheriyan&title=Pharmacokinetics%2C+pharmacodynamics+and+adverse+event+profile+of+GSK2256294%2C+a+novel+soluble+epoxide+hydrolase+inhibitor&doi=10.1111%2Fbcp.12855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor</span></div><div class="casAuthors">Lazaar, Aili L.; Yang, Lucy; Boardley, Rebecca L.; Goyal, Navin S.; Robertson, Jonathan; Baldwin, Sandra J.; Newby, David E.; Wilkinson, Ian B.; Tal-Singer, Ruth; Mayer, Ruth J.; Cheriyan, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">971-979</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Endothelial-derived epoxyeicosatrienoic acids may regulate vascular tone and are metabolized by sol. epoxide hydrolase enzymes (sEH).  GSK2256294 is a potent and selective sEH inhibitor that was tested in two phase I studies.  Single escalating doses of GSK2256294 2-20 mg or placebo were administered in a randomized crossover design to healthy male subjects or obese smokers.  Once daily doses of 6 or 18 mg or placebo were administered for 14 days to obese smokers.  Data were collected on safety, pharmacokinetics, sEH enzyme inhibition and blood biomarkers.  Single doses of GSK2256294 10 mg were also administered to healthy younger males or healthy elderly males and females with and without food.  Data on safety, pharmacokinetics and biliary metabolites were collected.  Results : GSK2256294 was well-tolerated with no serious adverse events (AEs) attributable to the drug.  The most frequent AEs were headache and contact dermatitis.  Plasma concns. of GSK2256294 increased with single doses, with a half-life averaging 25-43 h.  There was no significant effect of age, food or gender on pharmacokinetic parameters.  Inhibition of sEH enzyme activity was dose-dependent, from an av. of 41.9% on 2 mg (95% confidence interval [CI] -51.8, 77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 h.  There were no significant changes in serum VEGF or plasma fibrinogen.  GSK2256294 was well-tolerated and demonstrated sustained inhibition of sEH enzyme activity.  These data support further investigation in patients with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr37PHmVvZ8A7Vg90H21EOLACvtfcHk0lhMIlDS0_gshQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtF2ls7w%253D&md5=085db35368f6acb60aef7aa05d4aaa1c</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12855%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBoardley%26aufirst%3DR.%2BL.%26aulast%3DGoyal%26aufirst%3DN.%2BS.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DBaldwin%26aufirst%3DS.%2BJ.%26aulast%3DNewby%26aufirst%3DD.%2BE.%26aulast%3DWilkinson%26aufirst%3DI.%2BB.%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DMayer%26aufirst%3DR.%2BJ.%26aulast%3Dcheriyan%26aufirst%3DJ.%26atitle%3DPharmacokinetics%252C%2520pharmacodynamics%2520and%2520adverse%2520event%2520profile%2520of%2520GSK2256294%252C%2520a%2520novel%2520soluble%2520epoxide%2520hydrolase%2520inhibitor%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D81%26spage%3D971%26epage%3D979%26doi%3D10.1111%2Fbcp.12855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5212</span>– <span class="NLM_lpage">5216</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bmcl.2006.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=16870439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XoslCnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5212-5216&author=P.+D.+Jonesauthor=H.-J.+Tsaiauthor=Z.+N.+Doauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Synthesis+and+SAR+of+conformationally+restricted+inhibitors+of+soluble+epoxide+hydrolase&doi=10.1016%2Fj.bmcl.2006.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase</span></div><div class="casAuthors">Jones, Paul D.; Tsai, Hsing-Ju; Do, Zung N.; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5212-5216</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of conformationally restricted inhibitors of human sol. epoxide hydrolase (sEH) was synthesized.  Inhibition potency of the described compds. was studied against recombinant sEH.  N-(1-Acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea (I) was found to be a potent inhibitor that was also orally bioavailable in canines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI-6I7WMkpm7Vg90H21EOLACvtfcHk0lgywpJl2nq63w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XoslCnur0%253D&md5=d18b1510f26ea62837a63e93556d20a0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BD.%26aulast%3DTsai%26aufirst%3DH.-J.%26aulast%3DDo%26aufirst%3DZ.%2BN.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520conformationally%2520restricted%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5212%26epage%3D5216%26doi%3D10.1016%2Fj.bmcl.2006.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Orally bioavailable potent soluble epoxide hydrolase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3825</span>– <span class="NLM_lpage">3840</span>, <span class="refDoi"> DOI: 10.1021/jm070270t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070270t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2sXns1Cksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3825-3840&issue=16&author=S.+H.+Hwangauthor=H.+J.+Tsaiauthor=J.-Y.+Liuauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Orally+bioavailable+potent+soluble+epoxide+hydrolase+inhibitors&doi=10.1021%2Fjm070270t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Bioavailable Potent Soluble Epoxide Hydrolase Inhibitors</span></div><div class="casAuthors">Hwang, Sung Hee; Tsai, Hsing-Ju; Liu, Jun-Yan; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3825-3840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N,N'-disubstituted ureas having a conformationally restricted cis- or trans-1,4-cyclohexane α to the urea were prepd. and tested as sol. epoxide hydrolase (sEH) inhibitors.  This series of compds. showed low nanomolar to picomolar activities against recombinant human sEH.  Both isomers showed similar potencies, but the trans isomers were more metabolically stable in human hepatic microsomes.  Furthermore, these new potent inhibitors show a greater metabolic stability in vivo than previously described sEH inhibitors.  Trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid (I, t-AUCB, IC50 = 1.3 ± 0.05 nM) had excellent oral bioavailability (98%, n = 2) and blood area under the curve in dogs and was effective in vivo to treat hypotension in lipopolysaccharide challenged murine models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVS4Wx8hrt_bVg90H21EOLACvtfcHk0lgywpJl2nq63w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXns1Cksbg%253D&md5=ad2116c2671dc36d35b44ff93d55863d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm070270t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070270t%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DTsai%26aufirst%3DH.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.-Y.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DOrally%2520bioavailable%2520potent%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D16%26spage%3D3825%26epage%3D3840%26doi%3D10.1021%2Fjm070270t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rose, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure – activity relationships, pharmacokinetics, and reduction of inflammatory pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7067</span>– <span class="NLM_lpage">7075</span>, <span class="refDoi"> DOI: 10.1021/jm100691c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100691c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWlsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7067-7075&issue=19&author=T.+E.+Roseauthor=C.+Morisseauauthor=J.-Y.+Liuauthor=B.+Inceogluauthor=P.+D.+Jonesauthor=J.+R.+Sanbornauthor=B.+D.+Hammock&title=1-Aryl-3-%281-acylpiperidin-4-yl%29urea+inhibitors+of+human+and+murine+soluble+epoxide+hydrolase%3A+structure+%E2%80%93+activity+relationships%2C+pharmacokinetics%2C+and+reduction+of+inflammatory+pain&doi=10.1021%2Fjm100691c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">1-Aryl-3-(1-acylpiperidin-4-yl)urea Inhibitors of Human and Murine Soluble Epoxide Hydrolase: Structure-Activity Relationships, Pharmacokinetics, and Reduction of Inflammatory Pain</span></div><div class="casAuthors">Rose, Tristan E.; Morisseau, Christophe; Liu, Jun-Yan; Inceoglu, Bora; Jones, Paul D.; Sanborn, James R.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7067-7075</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine sol. epoxide hydrolase (sEH).  Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors.  For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea showed a 7-fold increase in potency, a 65-fold increase in Cmax, and a 3300-fold increase in AUC over its adamantane analog 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea.  This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mech. withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokUmpG9nURobVg90H21EOLACvtfcHk0lgywpJl2nq63w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWlsb%252FL&md5=bc2b151553d732942c1ac7e2e963d524</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm100691c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100691c%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DT.%2BE.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.-Y.%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DP.%2BD.%26aulast%3DSanborn%26aufirst%3DJ.%2BR.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3D1-Aryl-3-%25281-acylpiperidin-4-yl%2529urea%2520inhibitors%2520of%2520human%2520and%2520murine%2520soluble%2520epoxide%2520hydrolase%253A%2520structure%2520%25E2%2580%2593%2520activity%2520relationships%252C%2520pharmacokinetics%252C%2520and%2520reduction%2520of%2520inflammatory%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D19%26spage%3D7067%26epage%3D7075%26doi%3D10.1021%2Fjm100691c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anandan, S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aavula, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cases, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincelette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszczuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitcomb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gless, R.</span></span> <span> </span><span class="NLM_article-title">1-(1-Acethyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bmcl.2010.12.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=21211973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=983-988&issue=3&author=S.-K.+Anandanauthor=H.+K.+Webbauthor=D.+Chenauthor=Y.-X.+J.+Wangauthor=B.+R.+Aavulaauthor=S.+Casesauthor=Y.+Chengauthor=Z.+N.+Doauthor=U.+Mehraauthor=V.+Tranauthor=J.+Vinceletteauthor=J.+Waszczukauthor=K.+Whiteauthor=K.+R.+Wongauthor=L.-N.+Zhangauthor=P.+D.+Jonesauthor=B.+D.+Hammockauthor=D.+V.+Patelauthor=R.+Whitcombauthor=D.+E.+MacIntyreauthor=J.+Sabryauthor=R.+Gless&title=1-%281-Acethyl-piperidin-4-yl%29-3-adamantan-1-yl-urea+%28AR9281%29+as+a+potent%2C+selective%2C+and+orally+available+soluble+epoxide+hydrolase+inhibitor+with+efficacy+in+rodent+models+of+hypertension+and+dysglycemia&doi=10.1016%2Fj.bmcl.2010.12.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia</span></div><div class="casAuthors">Anandan, Sampath-Kumar; Webb, Heather Kay; Chen, Dawn; Wang, Yi-Xin; Aavula, Basker R.; Cases, Sylvaine; Cheng, Ying; Do, Zung N.; Mehra, Upasana; Tran, Vinh; Vincelette, Jon; Waszczuk, Joanna; White, Kathy; Wong, Kenneth R.; Zhang, Le-Ning; Jones, Paul D.; Hammock, Bruce D.; Patel, Dinesh V.; Whitcomb, Randall; MacIntyre, D. Euan; Sabry, James; Gless, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">983-988</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective sol. epoxide hydrolase inhibitor, was recently tested in a phase 2a clin. setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients.  In a mouse model of diet induced obesity, AR9281 attenuated the enhanced glucose excursion following an i.p. glucose tolerance test.  AR9281 also attenuated the increase in blood pressure in angiotensin-II-induced hypertension in rats.  These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the obsd. pharmacol. in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1h613kO4ASLVg90H21EOLACvtfcHk0lhvtuE29CVkiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVSjsA%253D%253D&md5=6731b9816864dcb005436896b526e8a1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.042%26sid%3Dliteratum%253Aachs%26aulast%3DAnandan%26aufirst%3DS.-K.%26aulast%3DWebb%26aufirst%3DH.%2BK.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.-X.%2BJ.%26aulast%3DAavula%26aufirst%3DB.%2BR.%26aulast%3DCases%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DDo%26aufirst%3DZ.%2BN.%26aulast%3DMehra%26aufirst%3DU.%26aulast%3DTran%26aufirst%3DV.%26aulast%3DVincelette%26aufirst%3DJ.%26aulast%3DWaszczuk%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DK.%2BR.%26aulast%3DZhang%26aufirst%3DL.-N.%26aulast%3DJones%26aufirst%3DP.%2BD.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DPatel%26aufirst%3DD.%2BV.%26aulast%3DWhitcomb%26aufirst%3DR.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DSabry%26aufirst%3DJ.%26aulast%3DGless%26aufirst%3DR.%26atitle%3D1-%25281-Acethyl-piperidin-4-yl%2529-3-adamantan-1-yl-urea%2520%2528AR9281%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520soluble%2520epoxide%2520hydrolase%2520inhibitor%2520with%2520efficacy%2520in%2520rodent%2520models%2520of%2520hypertension%2520and%2520dysglycemia%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D3%26spage%3D983%26epage%3D988%26doi%3D10.1016%2Fj.bmcl.2010.12.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakhomova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mara, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomer, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeldin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7016</span>– <span class="NLM_lpage">7030</span>, <span class="refDoi"> DOI: 10.1021/jm500694p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500694p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7016-7030&issue=16&author=K.+S.+S.+Leeauthor=J.-Y.+Liuauthor=K.+M.+Wagnerauthor=S.+Pakhomovaauthor=H.+Dongauthor=C.+Morisseauauthor=S.+H.+Fuauthor=J.+Yangauthor=P.+Wangauthor=A.+Uluauthor=C.+A.+Mateauthor=L.+V.+Nguyenauthor=S.+H.+Hwangauthor=M.+L.+Edinauthor=A.+A.+Maraauthor=H.+Wulffauthor=M.+E.+Newcomerauthor=D.+C.+Zeldinauthor=B.+D.+Hammock&title=Optimized+inhibitors+of+soluble+epoxide+hydrolase+improve+in+vitro+target+residence+time+and+in+vivo+efficacy&doi=10.1021%2Fjm500694p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Liu, Jun-Yan; Wagner, Karen M.; Pakhomova, Svetlana; Dong, Hua; Morisseau, Christophe; Fu, Samuel H.; Yang, Jun; Wang, Peng; Ulu, Arzu; Mate, Christina A.; Nguyen, Long V.; Hwang, Sung Hee; Edin, Matthew L.; Mara, Alexandria A.; Wulff, Heike; Newcomer, Marcia E.; Zeldin, Darryl C.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7016-7030</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diabetes is affecting the life of millions of people.  A large proportion of diabetic patients suffer from severe complications such as neuropathic pain, and current treatments for these complications have deleterious side effects.  Thus, alternate therapeutic strategies are needed.  Recently, the elevation of epoxy-fatty acids through inhibition of sol. epoxide hydrolase (sEH) was shown to reduce diabetic neuropathic pain in rodents.  In this report, the authors describe a series of newly synthesized sEH inhibitors I [R1 = 4-CF3C6H4, 4-CF3OC6H4; (CF3)2CFC6H4, etc.; R2 = MeCO, MeCH2CO, MeCH2CH2CO, etc.] with at least 5-fold higher potency and doubled residence time inside both the human and rodent sEH enzyme than previously reported inhibitors.  These inhibitors also have better phys. properties and optimized pharmacokinetic profiles.  The optimized inhibitor selected from this new series displayed improved efficacy of almost 10-fold in relieving pain perception in diabetic neuropathic rats as compared to the approved drug, gabapentin, and previously published sEH inhibitors.  Therefore, these new sEH inhibitors could be an attractive alternative to treat diabetic neuropathy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_j6x9O0dsd7Vg90H21EOLACvtfcHk0ljCxWGziJxeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77K&md5=1f57ad6909389ac8d101fb548b64c2e2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm500694p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500694p%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DLiu%26aufirst%3DJ.-Y.%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DPakhomova%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DS.%2BH.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DUlu%26aufirst%3DA.%26aulast%3DMate%26aufirst%3DC.%2BA.%26aulast%3DNguyen%26aufirst%3DL.%2BV.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DEdin%26aufirst%3DM.%2BL.%26aulast%3DMara%26aufirst%3DA.%2BA.%26aulast%3DWulff%26aufirst%3DH.%26aulast%3DNewcomer%26aufirst%3DM.%2BE.%26aulast%3DZeldin%26aufirst%3DD.%2BC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DOptimized%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%2520improve%2520in%2520vitro%2520target%2520residence%2520time%2520and%2520in%2520vivo%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D16%26spage%3D7016%26epage%3D7030%26doi%3D10.1021%2Fjm500694p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiserich, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase is a therapeutic target for acute inflammation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">9772</span>– <span class="NLM_lpage">9777</span>, <span class="refDoi"> DOI: 10.1073/pnas.0503279102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1073%2Fpnas.0503279102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=15994227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=9772-9777&issue=28&author=K.+R.+Schmelzerauthor=L.+Kubalaauthor=J.+W.+Newmanauthor=I.-H.+Kimauthor=J.+P.+Eiserichauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+is+a+therapeutic+target+for+acute+inflammation&doi=10.1073%2Fpnas.0503279102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase is a therapeutic target for acute inflammation</span></div><div class="casAuthors">Schmelzer, Kara R.; Kubala, Lukas; Newman, John W.; Kim, In-Hae; Eiserich, Jason P.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">9772-9777</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">As of 2004, >73 million people were prescribed antiinflammatory medication.  Despite the extensive no. of current products, many people still suffer from their diseases or the pharmacol. properties (side effects) of the medications.  Therefore, developing therapeutic strategies to treat inflammation remains an important endeavor.  Here, we demonstrate that the sol. epoxide hydrolase (sEH) is a key pharmacol. target for treating acute systemic inflammation.  Lipopolysaccharide-induced mortality, systemic hypotension, and histol. evaluated tissue injury were substantially diminished by administration of urea-based, small-mol. inhibitors of sEH to C57BL/6 mice.  Moreover, sEH inhibitors decreased plasma levels of proinflammatory cytokines and nitric oxide metabolites while promoting the formation of lipoxins, thus supporting inflammatory resoln.  These data suggest that sEH inhibitors have therapeutic efficacy in the treatment and management of acute inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-XGKhNB1YLrVg90H21EOLACvtfcHk0ljytltTE3PYEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFartb0%253D&md5=4abeedd569a3d36e20e06bfcc94b6a98</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0503279102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0503279102%26sid%3Dliteratum%253Aachs%26aulast%3DSchmelzer%26aufirst%3DK.%2BR.%26aulast%3DKubala%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DI.-H.%26aulast%3DEiserich%26aufirst%3DJ.%2BP.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520is%2520a%2520therapeutic%2520target%2520for%2520acute%2520inflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26issue%3D28%26spage%3D9772%26epage%3D9777%26doi%3D10.1073%2Fpnas.0503279102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McReynolds, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase regulation of lipid mediators limits pain</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">916</span>, <span class="refDoi"> DOI: 10.1007/s13311-020-00916-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1007%2Fs13311-020-00916-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32875445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslOgsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=900-916&author=K.+M.+Wagnerauthor=A.+Gomesauthor=C.+B.+McReynoldsauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+regulation+of+lipid+mediators+limits+pain&doi=10.1007%2Fs13311-020-00916-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain</span></div><div class="casAuthors">Wagner, Karen M.; Gomes, Aldrin; McReynolds, Cindy B.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">900-916</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review of the role of lipids in pain signaling is well established and built on decades of knowledge about the pain and inflammation produced by prostaglandin and leukotriene metabolites of cyclooxygenase and lipoxygenase metab., resp.  The analgesic properties of other lipid metabolites are more recently coming to light.  Lipid metabolites have been obsd. to act directly at ion channels and G protein-coupled receptors on nociceptive neurons as well as act indirectly at cellular membranes.  Cytochrome P 450 metab. of specifically long-chain fatty acids forms epoxide metabolites, the epoxy-fatty acids (EpFA).  The biol. role of these metabolites has been found to mediate analgesia in several types of pain pathol.  EpFA act through a variety of direct and indirect mechanisms to limit pain and inflammation including nuclear receptor agonism, limiting endoplasmic reticulum stress and blocking mitochondrial dysfunction.  Small mol. inhibitors of the sol. epoxide hydrolase can stabilize the EpFA in vivo, and this approach has demonstrated relief in preclin. modeled pain pathol.  Moreover, the ability to block neuroinflammation extends the potential benefit of targeting sol. epoxide hydrolase to maintain EpFA for neuroprotection in neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqry9A9-sTpnLVg90H21EOLACvtfcHk0lif0fkdY0VdtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslOgsbvL&md5=06d2bf8a4a484dbeeb6a8375b8b196b5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs13311-020-00916-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-020-00916-4%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DGomes%26aufirst%3DA.%26aulast%3DMcReynolds%26aufirst%3DC.%2BB.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520regulation%2520of%2520lipid%2520mediators%2520limits%2520pain%26jtitle%3DNeurotherapeutics%26date%3D2020%26volume%3D17%26spage%3D900%26epage%3D916%26doi%3D10.1007%2Fs13311-020-00916-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rand, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2017.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.lfs.2017.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=28522175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot1ent70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2017&pages=114-122&author=S.+K.+Goswamiauthor=A.+A.+Randauthor=D.+Wanauthor=J.+Yangauthor=B.+Inceogluauthor=M.+Thomasauthor=C.+Morisseauauthor=G.-Y.+Yangauthor=B.+D.+Hammock&title=Pharmacological+inhibition+of+soluble+epoxide+hydrolase+or+genetic+deletion+reduces+diclofenac-induced+gastric+ulcers&doi=10.1016%2Fj.lfs.2017.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers</span></div><div class="casAuthors">Goswami, Sumanta Kumar; Rand, Amelia Ann; Wan, Debin; Yang, Jun; Inceoglu, Bora; Thomas, Melany; Morisseau, Christophe; Yang, Guang-Yu; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114-122</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This research was conducted to evaluate the hypothesis that gastric ulcers caused by the NSAID diclofenac sodium (DCF) can be prevented by the sol. epoxide hydrolase inhibitor TPPU.  Mice were administered a single dose of 10, 30 or 100 mg/kg of DCF.  Once an ulcerative dose of DCF was chosen, mice were pretreated with TPPU for 7 days at 0.1 mg/kg to evaluate anti-ulcer effects of the sEH inhibitor on anatomy, histopathol., pH, inflammatory markers and epithelial apoptosis of stomachs.  Diclofenac caused ulceration of the stomach at a dose of 100 mg/kg and a time post dose of 6 h.  Ulcers generated under these conditions were assocd. with a significant increase in the levels of TNF-α and IL-6 in serum and increased apoptosis compared to control mice.  Pretreatment with TPPU resulted in a decrease of ulceration in mice treated with DCF with a significant decrease in the level of apoptosis, TNF-α and IL-6 in the serum in comparison to diclofenac-treated mice.  TPPU did not affect the pH of the stomach, whereas omeprazole elevated the pH of the stomach as expected.  A similar anti-ulcer effect was obsd. in sEH gene knockout mice treated with DCF.  The sEH inhibitor TPPU decreases the NSAID-induced stomach ulcers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg06JOt8-OBLVg90H21EOLACvtfcHk0liMHBPayDLawA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot1ent70%253D&md5=1fe89e4a2979476c1cb0d8c5c71ab869</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2017.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2017.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DGoswami%26aufirst%3DS.%2BK.%26aulast%3DRand%26aufirst%3DA.%2BA.%26aulast%3DWan%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DG.-Y.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DPharmacological%2520inhibition%2520of%2520soluble%2520epoxide%2520hydrolase%2520or%2520genetic%2520deletion%2520reduces%2520diclofenac-induced%2520gastric%2520ulcers%26jtitle%3DLife%2520Sci.%26date%3D2017%26volume%3D180%26spage%3D114%26epage%3D122%26doi%3D10.1016%2Fj.lfs.2017.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wecksler, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Rationally designed multitarget agents against inflammation and pain</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1783</span>– <span class="NLM_lpage">1799</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.2174%2F0929867311320130013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23410172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1783-1799&issue=13&author=S.+H.+Hwangauthor=A.+T.+Weckslerauthor=K.+Wagnerauthor=B.+D.+Hammock&title=Rationally+designed+multitarget+agents+against+inflammation+and+pain&doi=10.2174%2F0929867311320130013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally designed multitarget agents against inflammation and pain</span></div><div class="casAuthors">Hwang, S. H.; Wecksler, A. T.; Wagner, K.; Hammock, B. D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1783-1799</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Arachidonic acid (ARA) undergoes enzyme-mediated oxidative metab., resulting in the formation of a no. of biol. active metabolites.  For over a century, these biochem. transformations have been the target of numerous pharmacol. drugs for inflammation and pain.  In particular, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) selective inhibitors (coxibs) are widely used in the treatment of inflammation and pain.  However, gastrointestinal (GI) and cardiovascular adverse effects of NSAIDs and coxibs, and recent findings demonstrating that there are significant risks from the disruption of oxylipin levels when pharmacol. inhibiting a single ARA cascade metabolic pathway, have led to studies involving the simultaneous inhibition of multiple pathways in ARA cascade.  These studies suggest that multitarget inhibition represents a new and valuable option to enhance efficacy or reduce side-effects in the treatment of inflammation and pain.  This review focuses on the crosstalk within the three pathways of the ARA cascade (cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P 450 (CYP450)), and summarizes the current and future approaches of multitarget inhibitors for the treatment of eicosanoid driven inflammation and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ-JRx21Y2i7Vg90H21EOLACvtfcHk0liSupFEXyYrJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jurg%253D&md5=5ab2b5313e700cac5b7a009b2e0fd943</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130013%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DWecksler%26aufirst%3DA.%2BT.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DRationally%2520designed%2520multitarget%2520agents%2520against%2520inflammation%2520and%2520pain%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1783%26epage%3D1799%26doi%3D10.2174%2F0929867311320130013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodani, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time affects in vivo target occupancy through multiple pathways</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1614</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.9b00770</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.9b00770" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yntrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=1614-1624&author=K.+S.+S.+Leeauthor=J.+Yangauthor=J.+Niuauthor=C.+J.+Ngauthor=K.+M.+Wagnerauthor=H.+Dongauthor=S.+D.+Kodaniauthor=D.+Wanauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Drug-target+residence+time+affects+in+vivo+target+occupancy+through+multiple+pathways&doi=10.1021%2Facscentsci.9b00770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Target Residence Time Affects in Vivo Target Occupancy through Multiple Pathways</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Yang, Jun; Niu, Jun; Ng, Connie J.; Wagner, Karen M.; Dong, Hua; Kodani, Sean D.; Wan, Debin; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1614-1624</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The drug discovery and development process is greatly hampered by difficulties in translating in vitro potency to in vivo efficacy.  Recent studies suggest that the long-neglected drug-target residence time parameter complements classical drug affinity parameters (KI, Kd, IC50, or EC50) and is a better predictor of in vivo efficacy.  Compds. with a long drug-target residence time are often more efficacious in vivo.  The impact, however, of the drug-target residence time on in vivo efficacy remains controversial due to difficulties in exptl. detg. the in vivo target occupancy during drug treatment.  To tackle this problem, an in vivo displacement assay was developed using sol. epoxide hydrolase as a biol. model.  In this report, we exptl. demonstrated that drug-target residence time affects the duration of in vivo drug-target binding.  In addn., the drug-target residence time plays an important role in modulating the rate of drug metab. which also affects the efficacy of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrobn6bpYZnn7Vg90H21EOLACvtfcHk0liSupFEXyYrJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yntrzF&md5=442c2eb0a430cdfda3109692b2e7e55b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.9b00770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.9b00770%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DC.%2BJ.%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DKodani%26aufirst%3DS.%2BD.%26aulast%3DWan%26aufirst%3DD.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520affects%2520in%2520vivo%2520target%2520occupancy%2520through%2520multiple%2520pathways%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2019%26volume%3D5%26spage%3D1614%26epage%3D1624%26doi%3D10.1021%2Facscentsci.9b00770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudie, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langguth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span> <span> </span><span class="NLM_article-title">The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2014.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.ejps.2014.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=24486482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivF2ms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=152-163&author=Y.+Tsumeauthor=D.+M.+Mudieauthor=P.+Langguthauthor=G.+E.+Amidonauthor=G.+L.+Amidon&title=The+biopharmaceutics+classification+system%3A+subclasses+for+in+vivo+predictive+dissolution+%28IPD%29+methodology+and+IVIVC&doi=10.1016%2Fj.ejps.2014.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC</span></div><div class="casAuthors">Tsume, Yasuhiro; Mudie, Deanna M.; Langguth, Peter; Amidon, Greg E.; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">152-163</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) has found widespread utility in drug discovery, product development and drug product regulatory sciences.  The classification scheme captures the two most significant factors influencing oral drug absorption; soly. and intestinal permeability, and it has proven to be a very useful and a widely accepted starting point for drug product development and drug product regulation.  The mechanistic base of the BCS approach has, no doubt, contributed to its wide spread acceptance and utility.  Nevertheless, underneath the simplicity of BCS are many detailed complexities, both in vitro and in vivo which must be evaluated and investigated for any given drug and drug product.  In this manuscript we propose a simple extension of the BCS classes to include sub-specification of acid (a), base (b) and neutral (c) for classes II and IV.  Sub-classification for Classes I and III (high soly. drugs as currently defined) is generally not needed except perhaps in border line soly. cases.  It is well known that the , pKa phys. property of a drug (API) has a significant impact on the aq. soly. dissoln. of drug from the drug product both in vitro and in vivo for BCS Class II and IV acids and bases, and is the basis, we propose for a sub-classification extension of the original BCS classification.This BCS sub-classification is particularly important for in vivo predictive dissoln. methodol. development due to the complex and variable in vivo environment in the gastrointestinal tract, with its changing pH, buffer capacity, luminal vol., surfactant luminal conditions, permeability profile along the gastrointestinal tract and variable transit and fasted and fed states.  We believe this sub-classification is a step toward developing a more science-based mechanistic in vivo predictive dissoln. (IPD) methodol.  Such a dissoln. methodol. can be used by development scientists to assess the likelihood of a formulation and dosage form functioning as desired in humans, can be optimized along with parallel human pharmacokinetic studies to set a dissoln. methodol. for Quality by Design (QbD) and in vitro-in vivo correlations (IVIVC) and ultimately can be used as a basis for a dissoln. std. that will ensure continued in vivo product performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRBzV9OFo_8rVg90H21EOLACvtfcHk0lgbXVFfmqtVJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivF2ms7g%253D&md5=3f60c8bda03d0eae4505d6608ec2e3bd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2014.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2014.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DTsume%26aufirst%3DY.%26aulast%3DMudie%26aufirst%3DD.%2BM.%26aulast%3DLangguth%26aufirst%3DP.%26aulast%3DAmidon%26aufirst%3DG.%2BE.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DThe%2520biopharmaceutics%2520classification%2520system%253A%2520subclasses%2520for%2520in%2520vivo%2520predictive%2520dissolution%2520%2528IPD%2529%2520methodology%2520and%2520IVIVC%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D57%26spage%3D152%26epage%3D163%26doi%3D10.1016%2Fj.ejps.2014.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Repka, M. A.</span>; <span class="NLM_string-name">Gerding, T. G.</span></span> Polyethylene Glycol Ointment for Apthous Ulcers. U.S. Patent <span class="NLM_patent">5,112,620</span>, May 12, <span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Repka%2C+M.+A.%3B+Gerding%2C+T.+G.+Polyethylene+Glycol+Ointment+for+Apthous+Ulcers.+U.S.+Patent+5%2C112%2C620%2C+May+12%2C+1992."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRepka%26aufirst%3DM.%2BA.%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McReynolds, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.pharmthera.2017.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=28642117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyntLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2017&pages=62-76&author=K.+M.+Wagnerauthor=C.+B.+McReynoldsauthor=W.+K.+Schmidtauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+as+a+therapeutic+target+for+pain%2C+inflammatory+and+neurodegenerative+diseases&doi=10.1016%2Fj.pharmthera.2017.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases</span></div><div class="casAuthors">Wagner, Karen M.; McReynolds, Cindy B.; Schmidt, William K.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-76</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Eicosanoids are biol. active lipid signaling mols. derived from polyunsatd. fatty acids.  Many of the actions of eicosanoid metabolites formed by cyclooxygenase and lipoxygenase enzymes have been characterized, however, the epoxy-fatty acids (EpFAs) formed by cytochrome P 450 enzymes are newly described by comparison.  The EpFA metabolites modulate a diverse set of physiol. functions that include inflammation and nociception among others.  Regulation of EpFAs occurs primarily via release, biosynthesis and enzymic transformation by the sol. epoxide hydrolase (sEH).  Targeting sEH with small mol. inhibitors has enabled observation of the biol. activity of the EpFAs in vivo in animal models, greatly contributing to the overall understanding of their role in the inflammatory response.  Their role in modulating inflammation has been demonstrated in disease models including cardiovascular pathol. and inflammatory pain, but extends to neuroinflammation and neuroinflammatory disease.  Moreover, while EpFAs demonstrate activity against inflammatory pain, interestingly, this action extends to blocking chronic neuropathic pain as well.  This review outlines the role of modulating sEH and the biol. action of EpFAs in models of pain and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYpflNfJFI-LVg90H21EOLACvtfcHk0lgbXVFfmqtVJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyntLzN&md5=cce7ef34908084360e85c153a0c428ee</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DMcReynolds%26aufirst%3DC.%2BB.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520as%2520a%2520therapeutic%2520target%2520for%2520pain%252C%2520inflammatory%2520and%2520neurodegenerative%2520diseases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D180%26spage%3D62%26epage%3D76%26doi%3D10.1016%2Fj.pharmthera.2017.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4716</span>– <span class="NLM_lpage">4723</span>, <span class="refDoi"> DOI: 10.1021/bi036189j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi036189j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Ols7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=4716-4723&author=G.+A.+Gomezauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=D.+W.+Christianson&title=Structure+of+human+epoxide+hydrolase+reveals+mechanistic+inferences+on+bifunctional+catalysis+in+epoxide+and+phosphate+ester+hydrolysis&doi=10.1021%2Fbi036189j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis</span></div><div class="casAuthors">Gomez, German A.; Morisseau, Christophe; Hammock, Bruce D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4716-4723</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The x-ray crystal structure of human sol. epoxide hydrolase (sEH) was detd. at 2.6 Å resoln., revealing a domain-swapped quaternary structure identical to that obsd. for the murine enzyme.  As with the murine enzyme, the epoxide hydrolytic mechanism of the human enzyme proceeded through an alkyl-enzyme intermediate with Asp-333 in the C-terminal domain.  The structure of human sEH complexed with the inhibitor, N-cyclohexyl-N'-(iodophenyl)urea (CIU), at 2.35 Å resoln. was also detd.  Tyr-381 and Tyr-465 donated H-bonds to the alkylurea carbonyl group of CIU, consistent with the proposed roles of these residues as proton donors in the 1st step of catalysis.  The N-terminal domain of mammalian sEH contained a 15 Å deep cleft, but its biol. function was unclear.  Recent expts. demonstrated that the N-terminal domain of human sEH catalyzes the metal-dependent hydrolysis of phosphate esters.  The binding of Mg2+-HPO42- to the N-terminal domain of human sEH in its CIU complex revealed structural features relevant to those of the enzyme-substrate complex in the phosphatase reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgQ3Rx-U2trVg90H21EOLACvtfcHk0lgvRXxIxVG6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Ols7g%253D&md5=c6cc1850d50daf2d1690c4024cb8d7bb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi036189j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi036189j%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DG.%2BA.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%2520of%2520human%2520epoxide%2520hydrolase%2520reveals%2520mechanistic%2520inferences%2520on%2520bifunctional%2520catalysis%2520in%2520epoxide%2520and%2520phosphate%2520ester%2520hydrolysis%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26spage%3D4716%26epage%3D4723%26doi%3D10.1021%2Fbi036189j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1110/ps.051720206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1110%2Fps.051720206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=16322563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XktlSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=58-64&author=G.+A.+Gomezauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=D.+W.+Christianson&title=Human+soluble+epoxide+hydrolase%3A+structural+basis+of+inhibition+by+4-%283-cyclohexylureido%29-carboxylic+acids&doi=10.1110%2Fps.051720206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Human soluble epoxide hydrolase: Structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids</span></div><div class="casAuthors">Gomez, German A.; Morisseau, Christophe; Hammock, Bruce D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-64</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">X-ray crystal structures of human sol. epoxide hydrolase (sEH) complexed with four different dialkylurea inhibitors bearing pendant carboxylate "tails" of varying length have been detd. at 2.3-3.0 Å resoln.  Similarities among inhibitor binding modes reinforce the proposed roles of Y381 and/or Y465 as general acids that protonate the epoxide ring of the substrate in concert with nucleophilic attack of D333 at the electrophilic epoxide carbon.  Addnl., the binding of these inhibitors allows us to model the binding mode of the endogenous substrate 14,15-epoxyeicosatrienoic acid.  Contrasts among inhibitor binding modes include opposite orientations of inhibitor binding in the active-site hydrophobic tunnel.  Alternative binding orientations obsd. for this series of inhibitors to human sEH, as well as the binding of certain dialkylurea inhibitors to human sEH and murine sEH, complicate the structure-based design of human sEH inhibitors with potential pharmaceutical applications in the treatment of hypertension.  Thus, with regard to the optimization of inhibitor designs targeting human sEH, it is crit. that human sEH and not murine sEH be utilized for inhibitor screening, and it is crit. that structures of human sEH-inhibitor complexes be detd. to verify inhibitor binding orientations that correlate with measured affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCrqO7mSzRPrVg90H21EOLACvtfcHk0lgvRXxIxVG6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktlSrsQ%253D%253D&md5=b16bb0c99a177acc885cbbb789374f2b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1110%2Fps.051720206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.051720206%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DG.%2BA.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHuman%2520soluble%2520epoxide%2520hydrolase%253A%2520structural%2520basis%2520of%2520inhibition%2520by%25204-%25283-cyclohexylureido%2529-carboxylic%2520acids%26jtitle%3DProtein%2520Sci.%26date%3D2006%26volume%3D15%26spage%3D58%26epage%3D64%26doi%3D10.1110%2Fps.051720206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriksen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>613</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2016.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.abb.2016.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=27983948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVagsr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=613&publication_year=2017&pages=1-11&author=K.+S.+Leeauthor=N.+M.+Henriksenauthor=C.+J.+Ngauthor=J.+Yangauthor=W.+Jiaauthor=C.+Morisseauauthor=A.+Andayaauthor=M.+K.+Gilsonauthor=B.+D.+Hammock&title=Probing+the+orientation+of+inhibitor+and+epoxy-eicosatrienoic+acid+binding+in+the+active+site+of+soluble+epoxide+hydrolase&doi=10.1016%2Fj.abb.2016.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Henriksen, Niel M.; Ng, Connie J.; Yang, Jun; Jia, Weitao; Morisseau, Christophe; Andaya, Armann; Gilson, Michael K.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">613</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH) is an important therapeutic target of many diseases, such as chronic obstructive pulmonary disease (COPD) and diabetic neuropathic pain.  It acts by hydrolyzing and thus regulating specific bioactive long chain polyunsatd. fatty acid epoxides (lcPUFA), like epoxyeicosatrienoic acids (EETs).  To better predict which epoxides could be hydrolyzed by sEH, one needs to dissect the important factors and structural requirements that govern the binding of the substrates to sEH.  This knowledge allows further exploration of the physiol. role played by sEH.  Unfortunately, a crystal structure of sEH with a substrate bound has not yet been reported.  In this report, new photoaffinity mimics of a sEH inhibitor and EET regioisomers were prepd. and used in combination with peptide sequencing and computational modeling, to identify the binding orientation of different regioisomers and enantiomers of EETs into the catalytic cavity of sEH.  Results indicate that the stereochem. of the epoxide plays a crucial role in dictating the binding orientation of the substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ1ih65m797bVg90H21EOLACvtfcHk0lgvRXxIxVG6Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVagsr7J&md5=cbcbfa84e051c25c57d95a56774fd710</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2016.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2016.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DHenriksen%26aufirst%3DN.%2BM.%26aulast%3DNg%26aufirst%3DC.%2BJ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DW.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DAndaya%26aufirst%3DA.%26aulast%3DGilson%26aufirst%3DM.%2BK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DProbing%2520the%2520orientation%2520of%2520inhibitor%2520and%2520epoxy-eicosatrienoic%2520acid%2520binding%2520in%2520the%2520active%2520site%2520of%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2017%26volume%3D613%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.abb.2016.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burmistrov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitushkin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernigora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasskazova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butov, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">127430</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bmcl.2020.127430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32736212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVyis77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127430&issue=18&author=V.+Burmistrovauthor=C.+Morisseauauthor=D.+Karlovauthor=D.+Pitushkinauthor=A.+Vernigoraauthor=E.+Rasskazovaauthor=G.+M.+Butovauthor=B.+D.+Hammock&title=Bioisosteric+substitution+of+adamantane+with+bicyclic+lipophilic+groups+improves+water+solubility+of+human+soluble+epoxide+hydrolase+inhibitors&doi=10.1016%2Fj.bmcl.2020.127430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors</span></div><div class="casAuthors">Burmistrov, Vladimir; Morisseau, Christophe; Karlov, Dmitry; Pitushkin, Dmitry; Vernigora, Andrey; Rasskazova, Elena; Butov, Gennady M.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">127430</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of inhibitors of the sol. epoxide hydrolase (sEH) contg. lipophilic groups of natural origin (camphanyl, norcamphanyl, furan-2-yl) were developed.  Inhibitory potency ranging from 0.4 nM to 2.16 μM were obtained.  While having the same level of inhibitory activity bicyclic ureas are up to 10-fold more sol. than the corresponding ureas contg. adamantyl or 4-trifluoromethoxyphenyl substituents.  This makes them easier to formulate, more bioavailable and thus more promising as therapeutic sEH inhibitors.  Endo/exo-form of compd. 2b derived from L-camphor is 14-fold more potent than the corresponding analog derived from D-camphor (IC50 = 3.7 nM vs. 50.6 nM) indicating enantiomeric preference.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO4jRQU49uprVg90H21EOLACvtfcHk0lj-3KnABMUUOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVyis77P&md5=381b64d2afdd43659a8f0a2bec833d2b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127430%26sid%3Dliteratum%253Aachs%26aulast%3DBurmistrov%26aufirst%3DV.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DKarlov%26aufirst%3DD.%26aulast%3DPitushkin%26aufirst%3DD.%26aulast%3DVernigora%26aufirst%3DA.%26aulast%3DRasskazova%26aufirst%3DE.%26aulast%3DButov%26aufirst%3DG.%2BM.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DBioisosteric%2520substitution%2520of%2520adamantane%2520with%2520bicyclic%2520lipophilic%2520groups%2520improves%2520water%2520solubility%2520of%2520human%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D18%26spage%3D127430%26doi%3D10.1016%2Fj.bmcl.2020.127430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Förster resonance energy transfer (FRET) competitive displacement assay for human soluble epoxide hydrolase</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>434</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2012.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.ab.2012.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23219719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVGjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2013&pages=259-268&issue=2&author=K.+S.+S.+Leeauthor=C.+Morisseauauthor=J.+Yangauthor=P.+Wangauthor=S.+H.+Hwangauthor=B.+D.+Hammock&title=F%C3%B6rster+resonance+energy+transfer+%28FRET%29+competitive+displacement+assay+for+human+soluble+epoxide+hydrolase&doi=10.1016%2Fj.ab.2012.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Foerster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Morisseau, Christophe; Yang, Jun; Wang, Peng; Hwang, Sung Hee; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-268</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sol. epoxide hydrolase (sEH), responsible for the hydrolysis of various fatty acid epoxides to their corresponding 1,2-diols, is becoming an attractive pharmaceutical target.  These fatty acid epoxides, particularly epoxyeicosatrienoic acids (EETs), play an important role in human homeostatic and inflammation processes.  Therefore, inhibition of human sEH, which stabilizes EETs in vivo, brings several beneficial effects to human health.  Although there are several catalytic assays available to det. the potency of sEH inhibitors, measuring the in vitro inhibition const. (Ki) for these inhibitors using catalytic assay is laborious.  In addn., koff, which has been recently suggested to correlate better with the in vivo potency of inhibitors, has never been measured for sEH inhibitors.  To better measure the potency of sEH inhibitors, a reporting ligand, 1-(adamantan-1-yl)-3-(1-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl) piperidin-4-yl)urea (ACPU), was designed and synthesized.  With ACPU, we have developed a Foerster resonance energy transfer (FRET)-based competitive displacement assay using intrinsic tryptophan fluorescence from sEH.  In addn., the resulting assay allows us to measure the Ki values of very potent compds. to the picomolar level and to obtain relative koff values of the inhibitors.  This assay provides addnl. data to evaluate the potency of sEH inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBfo3H10EZfbVg90H21EOLACvtfcHk0lj-3KnABMUUOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVGjtL4%253D&md5=8776c1bc83265e6b6b3f66e963c88e5b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2012.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2012.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DF%25C3%25B6rster%2520resonance%2520energy%2520transfer%2520%2528FRET%2529%2520competitive%2520displacement%2520assay%2520for%2520human%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DAnal.%2520Biochem.%26date%3D2013%26volume%3D434%26issue%3D2%26spage%3D259%26epage%3D268%26doi%3D10.1016%2Fj.ab.2012.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Measurement of soluble epoxide hydrolase (sEH) activity</span>. <i>Curr. Protoc. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">4.23.1</span>– <span class="NLM_lpage">4.23.18</span>, <span class="refDoi"> DOI: 10.1002/0471140856.tx0423s33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1002%2F0471140856.tx0423s33" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=4.23.1-4.23.18&author=C.+Morisseauauthor=B.+D.+Hammock&title=Measurement+of+soluble+epoxide+hydrolase+%28sEH%29+activity&doi=10.1002%2F0471140856.tx0423s33"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2F0471140856.tx0423s33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471140856.tx0423s33%26sid%3Dliteratum%253Aachs%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DMeasurement%2520of%2520soluble%2520epoxide%2520hydrolase%2520%2528sEH%2529%2520activity%26jtitle%3DCurr.%2520Protoc.%2520Toxicol.%26date%3D2007%26volume%3D33%26spage%3D4.23.1%26epage%3D4.23.18%26doi%3D10.1002%2F0471140856.tx0423s33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinks, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">18901</span>– <span class="NLM_lpage">18906</span>, <span class="refDoi"> DOI: 10.1073/pnas.0809765105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1073%2Fpnas.0809765105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=19028872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2rtLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=18901-18906&issue=48&author=B.+Inceogluauthor=S.+L.+Jinksauthor=A.+Uluauthor=C.+M.+Hegedusauthor=K.+Georgiauthor=K.+R.+Schmelzerauthor=K.+Wagnerauthor=P.+D.+Jonesauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+and+epoxyeicosatrienoic+acids+modulate+two+distinct+analgesic+pathways&doi=10.1073%2Fpnas.0809765105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways</span></div><div class="casAuthors">Inceoglu, Bora; Jinks, Steven L.; Ulu, Arzu; Hegedus, Christine M.; Georgi, Katrin; Schmelzer, Kara R.; Wagner, Karen; Jones, Paul D.; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">18901-18906</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">During inflammation, a large amt. of arachidonic acid (AA) is released into the cellular milieu and cyclooxygenase enzymes convert this AA to prostaglandins that in turn sensitize pain pathways.  However, AA is also converted to natural epoxyeicosatrienoic acids (EETs) by cytochrome P 450 enzymes.  EET levels are typically regulated by sol. epoxide hydrolase (sEH), the major enzyme degrading EETs.  Here we demonstrate that EETs or inhibition of sEH lead to antihyperalgesia by at least 2 spinal mechanisms, first by repressing the induction of the COX2 gene and second by rapidly up-regulating an acute neurosteroid-producing gene, StARD1, which requires the synchronized presence of elevated cAMP and EET levels.  The analgesic activities of neurosteroids are well known; however, here we describe a clear course toward augmenting the levels of these mols.  Redirecting the flow of pronociceptive intracellular cAMP toward up-regulation of StARD1 mRNA by concomitantly elevating EETs is a novel path to accomplish pain relief in both inflammatory and neuropathic pain states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwtxbwVAXe-7Vg90H21EOLACvtfcHk0lg40UVkAya_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2rtLrI&md5=d0cd74a5a3de8c9aeb90bda6dfda8b0e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0809765105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0809765105%26sid%3Dliteratum%253Aachs%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DJinks%26aufirst%3DS.%2BL.%26aulast%3DUlu%26aufirst%3DA.%26aulast%3DHegedus%26aufirst%3DC.%2BM.%26aulast%3DGeorgi%26aufirst%3DK.%26aulast%3DSchmelzer%26aufirst%3DK.%2BR.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DP.%2BD.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520and%2520epoxyeicosatrienoic%2520acids%2520modulate%2520two%2520distinct%2520analgesic%2520pathways%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D48%26spage%3D18901%26epage%3D18906%26doi%3D10.1073%2Fpnas.0809765105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettaieb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbouBechara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chahed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haj, F. G.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">14189</span>– <span class="NLM_lpage">114199</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.458414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1074%2Fjbc.M113.458414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23576437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=14189-114199&issue=20&author=A.+Bettaiebauthor=N.+Nagataauthor=D.+AbouBecharaauthor=S.+Chahedauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=F.+G.+Haj&title=Soluble+epoxide+hydrolase+deficiency+or+inhibition+attenuates+diet-induced+endoplasmic+reticulum+stress+in+liver+and+adipose+tissue&doi=10.1074%2Fjbc.M113.458414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue</span></div><div class="casAuthors">Bettaieb, Ahmed; Nagata, Naoto; Abou Bechara, Daniel; Chahed, Samah; Morisseau, Christophe; Hammock, Bruce D.; Haj, Fawaz G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">14189-14199</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has beneficial effects in cardiovascular, inflammatory, and metabolic diseases in murine models.  Mice with targeted deletion or pharmacol. inhibition of sEH exhibit improved insulin signaling in liver and adipose tissue.  Herein, we assessed the role of sEH in regulating endoplasmic reticulum (ER) stress in liver and adipose tissue.  We report that sEH expression was increased in the livers and adipose tissue of mice fed a high fat diet, the adipose tissue of overweight humans, and palmitate-treated cells.  Importantly, sEH deficiency or inhibition in mice attenuated chronic high fat diet-induced ER stress in liver and adipose tissue.  Similarly, pharmacol. inhibition of sEH in HepG2 cells and 3T3-L1 adipocytes mitigated chem.-induced ER stress and activation of JNK, p38, and cell death.  In addn., insulin signaling was enhanced in HepG2 cells treated with sEH substrates and attenuated in cells treated with sEH products.  In summary, these findings demonstrate that sEH is a physiol. modulator of ER stress and a potential target for mitigating complications assocd. with obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJbIQBLHGVjbVg90H21EOLACvtfcHk0lg40UVkAya_rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGksL4%253D&md5=17bcaac765ee90fa89f1efcd96b5648a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.458414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.458414%26sid%3Dliteratum%253Aachs%26aulast%3DBettaieb%26aufirst%3DA.%26aulast%3DNagata%26aufirst%3DN.%26aulast%3DAbouBechara%26aufirst%3DD.%26aulast%3DChahed%26aufirst%3DS.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DHaj%26aufirst%3DF.%2BG.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520deficiency%2520or%2520inhibition%2520attenuates%2520diet-induced%2520endoplasmic%2520reticulum%2520stress%2520in%2520liver%2520and%2520adipose%2520tissue%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D20%26spage%3D14189%26epage%3D114199%26doi%3D10.1074%2Fjbc.M113.458414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiamvimonvat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">The soluble epoxide hydrolase as a pharmaceutical target for hypertension</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1097/FJC.0b013e3181506445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1097%2FFJC.0b013e3181506445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=17878749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCktbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=225-237&author=N.+Chiamvimonvatauthor=C.-M.+Hoauthor=H.-J.+Tsaiauthor=B.+D.+Hammock&title=The+soluble+epoxide+hydrolase+as+a+pharmaceutical+target+for+hypertension&doi=10.1097%2FFJC.0b013e3181506445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The Soluble Epoxide Hydrolase as a Pharmaceutical Target for Hypertension</span></div><div class="casAuthors">Chiamvimonvat, Nipavan; Ho, Chin-Min; Tsai, Hsing-Ju; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-237</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The sol. epoxide hydrolase appears to be a promising target for the development of antihypertensive therapies based on a previously unexplored mechanism of action.  Epoxide hydrolases are enzymes that add water to three membered cyclic ethers known as epoxides.  The sol. epoxide hydrolase in mammalian systems (sEH) is a member of the α/β-hydrolase fold family of enzymes and it shows a high degree of selectivity for epoxides of fatty acids.  The regioisomeric epoxides of arachidonic acid or epoxyeicosanoids (EETs) are particularly good substrates.  These EETs appear to be major components of the endothelium-derived hyperpolarizing factors (EDHFs).  As such, EETs cause vasodilation and reduce blood pressure.  The EETs also are strongly anti-inflammatory and analgesic.  By inhibiting sEH, the increase in circulating EETs leads to a redn. in blood pressure in a no. of animal models.  Potent transition state mimic inhibitors have been developed for the sEH.  Some of these sEH inhibitors (sEHIs) show nanomolar to picomolar potency and good pharmacokinetic properties.  Because of their unique mode of action they show promise in treating hypertension while reducing problems with end organ failure, vascular inflammation and diabetes.  Indeed, the anti-inflammatory properties of the sEHI may make them particularly suitable for treating hypertension in patients with other concomitant metabolic syndromes.  They are more potent on a molar basis than most nonsteroidal anti-inflammatory drugs (NSAIDs) in reducing PGE2 in inflammation models, they strongly synergize with NSAIDs, and appear to ameliorate apparently unfavorable eicosanoid profiles assocd. with some cyclo-oxygenase-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxCeaJbKdxrrVg90H21EOLACvtfcHk0lhfKkJiLItn8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCktbjJ&md5=7ee1c71bf0db07c05eafba50b4096a09</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1097%2FFJC.0b013e3181506445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFJC.0b013e3181506445%26sid%3Dliteratum%253Aachs%26aulast%3DChiamvimonvat%26aufirst%3DN.%26aulast%3DHo%26aufirst%3DC.-M.%26aulast%3DTsai%26aufirst%3DH.-J.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DThe%2520soluble%2520epoxide%2520hydrolase%2520as%2520a%2520pharmaceutical%2520target%2520for%2520hypertension%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2007%26volume%3D50%26spage%3D225%26epage%3D237%26doi%3D10.1097%2FFJC.0b013e3181506445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeyev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuteja, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, R. K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singapuri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiamvimonvat, N.</span></span> <span> </span><span class="NLM_article-title">Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">18733</span>– <span class="NLM_lpage">18738</span>, <span class="refDoi"> DOI: 10.1073/pnas.0609158103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1073%2Fpnas.0609158103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=17130447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlahtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=18733-18738&author=D.+Xuauthor=N.+Liauthor=Y.+Heauthor=V.+Timofeyevauthor=L.+Luauthor=H.-J.+Tsaiauthor=I.-H.+Kimauthor=D.+Tutejaauthor=R.+K.+P.+Mateoauthor=A.+Singapuriauthor=B.+Davisauthor=R.+Lowauthor=B.+D.+Hammockauthor=N.+Chiamvimonvat&title=Prevention+and+reversal+of+cardiac+hypertrophy+by+soluble+epoxide+hydrolase+inhibitors&doi=10.1073%2Fpnas.0609158103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors</span></div><div class="casAuthors">Xu, Danyan; Li, Ning; He, Yuxia; Timofeyev, Valeriy; Lu, Ling; Tsai, Hsing-Ju; Kim, In-Hae; Tuteja, Dipika; Mateo, Robertino Karlo P.; Singapuri, Anil; Davis, Benjamin B.; Low, Reginald; Hammock, Bruce D.; Chiamvimonvat, Nipavan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">18733-18738</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sustained cardiac hypertrophy represents one of the most common causes leading to cardiac failure.  There is emerging evidence to implicate the involvement of NF-κB in the development of cardiac hypertrophy.  However, several crit. questions remain unanswered.  The authors tested the use of sol. epoxide hydrolase (sEH) inhibitors as a means to enhance the biol. activities of epoxyeicosatrienoic acids (EETs) to treat cardiac hypertrophy.  SEH catalyzes the conversion of EETs to form the corresponding dihydroxyeicosatrienoic acids.  Previous data have suggested that EETs may inhibit the activation of NF-KB-mediated gene transcription.  The authors directly demonstrate the beneficial effects of several potent sEH inhibitors (sEHIs) in cardiac hypertrophy.  Specifically, the authors show that sEHIs can prevent the development of cardiac hypertrophy using a murine model of pressure-induced cardiac hypertrophy.  In addn., sEHIs reverse the preestablished cardiac hypertrophy caused by chronic pressure overload.  The authors further demonstrate that these compds. potently block the NF-κB activation in cardiac myocytes.  Moreover, by using in vivo electrophysiol. recordings, our study shows a beneficial effect of the compds. in the prevention of cardiac arrhythmias that occur in assocn. with cardiac hypertrophy.  The authors conclude that the use of sEHIs to increase the level of the endogenous lipid epoxides such as EETs may represent a viable and completely unexplored avenue to reduce cardiac hypertrophy by blocking NF-κB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpt96mXNMo7Vg90H21EOLACvtfcHk0lhfKkJiLItn8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlahtLrN&md5=1c323e41ece67fb2f5708632e4284b0d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609158103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609158103%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DTimofeyev%26aufirst%3DV.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DTsai%26aufirst%3DH.-J.%26aulast%3DKim%26aufirst%3DI.-H.%26aulast%3DTuteja%26aufirst%3DD.%26aulast%3DMateo%26aufirst%3DR.%2BK.%2BP.%26aulast%3DSingapuri%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DB.%26aulast%3DLow%26aufirst%3DR.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DChiamvimonvat%26aufirst%3DN.%26atitle%3DPrevention%2520and%2520reversal%2520of%2520cardiac%2520hypertrophy%2520by%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D18733%26epage%3D18738%26doi%3D10.1073%2Fpnas.0609158103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comerota, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Propson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span> <span> </span><span class="NLM_article-title">An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">573</span>),  <span class="NLM_fpage">eabb1206</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.abb1206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1126%2Fscitranslmed.abb1206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=33298560" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eabb1206&issue=573&author=A.+Ghoshauthor=M.+M.+Comerotaauthor=D.+Wanauthor=F.+Chenauthor=N.+E.+Propsonauthor=S.+H.+Hwangauthor=B.+D.+Hammockauthor=H.+Zheng&title=An+epoxide+hydrolase+inhibitor+reduces+neuroinflammation+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1126%2Fscitranslmed.abb1206"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.abb1206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.abb1206%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DComerota%26aufirst%3DM.%2BM.%26aulast%3DWan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DPropson%26aufirst%3DN.%2BE.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DZheng%26aufirst%3DH.%26atitle%3DAn%2520epoxide%2520hydrolase%2520inhibitor%2520reduces%2520neuroinflammation%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26issue%3D573%26spage%3Deabb1206%26doi%3D10.1126%2Fscitranslmed.abb1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashidian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, C.</span></span> <span> </span><span class="NLM_article-title">Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial</span>. <i>J. Neuroeng. Rehabil.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">125</span>, <span class="refDoi"> DOI: 10.1186/1743-0003-11-125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1186%2F1743-0003-11-125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=25139539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252Fjtlajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=125&author=S.+Karmakarauthor=H.+Rashidianauthor=C.+Chanauthor=C.+Liuauthor=C.+Toth&title=Investigating+the+role+of+neuropathic+pain+relief+in+decreasing+gait+variability+in+diabetes+mellitus+patients+with+neuropathic+pain%3A+a+randomized%2C+double-blind+crossover+trial&doi=10.1186%2F1743-0003-11-125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial</span></div><div class="casAuthors">Karmakar Surshen; Rashidian Houman; Chan Cynthia; Liu CaiXia; Toth Cory</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroengineering and rehabilitation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">125</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Subjects with diabetes mellitus (DM) develop gait dysfunction contributing to falls, reluctance to perform activities and injuries.  Neuropathic pain (NeP) related to diabetic peripheral neuropathy (DPN) is associated with increased gait variability that may contribute to gait dysfunction.  We used a portable device (GaitMeter®) and related gait and balance measures to measure gait parameters in painful DPN (PDPN) subjects prior to and during analgesia.  Our hypothesis was that PDPN subjects would have decreased gait step variability when receiving pharmacological relief of NeP.  METHODS:  DPN subjects with at least moderate NeP were assessed in a randomized, double-blind crossover study of pregabalin versus placebo.  The outcome measure was variability in step length and step velocity.  Testing for Timed Get-Up-and-Go Test, Tinetti Mobility Scales, Sway Testing, a Physiological Profile Approach, and fall-related surveys were also performed.  DPN severity was quantified using the Utah Early Neuropathy Score.  RESULTS:  PDPN subjects developed increased, rather than decreased, step length and step velocity variability during pregabalin treatment.  There were no significant differences between cohorts for other physiological gait and balance testing.  Non-significant NeP relief occurred in the pregabalin phase of study as compared with placebo.  There was a negative relationship for step length with pain severity.  CONCLUSION:  Analgesia did not decrease gait variability in PDPN patients, and in fact, increased gait variability was seen during pregabalin treatment.  Other important relationships of gait dysfunction with PDPN should be sought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJ5_69URqBZresJRIHUP1ofW6udTcc2eZM-4lIV03Pi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252Fjtlajtg%253D%253D&md5=0270d6568677ecac497d04281de8b189</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1186%2F1743-0003-11-125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1743-0003-11-125%26sid%3Dliteratum%253Aachs%26aulast%3DKarmakar%26aufirst%3DS.%26aulast%3DRashidian%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DToth%26aufirst%3DC.%26atitle%3DInvestigating%2520the%2520role%2520of%2520neuropathic%2520pain%2520relief%2520in%2520decreasing%2520gait%2520variability%2520in%2520diabetes%2520mellitus%2520patients%2520with%2520neuropathic%2520pain%253A%2520a%2520randomized%252C%2520double-blind%2520crossover%2520trial%26jtitle%3DJ.%2520Neuroeng.%2520Rehabil.%26date%3D2014%26volume%3D11%26spage%3D125%26doi%3D10.1186%2F1743-0003-11-125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kharasch, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheterpal, S.</span></span> <span> </span><span class="NLM_article-title">Perioperative Gabapentinoids: Deflating the Bubble</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1097/ALN.0000000000003394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1097%2FALN.0000000000003394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32667153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BB38jis12ksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2020&pages=251-254&issue=2&author=E.+D.+Kharaschauthor=J.+D.+Clarkauthor=S.+Kheterpal&title=Perioperative+Gabapentinoids%3A+Deflating+the+Bubble&doi=10.1097%2FALN.0000000000003394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Perioperative Gabapentinoids: Deflating the Bubble</span></div><div class="casAuthors">Kharasch Evan D; Clark J David; Kheterpal Sachin</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-254</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbA4WdK1-lWEBuFdjgVNKSfW6udTcc2eZM-4lIV03Pi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38jis12ksA%253D%253D&md5=6997691200c75c5ad56e59c3c5052eda</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1097%2FALN.0000000000003394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0000000000003394%26sid%3Dliteratum%253Aachs%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DKheterpal%26aufirst%3DS.%26atitle%3DPerioperative%2520Gabapentinoids%253A%2520Deflating%2520the%2520Bubble%26jtitle%3DAnesthesiology%26date%3D2020%26volume%3D133%26issue%3D2%26spage%3D251%26epage%3D254%26doi%3D10.1097%2FALN.0000000000003394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Said, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. C.</span></span> <span> </span><span class="NLM_article-title">Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population</span>. <i>Clin. J. Pain.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1097/AJP.0000000000000124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1097%2FAJP.0000000000000124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=25853725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BC2MjisVWntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2015&pages=414-424&issue=5&author=P.+R.+Patilauthor=J.+Wolfeauthor=Q.+Saidauthor=J.+Thomasauthor=B.+C.+Martin&title=Opioid+use+in+the+management+of+diabetic+peripheral+neuropathy+%28DPN%29+in+a+large+commercially+insured+population&doi=10.1097%2FAJP.0000000000000124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population</span></div><div class="casAuthors">Patil Pravinkumar R; Wolfe Jonathan; Said Qayyim; Thomas Jeremy; Martin Bradley C</div><div class="citationInfo"><span class="NLM_cas:title">The Clinical journal of pain</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">414-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine the proportion of diabetic peripheral neuropathy (DPN) patients receiving pharmacologic DPN treatments and specifically to identify the rates and factors associated with opioid use and first-line opioid use.  METHODS:  A 10% sample of IMS-LifeLink claims data from 1998 through 2008 was used.  The study population consisted of diabetic patients who met DPN criteria using a validated DPN algorithm.  Multivariable logistic regression controlling for demographics, comorbidities, and other clinical characteristics was used to identify factors associated with any DPN pharmacologic treatment, any opioid use, and first-line opioid treatment.  Sensitivity analyses were conducted to explore variations in exclusion criteria as well as opioid use definitions.  RESULTS:  A total of 666 DPN patients met inclusion criteria and pharmacologic treatment was received by 288 patients (43.24%) and of those, 154 (53.47%) had DPN-related opioid use and 96 (33.33%) received opioid as first-line treatment.  Persons with diabetic complications were more likely to use opioids (odds ratio=4.53; 95% confidence interval, 1.09-18.92).  Food and Drug Administration-approved DPN agents duloxetine 1.04% (n=3) and pregabalin 5.56% (n=16) had much lower rates of use.  DPN-related drug use and DPN-related opioid usage increased as we used less restrictive samples in sensitivity analyses.  CONCLUSIONS:  Opioids were the most frequently prescribed first-line agents for DPN.  More than 50% of DPN patients remained untreated with pharmacologic agents 1 year after a DPN diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRejOMaiBELaVZoq0fPSOTvfW6udTcc2eZM-4lIV03Pi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjisVWntQ%253D%253D&md5=b67345d11c3830e6a51cb4efb8556c89</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2FAJP.0000000000000124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FAJP.0000000000000124%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BR.%26aulast%3DWolfe%26aufirst%3DJ.%26aulast%3DSaid%26aufirst%3DQ.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DB.%2BC.%26atitle%3DOpioid%2520use%2520in%2520the%2520management%2520of%2520diabetic%2520peripheral%2520neuropathy%2520%2528DPN%2529%2520in%2520a%2520large%2520commercially%2520insured%2520population%26jtitle%3DClin.%2520J.%2520Pain.%26date%3D2015%26volume%3D31%26issue%3D5%26spage%3D414%26epage%3D424%26doi%3D10.1097%2FAJP.0000000000000124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">914</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2014.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.jpain.2014.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=24924124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGltrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=907-914&issue=9&author=K.+Wagnerauthor=J.+Yangauthor=B.+Inceogluauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+inhibition+is+antinociceptive+in+a+mouse+model+of+diabetic+neuropathy&doi=10.1016%2Fj.jpain.2014.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble Epoxide Hydrolase Inhibition Is Antinociceptive in a Mouse Model of Diabetic Neuropathy</span></div><div class="casAuthors">Wagner, Karen; Yang, Jun; Inceoglu, Bora; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">907-914</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Neuropathic pain is currently an insufficiently treated clin. condition.  There remains a crit. need for efficacious therapies without severe side effects to treat the uniquely persistent and tonic pain of neuropathy.  Inhibitors of the sol. epoxide hydrolase (sEH) enzyme that stabilize endogenous epoxy fatty acids have demonstrated antihyperalgesia in clin. chronic inflammatory pain and modeled neuropathic pain.  Recently, the conditioned place preference assay has been used to evaluate the tonic nature of neuropathy in several animal models.  The current expts. use the conditioned place preference assay alongside withdrawal thresholds to investigate the antihyperalgesic efficacy of sEH inhibitors in a murine model of diabetic neuropathy.  Here, the sEH inhibitor trans-4-[4-(3-trifluoromethoxyphenyl-1-ureido)-cyclohexyloxy]-benzoic acid (t-TUCB) at 10 mg/kg induced a robust place preference in diabetic neuropathic mice representative of pain relief.  Importantly, this effect was absent both in control mice and in sEH-knockout mice at the same dose, indicating that t-TUCB is not pos. reinforcing or rewarding.  When compared to gabapentin, t-TUCB elicited a similar degree of withdrawal threshold improvement without the same degree of spontaneous locomotion decline in neuropathic mice.  Overall, these expts. show that inhibiting the sEH enzyme attenuates chronic pain and offers an alternative to current side-effect-limited therapies to meet this clin. need.These expts. demonstrate antihyperalgesia in a murine chronic pain model mediated by inhibiting the sEH enzyme.  The results of this study indicate that inhibiting the sEH is a promising alternative for blocking chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcdA-epFDZyLVg90H21EOLACvtfcHk0lgXjAaRKHETUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGltrzM&md5=fa282d9b07810ca941454259e5532cb9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2014.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2014.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520inhibition%2520is%2520antinociceptive%2520in%2520a%2520mouse%2520model%2520of%2520diabetic%2520neuropathy%26jtitle%3DJ.%2520Pain%26date%3D2014%26volume%3D15%26issue%3D9%26spage%3D907%26epage%3D914%26doi%3D10.1016%2Fj.jpain.2014.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backonja, M. M.</span></span> <span> </span><span class="NLM_article-title">Combination drug therapy for chronic pain: a call for more clinical studies</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2010.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.jpain.2010.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=20851058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=157-166&issue=2&author=J.+Maoauthor=M.+S.+Goldauthor=M.+M.+Backonja&title=Combination+drug+therapy+for+chronic+pain%3A+a+call+for+more+clinical+studies&doi=10.1016%2Fj.jpain.2010.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Drug Therapy for Chronic Pain: A Call for More Clinical Studies</span></div><div class="casAuthors">Mao, Jianren; Gold, Michael S.; Backonja, Miroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chronic pain is a debilitating clin. condition assocd. with a variety of disease entities including diabetic neuropathy, postherpetic neuralgia, low back pathol., fibromyalgia, and neurol. disorders.  For many general practitioners and specialists, managing chronic pain has become a daunting challenge.  As a modality of multidisciplinary chronic pain management, medications are often prescribed in combinations, an approach referred to as combination drug therapy (CDT).  However, many medications for pain therapy, including antidepressants and opioid analgesics, have significant side effects that can compd. when used in combination and impact the effectiveness of CDT.  To date, clin. practice of CDT for chronic pain has been based largely on clin. experiences.  In this article, we will focus on (1) the scientific basis and rationales for CDT, (2) current clin. data on CDT, and (3) the need for more clin. studies to establish a framework for the use of CDT.  Perspective: More preclin., clin., and translational studies are needed to improve the efficacy of combination drug therapy that is an integral part of a comprehensive approach to the management of chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjDPNs-xJvEbVg90H21EOLACvtfcHk0lg3jdAFOMskkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D&md5=955711ac2946dd44adc0e8b96b6ee423</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2010.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2010.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DGold%26aufirst%3DM.%2BS.%26aulast%3DBackonja%26aufirst%3DM.%2BM.%26atitle%3DCombination%2520drug%2520therapy%2520for%2520chronic%2520pain%253A%2520a%2520call%2520for%2520more%2520clinical%2520studies%26jtitle%3DJ.%2520Pain%26date%3D2011%26volume%3D12%26issue%3D2%26spage%3D157%26epage%3D166%26doi%3D10.1016%2Fj.jpain.2010.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielenberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benny, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaponis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergilio, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietramaggiori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer-Pietramaggiori, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lih, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomer, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwendener, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falck, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthati, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaipainen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amore, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeldin, D. C.</span></span> <span> </span><span class="NLM_article-title">Epoxyeicosanoids stimulate mutiorgan metastasis and tumor dormancy escape in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1172/JCI58128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1172%2FJCI58128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=22182838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=178-191&issue=1&author=D.+Panigrahyauthor=M.+L.+Edinauthor=C.+R.+Leeauthor=S.+Huangauthor=D.+R.+Bielenbergauthor=C.+E.+Butterfieldauthor=C.+M.+Barnesauthor=A.+Mammotoauthor=T.+Mammotoauthor=A.+Luriaauthor=O.+Bennyauthor=D.+M.+Chaponisauthor=A.+C.+Dudleyauthor=E.+R.+Greeneauthor=J.-A.+Vergilioauthor=G.+Pietramaggioriauthor=S.+S.+Scherer-Pietramaggioriauthor=S.+M.+Shortauthor=M.+Sethauthor=F.+B.+Lihauthor=K.+B.+Tomerauthor=J.+Yangauthor=R.+A.+Schwendenerauthor=B.+D.+Hammockauthor=J.+R.+Falckauthor=V.+L.+Manthatiauthor=D.+E.+Ingberauthor=A.+Kaipainenauthor=P.+A.+D%E2%80%99Amoreauthor=M.+W.+Kieranauthor=D.+C.+Zeldin&title=Epoxyeicosanoids+stimulate+mutiorgan+metastasis+and+tumor+dormancy+escape+in+mice&doi=10.1172%2FJCI58128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice</span></div><div class="casAuthors">Panigrahy, Dipak; Edin, Matthew L.; Lee, Craig R.; Huang, Sui; Bielenberg, Diane R.; Butterfield, Catherine E.; Barnes, Carmen M.; Mammoto, Akiko; Mammoto, Tadanori; Luria, Ayala; Benny, Ofra; Chaponis, Deviney M.; Dudley, Andrew C.; Greene, Emily R.; Vergilio, Jo-Anne; Pietramaggiori, Giorgio; Scherer-Pietramaggiori, Sandra S.; Short, Sarah M.; Seth, Meetu; Lih, Fred B.; Tomer, Kenneth B.; Yang, Jun; Schwendener, Reto A.; Hammock, Bruce D.; Falck, John R.; Manthati, Vijaya L.; Ingber, Donald E.; Kaipainen, Arja; D'Amore, Patricia A.; Kieran, Mark W.; Zeldin, Darryl C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-191</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Epoxyeicosatrienoic acids (EETs) are small mols. produced by cytochrome P 450 epoxygenases.  They are lipid mediators that act as autocrine or paracrine factors to regulate inflammation and vascular tone.  As a result, drugs that raise EET levels are in clin. trials for the treatment of hypertension and many other diseases.  However, despite their pleiotropic effects on cells, little is known about the role of these epoxyeicosanoids in cancer.  Here, using genetic and pharmacol. manipulation of endogenous EET levels, we demonstrate that EETs are crit. for primary tumor growth and metastasis in a variety of mouse models of cancer.  Remarkably, we found that EETs stimulated extensive multiorgan metastasis and escape from tumor dormancy in several tumor models.  This systemic metastasis was not caused by excessive primary tumor growth but depended on endothelium-derived EETs at the site of metastasis.  Administration of synthetic EETs recapitulated these results, while EET antagonists suppressed tumor growth and metastasis, demonstrating in vivo that pharmacol. modulation of EETs can affect cancer growth.  Furthermore, inhibitors of sol. epoxide hydrolase (sEH), the enzyme that metabolizes EETs, elevated endogenous EET levels and promoted primary tumor growth and metastasis.  Thus, our data indicate a central role for EETs in tumorigenesis, offering a mechanistic link between lipid signaling and cancer and emphasizing the crit. importance of considering possible effects of EET-modulating drugs on cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAwAKcpa92frVg90H21EOLACvtfcHk0lg3jdAFOMskkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFCltQ%253D%253D&md5=856c7a0ae6b8db3e747f8bfcbe11a8f0</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1172%2FJCI58128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI58128%26sid%3Dliteratum%253Aachs%26aulast%3DPanigrahy%26aufirst%3DD.%26aulast%3DEdin%26aufirst%3DM.%2BL.%26aulast%3DLee%26aufirst%3DC.%2BR.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DBielenberg%26aufirst%3DD.%2BR.%26aulast%3DButterfield%26aufirst%3DC.%2BE.%26aulast%3DBarnes%26aufirst%3DC.%2BM.%26aulast%3DMammoto%26aufirst%3DA.%26aulast%3DMammoto%26aufirst%3DT.%26aulast%3DLuria%26aufirst%3DA.%26aulast%3DBenny%26aufirst%3DO.%26aulast%3DChaponis%26aufirst%3DD.%2BM.%26aulast%3DDudley%26aufirst%3DA.%2BC.%26aulast%3DGreene%26aufirst%3DE.%2BR.%26aulast%3DVergilio%26aufirst%3DJ.-A.%26aulast%3DPietramaggiori%26aufirst%3DG.%26aulast%3DScherer-Pietramaggiori%26aufirst%3DS.%2BS.%26aulast%3DShort%26aufirst%3DS.%2BM.%26aulast%3DSeth%26aufirst%3DM.%26aulast%3DLih%26aufirst%3DF.%2BB.%26aulast%3DTomer%26aufirst%3DK.%2BB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSchwendener%26aufirst%3DR.%2BA.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DFalck%26aufirst%3DJ.%2BR.%26aulast%3DManthati%26aufirst%3DV.%2BL.%26aulast%3DIngber%26aufirst%3DD.%2BE.%26aulast%3DKaipainen%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DZeldin%26aufirst%3DD.%2BC.%26atitle%3DEpoxyeicosanoids%2520stimulate%2520mutiorgan%2520metastasis%2520and%2520tumor%2520dormancy%2520escape%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26issue%3D1%26spage%3D178%26epage%3D191%26doi%3D10.1172%2FJCI58128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McReynolds, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnych, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blocher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title"><i>In vitro</i> and <i>in vivo</i> metabolism of a potent inhibitor of soluble epoxide hydrolase, 1-(1-propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">464</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.3389%2Ffphar.2019.00464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=31143115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGksLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=464&author=D.+Wanauthor=J.+Yangauthor=C.+B.+McReynoldsauthor=B.+Barnychauthor=K.+M.+Wagnerauthor=C.+Morisseauauthor=S.+H.+Hwangauthor=J.+Sunauthor=R.+Blocherauthor=B.+D.+Hammock&title=In+vitro+and+in+vivo+metabolism+of+a+potent+inhibitor+of+soluble+epoxide+hydrolase%2C+1-%281-propionylpiperidin-4-yl%29-3-%284-%28trifluoromethoxy%29phenyl%29urea&doi=10.3389%2Ffphar.2019.00464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo metabolism of a potent inhibitor of soluble epoxide hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea</span></div><div class="casAuthors">Wan, Debin; Yang, Jun; McReynolds, Cindy B.; Barnych, Bogdan; Wagner, Karen M.; Morisseau, Christophe; Hwang, Sung Hee; Sun, Jia; Blocher, Rene; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">464</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (TPPU) is a potent sol. epoxide hydrolase inhibitor that is used extensively in research for modulating inflammation and protecting against hypertension, neuropathic pain, and neurodegeneration.  Herein, we describe the identification of TPPU metabolites using LC-MS/MS.  Four metabolites of TPPU (M1-M4) were identified from rat urine by a sensitive and specific LC-MS/MS method with double precursor ion scans.  Metabolites M1 and M2 were formed from hydroxylation on a propionyl group of TPPU; M3 was formed by amide hydrolysis of the 1-propionylpiperdinyl group on TPPU; and M4 was formed by further oxidn. of the hydroxylated metabolite M2.  M1, M2, and M3 were generated in liver S9 fractions from all species, and higher amts. of M3 were generated in monkey S9 fractions compared to other species.  In addn., rat and human S9 metab. showed the highest species similarity based on the quantities of each metabolite.  The presence of all four metabolites were confirmed in vivo in rats over 72-h post single oral dose of TPPU.  All four metabolites were potent inhibitors of human sEH but were less potent than the parent TPPU.  In conclusion, TPPU is metabolized via oxidn. and amide hydrolysis without apparent breakdown of the urea.  Our findings increase the confidence in the ability to translate preclin. PK of TPPU in rats to humans and facilitates the potential clin. development of TPPU and other sEH inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVf1dfQAbZ47Vg90H21EOLACvtfcHk0ljdCueosROqpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGksLbF&md5=1f98a0e3d72191d2f19994d4d9cdf831</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00464%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMcReynolds%26aufirst%3DC.%2BB.%26aulast%3DBarnych%26aufirst%3DB.%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DBlocher%26aufirst%3DR.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520metabolism%2520of%2520a%2520potent%2520inhibitor%2520of%2520soluble%2520epoxide%2520hydrolase%252C%25201-%25281-propionylpiperidin-4-yl%2529-3-%25284-%2528trifluoromethoxy%2529phenyl%2529urea%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D464%26doi%3D10.3389%2Ffphar.2019.00464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schebb, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects</span>. <i>Environ. Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3115</span>, <span class="refDoi"> DOI: 10.1021/es103650m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/es103650m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVSgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2011&pages=3109-3115&issue=7&author=N.+H.+Schebbauthor=B.+Inceogluauthor=K.+C.+Ahnauthor=C.+Morisseauauthor=S.+J.+Geeauthor=B.+D.+Hammock&title=Investigation+of+human+exposure+to+triclocarban+after+showering+and+preliminary+evaluation+of+its+biological+effects&doi=10.1021%2Fes103650m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of Human Exposure to Triclocarban after Showering and Preliminary Evaluation of Its Biological Effects</span></div><div class="casAuthors">Schebb, Nils Helge; Inceoglu, Bora; Ahn, Ki Chang; Morisseau, Christophe; Gee, Shirley J.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Environmental Science & Technology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3109-3115</span>CODEN:
                <span class="NLM_cas:coden">ESTHAG</span>;
        ISSN:<span class="NLM_cas:issn">0013-936X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antibacterial soap additive triclocarban (TCC) is widely used in personal care products.  TCC has a high environmental persistence.  We developed and validated a sensitive online solid-phase extn.-LC-MS/MS method to rapidly analyze TCC and its major metabolites in urine and other biol. samples to assess human exposure.  We measured human urine concns. 0-72 h after showering with a com. bar soap contg. 0.6% TCC.  The major route of renal elimination was excretion as N-glucuronides.  The absorption was estd. at 0.6% of the 70 ± 15 mg of TCC in the soap used.  The TCC-N-glucuronide urine concn. varied widely among the subjects, and continuous daily use of the soap led to steady state levels of excretion.  In order to assess potential biol. effects arising from this exposure, we screened TCC for the inhibition of human enzymes in vitro.  We demonstrate that TCC is a potent inhibitor of the enzyme sol. epoxide hydrolase (sEH), whereas TCC's major metabolites lack strong inhibitory activity.  Topical administration of TCC at similar levels to rats in a preliminary in vivo study, however, failed to alter plasma biomarkers of sEH activity.  Overall the anal. strategy described here revealed that use of TCC soap causes exposure levels that warrant further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoHOcjmXd8d7Vg90H21EOLACvtfcHk0ljdCueosROqpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVSgtbo%253D&md5=802ca941b7bbfd6ed8485f1414109d45</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fes103650m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fes103650m%26sid%3Dliteratum%253Aachs%26aulast%3DSchebb%26aufirst%3DN.%2BH.%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DAhn%26aufirst%3DK.%2BC.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DGee%26aufirst%3DS.%2BJ.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DInvestigation%2520of%2520human%2520exposure%2520to%2520triclocarban%2520after%2520showering%2520and%2520preliminary%2520evaluation%2520of%2520its%2520biological%2520effects%26jtitle%3DEnviron.%2520Sci.%2520Technol.%26date%3D2011%26volume%3D45%26issue%3D7%26spage%3D3109%26epage%3D3115%26doi%3D10.1021%2Fes103650m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulciner, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhasin, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielenberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwowarski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler-Ferran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staffa, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhatme, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhasin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhatme, V. P.</span></span> <span> </span><span class="NLM_article-title">2019. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2964</span>– <span class="NLM_lpage">2979</span>, <span class="refDoi"> DOI: 10.1172/JCI127282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1172%2FJCI127282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=31205032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BB3M3ntlemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2019&pages=2964-2979&issue=7&author=D.+Panigrahyauthor=A.+Gartungauthor=J.+Yangauthor=H.+Yangauthor=M.+M.+Gilliganauthor=M.+L.+Sulcinerauthor=S.+S.+Bhasinauthor=D.+R.+Bielenbergauthor=J.+Changauthor=B.+A.+Schmidtauthor=J.+Piwowarskiauthor=A.+Fishbeinauthor=D.+Soler-Ferranauthor=M.+A.+Sparksauthor=S.+J.+Staffaauthor=V.+Sukhatmeauthor=B.+D.+Hammockauthor=M.+W.+Kieranauthor=S.+Huangauthor=M.+Bhasinauthor=C.+N.+Serhanauthor=V.+P.+Sukhatme&title=2019.+Preoperative+stimulation+of+resolution+and+inflammation+blockade+eradicates+micrometastases&doi=10.1172%2FJCI127282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases</span></div><div class="casAuthors">Panigrahy Dipak; Gartung Allison; Yang Haixia; Gilligan Molly M; Sulciner Megan L; Chang Jaimie; Piwowarski Julia; Fishbein Anna; Soler-Ferran Dulce; Panigrahy Dipak; Gartung Allison; Yang Haixia; Gilligan Molly M; Sulciner Megan L; Chang Jaimie; Piwowarski Julia; Fishbein Anna; Soler-Ferran Dulce; Panigrahy Dipak; Gartung Allison; Yang Haixia; Gilligan Molly M; Sulciner Megan L; Chang Jaimie; Piwowarski Julia; Fishbein Anna; Soler-Ferran Dulce; Sukhatme Vikas P; Yang Jun; Hammock Bruce D; Bhasin Swati S; Bhasin Manoj; Sukhatme Vikas P; Bielenberg Diane R; Schmidt Birgitta A; Sparks Matthew A; Staffa Steven J; Sukhatme Vidula; Kieran Mark W; Kieran Mark W; Huang Sui; Serhan Charles N; Sukhatme Vikas P</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2964-2979</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer therapy is a double-edged sword, as surgery and chemotherapy can induce an inflammatory/immunosuppressive injury response that promotes dormancy escape and tumor recurrence.  We hypothesized that these events could be altered by early blockade of the inflammatory cascade and/or by accelerating the resolution of inflammation.  Preoperative, but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival.  Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint blockade, negated by adjuvant chemotherapy, and dependent on inhibition of the COX-1/thromboxane A2 (TXA2) pathway.  Preoperative stimulation of inflammation resolution via resolvins (RvD2, RvD3, and RvD4) inhibited metastases and induced T cell responses.  Ketorolac and resolvins exhibited synergistic antitumor activity and prevented surgery- or chemotherapy-induced dormancy escape.  Thus, simultaneously blocking the ensuing proinflammatory response and activating endogenous resolution programs before surgery may eliminate micrometastases and reduce tumor recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR94q3w7H_kvENoizSOkG_FfW6udTcc2eZ8-l00lf5f_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3ntlemtA%253D%253D&md5=f52a90d982a135491f4ba64799b4ca2d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1172%2FJCI127282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI127282%26sid%3Dliteratum%253Aachs%26aulast%3DPanigrahy%26aufirst%3DD.%26aulast%3DGartung%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DGilligan%26aufirst%3DM.%2BM.%26aulast%3DSulciner%26aufirst%3DM.%2BL.%26aulast%3DBhasin%26aufirst%3DS.%2BS.%26aulast%3DBielenberg%26aufirst%3DD.%2BR.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DB.%2BA.%26aulast%3DPiwowarski%26aufirst%3DJ.%26aulast%3DFishbein%26aufirst%3DA.%26aulast%3DSoler-Ferran%26aufirst%3DD.%26aulast%3DSparks%26aufirst%3DM.%2BA.%26aulast%3DStaffa%26aufirst%3DS.%2BJ.%26aulast%3DSukhatme%26aufirst%3DV.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DBhasin%26aufirst%3DM.%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26aulast%3DSukhatme%26aufirst%3DV.%2BP.%26atitle%3D2019.%2520Preoperative%2520stimulation%2520of%2520resolution%2520and%2520inflammation%2520blockade%2520eradicates%2520micrometastases%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2019%26volume%3D129%26issue%3D7%26spage%3D2964%26epage%3D2979%26doi%3D10.1172%2FJCI127282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahy, D.</span></span> <span> </span><span class="NLM_article-title">Eicosanoids: the overlooked storm in COVID-19?</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1782</span>– <span class="NLM_lpage">1788</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2020.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.ajpath.2020.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32650004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWqtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=1782-1788&issue=9&author=B.+D.+Hammockauthor=W.+Wangauthor=M.+M.+Gilliganauthor=D.+Panigrahy&title=Eicosanoids%3A+the+overlooked+storm+in+COVID-19%3F&doi=10.1016%2Fj.ajpath.2020.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Eicosanoids</span></div><div class="casAuthors">Hammock, Bruce D.; Wang, Weicang; Gilligan, Molly M.; Panigrahy, Dipak</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1782-1788</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Coronavirus infection causes tissue damage, which triggers the endoplasmic reticulum stress response and subsequent eicosanoid and cytokine storms.  Although proinflammatory eicosanoids, including prostaglandins, thromboxanes, and leukotrienes, are crit. mediators of physiol. processes, such as inflammation, fever, allergy, and pain, their roles in COVID-19 are poorly characterized.  Sol. epoxide hydrolase (sEH) inhibitors, which increase endogenous epoxyeicosatrienoic acid levels, exhibit potent anti-inflammatory activity and inhibit various pathol. processes in preclin. disease models, including pulmonary fibrosis, thrombosis, and acute respiratory distress syndrome.  Therefore, targeting eicosanoids and sEH could be a novel therapeutic approach in combating COVID-19.  In this review, we discuss the predominant role of eicosanoids in regulating the inflammatory cascade and propose the potential application of sEH inhibitors in alleviating COVID-19 symptoms.  The host-protective action of omega-3 fatty acid-derived epoxyeicosanoids and specialized proresolving mediators in regulating anti-inflammation and antiviral response is also discussed.  Future studies detg. the eicosanoid profile in COVID-19 patients or preclin. models are pivotal in providing novel insights into coronavirus-host interaction and inflammation modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtsUL0nMdG8bVg90H21EOLACvtfcHk0licuvWbEi-j_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWqtb3O&md5=5fa7d7375eacd897cb1f0a67a9821821</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2020.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2020.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DGilligan%26aufirst%3DM.%2BM.%26aulast%3DPanigrahy%26aufirst%3DD.%26atitle%3DEicosanoids%253A%2520the%2520overlooked%2520storm%2520in%2520COVID-19%253F%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2020%26volume%3D190%26issue%3D9%26spage%3D1782%26epage%3D1788%26doi%3D10.1016%2Fj.ajpath.2020.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Increased expression of soluble epoxide hydrolase in the brain and liver from patients with major psychiatric disorders: A role of brain - liver axis</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2020.03.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.jad.2020.03.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32339103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnt1Wmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=2020&pages=131-134&author=J.+Zhangauthor=Y.+Tanauthor=L.+Changauthor=B.+D.+Hammockauthor=K.+Hashimoto&title=Increased+expression+of+soluble+epoxide+hydrolase+in+the+brain+and+liver+from+patients+with+major+psychiatric+disorders%3A+A+role+of+brain+-+liver+axis&doi=10.1016%2Fj.jad.2020.03.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of soluble epoxide hydrolase in the brain and liver from patients with major psychiatric disorders: A role of brain - liver axis</span></div><div class="casAuthors">Zhang, Jiancheng; Tan, Yunfei; Chang, Lijia; Hammock, Bruce D.; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">131-134</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH) in the metab. of polyunsatd. fatty acids might play a role in the pathogenesis of major psychiatric disorders.  Here we studied whether expression of sEH protein is altered in the postmortem samples (parietal cortex, and liver) from patients with major psychiatric disorders.  Protein expression of sEH in the parietal cortex and liver from control, major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ) groups was measured.  Levels of sEH in the parietal cortex and liver from MDD, BD, and SZ groups were significantly higher than the control group.  Interestingly, there was a pos. correlation between sEH protein in the parietal cortex and sEH protein the liver in all groups.  The small no. in each group may limit our interpretation.  This study shows that the increased expression of sEH in the brain and liver might play a role in the pathogenesis of major psychiatric disorders, suggesting a role of brain - liver axis in major psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_UW8wP5n0W7Vg90H21EOLACvtfcHk0licuvWbEi-j_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnt1Wmsrc%253D&md5=11fe220d337c157381d80100cd0d888d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2020.03.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2020.03.070%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DIncreased%2520expression%2520of%2520soluble%2520epoxide%2520hydrolase%2520in%2520the%2520brain%2520and%2520liver%2520from%2520patients%2520with%2520major%2520psychiatric%2520disorders%253A%2520A%2520role%2520of%2520brain%2520-%2520liver%2520axis%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2020%26volume%3D270%26spage%3D131%26epage%3D134%26doi%3D10.1016%2Fj.jad.2020.03.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sole, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis</span>. <i>Vet. Anaesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">440</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1111/vaa.12030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1111%2Fvaa.12030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23463912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1Cltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=440-448&issue=4&author=A.+Guedesauthor=C.+Morisseauauthor=A.+Soleauthor=J.+H.+Soaresauthor=A.+Uluauthor=H.+Dongauthor=B.+D.+Hammock&title=Use+of+a+soluble+epoxide+hydrolase+inhibitor+as+an+adjunctive+analgesic+in+a+horse+with+laminitis&doi=10.1111%2Fvaa.12030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis</span></div><div class="casAuthors">Guedes, Alonso G. P.; Morisseau, Christophe; Sole, Albert; Soares, Joao H. N.; Ulu, Arzu; Dong, Hua; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Veterinary Anaesthesia and Analgesia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">440-448</span>CODEN:
                <span class="NLM_cas:coden">VANAFV</span>;
        ISSN:<span class="NLM_cas:issn">1467-2987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">History : A 4-yr old, 500 kg Thoroughbred female horse diagnosed with bilateral forelimb laminitis and cellulitis on the left forelimb became severely painful and refractory to non-steroidal anti-inflammatory therapy (flunixin meglumine on days 1, 2, 3 and 4; and phenylbutazone on days 5, 6 and 7) alone or in combination with gabapentin (days 6 and 7).  Phys. examn. : Pain scores assessed independently by three individuals with a visual analog scale (VAS; 0 = no pain and 10 = worst possible pain) were 8.5 on day 6, and it increased to 9.5 on day 7.  Non-invasive blood pressure monitoring revealed severe hypertension.  Management : As euthanasia was being considered for humane reasons, a decision was made to add an exptl. new drug, trans-4-{4-[3-(4-Trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB), which is a sol. epoxide hydrolase (sEH) inhibitor, to the treatment protocol.  Dose and frequency of administration were selected based on the drug potency against equine sEH to produce plasma concns. within the range of 30 nmol L-1 and 2.5 μmol L-1.  Pain scores decreased sharply and remarkably following t-TUCB administration and blood pressure progressively decreased to physiol. normal values.  Plasma concns. of t-TUCB, measured daily, were within the expected range, whereas phenylbutazone and gabapentin plasma levels were below the suggested efficacious concns.  Follow up : No adverse effects were detected on clin. and lab. examns. during and after t-TUCB administration.  No new episodes of laminitis have been noted up to the time of writing (120 days following treatment).  Conclusions : Inhibition of sEH with t-TUCB was assocd. with a significant improvement in pain scores in one horse with laminitis whose pain was refractory to the std. of care therapy.  No adverse effects were noticed.  Future studies evaluating the analgesic and protective effects of these compds. in painful inflammatory diseases in animals are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLqZiVpk8sCrVg90H21EOLACvtfcHk0licuvWbEi-j_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1Cltb4%253D&md5=073191c368edf26b1e2152fafd71334c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fvaa.12030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fvaa.12030%26sid%3Dliteratum%253Aachs%26aulast%3DGuedes%26aufirst%3DA.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DSole%26aufirst%3DA.%26aulast%3DSoares%26aufirst%3DJ.%2BH.%26aulast%3DUlu%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DUse%2520of%2520a%2520soluble%2520epoxide%2520hydrolase%2520inhibitor%2520as%2520an%2520adjunctive%2520analgesic%2520in%2520a%2520horse%2520with%2520laminitis%26jtitle%3DVet.%2520Anaesth.%2520Analg.%26date%3D2013%26volume%3D40%26issue%3D4%26spage%3D440%26epage%3D448%26doi%3D10.1111%2Fvaa.12030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuppo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis</span>. <i>Equine Vet. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1111/evj.12603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1111%2Fevj.12603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=27338788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BC2s7jt1Kltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=345-351&issue=3&author=A.+Guedesauthor=L.+Galuppoauthor=D.+Hoodauthor=S.+H.+Hwangauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+activity+and+pharmacologic+inhibition+in+horses+with+chronic+severe+laminitis&doi=10.1111%2Fevj.12603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis</span></div><div class="casAuthors">Guedes A; Guedes A; Galuppo L; Hood D; Hwang S H; Morisseau C; Hammock B D</div><div class="citationInfo"><span class="NLM_cas:title">Equine veterinary journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-351</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The roles of soluble epoxide hydrolase and lipid mediators in inflammatory and neuropathic pain could be relevant in laminitis pain management.  OBJECTIVES:  To determine soluble epoxide hydrolase (sEH) activity in the digital laminae, sEH inhibitor potency in vitro, and efficacy of a sEH inhibitor as an adjunct analgesic therapy in chronic laminitic horses.  STUDY DESIGN:  In vitro experiments and clinical case series.  METHODS:  sEH activity was measured in digital laminae from euthanised healthy and laminitic horses (n = 5-6/group).  Potency of 7 synthetic sEH inhibitors was determined in vitro using equine liver cytosol.  One of them (t-TUCB; 0.1 mg/kg bwt i.v. every 24 h) was selected based on potency and stability, and used as adjunct therapy in 10 horses with severe chronic laminitis (Obel grades 2, one horse; 3-4, nine horses).  Daily assessments of forelimb lifts, pain scores, physiologic and laboratory examinations were performed before (baseline) and during t-TUCB treatment.  Data are presented as mean ± s.d. and 95% confidence intervals (CI).  RESULTS:  sEH activity in the digital laminae from laminitic horses (0.9±0.6 nmol/min/mg; 95% CI 0.16-1.55 nmol/min/mg) was significantly greater (P = 0.01) than in healthy horses (0.17±0.09 nmol/min/mg; CI 0.07-0.26 nmol/min/mg). t-TUCB as an adjunct analgesic up to 10 days (4.3±3 days) in laminitic horses was associated with significant reduction in forelimb lifts (36±22%; 95% CI 9-64%) and in pain scores (18±23%; 95% CI 2-35%) compared with baseline (P = 0.04).  One horse developed gas colic and another corneal vascularisation in a blind eye during treatment.  No other significant changes were observed.  MAIN LIMITATIONS:  Absence of control group and evaluator blinding in case series.  CONCLUSIONS:  sEH activity is significantly higher in the digital laminae of actively laminitic compared with healthy horses, and use of a potent inhibitor of equine sEH as adjunct analgesic therapy appears to decrease signs of pathologic pain in laminitic horses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUX3G0aXvxAUcLvDNbOD4DfW6udTcc2ebPbDUZ3Stoubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7jt1Kltg%253D%253D&md5=53234423e0ea1c9ce9a1585f310520e5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fevj.12603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fevj.12603%26sid%3Dliteratum%253Aachs%26aulast%3DGuedes%26aufirst%3DA.%26aulast%3DGaluppo%26aufirst%3DL.%26aulast%3DHood%26aufirst%3DD.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520activity%2520and%2520pharmacologic%2520inhibition%2520in%2520horses%2520with%2520chronic%2520severe%2520laminitis%26jtitle%3DEquine%2520Vet.%2520J.%26date%3D2017%26volume%3D49%26issue%3D3%26spage%3D345%26epage%3D351%26doi%3D10.1111%2Fevj.12603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McReynolds, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical effects of inhibiting the soluble epoxide hydrolase in canine osteoarthritis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">533</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.3389%2Ffphar.2019.00533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=31214021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlGqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=533&author=C.+B.+McReynoldsauthor=S.+H.+Hwangauthor=J.+Yangauthor=D.+Wanauthor=K.+Wagnerauthor=C.+Morisseauauthor=D.+Liauthor=W.+K.+Schmidtauthor=B.+D.+Hammock&title=Pharmaceutical+effects+of+inhibiting+the+soluble+epoxide+hydrolase+in+canine+osteoarthritis&doi=10.3389%2Ffphar.2019.00533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceutical effects of inhibiting the soluble epoxide hydrolase in canine osteoarthritis</span></div><div class="casAuthors">McReynolds, Cindy B.; Hwang, Sung Hee; Yang, Jun; Wan, Debin; Wagner, Karen; Morisseau, Christophe; Li, Dongyang; Schmidt, William K.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">533</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Osteoarthritis (OA) is a degenerative joint disease that causes pain and bone deterioration driven by an increase in prostaglandins (PGs) and inflammatory cytokines.  Current treatments focus on inhibiting prostaglandin prodn., a pro-inflammatory lipid metabolite, with NSAID drugs; however, other lipid signaling targets could provide safer and more effective treatment strategies.  Epoxides of polyunsatd. fatty acids (PUFAs) are anti-inflammatory lipid mediators that are rapidly metabolized by the sol. epoxide hydrolase (sEH) into corresponding vicinal diols.  Interestingly, diol levels are increased in the synovial fluid of humans with OA, warranting further research on the biol. role of this lipid pathway in the progression of OA. sEH inhibitors (sEHI) stabilize these biol. active, anti-inflammatory lipid epoxides, resulting in analgesia in both neuropathic, and inflammatory pain conditions.  Most exptl. studies testing the analgesic effects of sEH inhibitors have used exptl. rodent models, which do not completely represent the complex etiol. of painful diseases.  Here, we tested the efficacy of sEHI in aged dogs with natural arthritis to provide a better representation of the clin. manifestations of pain.  Two sEHI were administered orally, once daily for 5 days to dogs with naturally occurring arthritis to assess efficacy and pharmacokinetics.  Blinded technicians recorded the behavior of the arthritic dogs based on pre-detd. criteria to assess pain and function.  After 5 days, EC1728 significantly reduced pain at a dose of 5 mg/kg compared to vehicle controls.  Pharmacokinetic evaluation showed concns. exceeding the enzyme potency in both plasma and synovial fluid.  In vitro data showed that epoxyeicosatrienoic acid (EETs), epoxide metabolites of arachidonic acid, decreased inflammatory cytokines, IL-6 and TNF-α, and reduced cytotoxicity in canine chondrocytes challenged with IL1β to simulate an arthritic environment.  These results provide the first example of altering lipid epoxides as a therapeutic target for OA potentially acting by protecting chondrocytes from inflammatory induced cytotoxicity.  Considering the challenges and high variability of naturally occurring disease in aged dogs, these data provide initial proof of concept justification that inhibiting the sEH is a non-NSAID, non-opioid, disease altering strategy for treating OA, and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDYCxYyjkySrVg90H21EOLACvtfcHk0lh3KHVOgZz2jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlGqsLg%253D&md5=60f714d2bf594d46934d6146310a922c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00533%26sid%3Dliteratum%253Aachs%26aulast%3DMcReynolds%26aufirst%3DC.%2BB.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DPharmaceutical%2520effects%2520of%2520inhibiting%2520the%2520soluble%2520epoxide%2520hydrolase%2520in%2520canine%2520osteoarthritis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D533%26doi%3D10.3389%2Ffphar.2019.00533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, G.</span></span> <span> </span><span class="NLM_article-title">Simultaneous target-mediated drug disposition (TMDD) model for two small-molecule compounds competing for their pharmacological target: soluble epoxide hydrolase</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>374</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1124/jpet.120.265330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1124%2Fjpet.120.265330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32238455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFWksbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2020&pages=223-232&issue=1&author=N.+Wuauthor=B.+Hammockauthor=K.+S.+S.+Leeauthor=G.+An&title=Simultaneous+target-mediated+drug+disposition+%28TMDD%29+model+for+two+small-molecule+compounds+competing+for+their+pharmacological+target%3A+soluble+epoxide+hydrolase&doi=10.1124%2Fjpet.120.265330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous target-mediated drug disposition model for two small-molecule compounds competing for their pharmacological target: soluble epoxide hydrolase</span></div><div class="casAuthors">Wu, Nan; Hammock, Bruce D.; Lee, Kin Sing Stephen; An, Guohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-241</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">1-(1-Propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU) and 1-(4-trifluoro-methoxy-phenyl)-3-(1-cyclopropanecarbonyl-piperidin-4-yl)-urea (TCPU) are potent inhibitors of sol. epoxide hydrolase (sEH) that have much better efficacy in relieving nociceptive response than the Food and Drug Administration-approved drug gabapentin in a rodent model of diabetic neuropathy.  Expts. conducted in sEH knockout mice or with coadministration of a potent sEH displacer demonstrated that the pharmacokinetics of TPPU and TCPU were influenced by the specific binding to their pharmacol. target sEH, a phenomenon known as target-mediated drug disposition (TMDD).  To quant. characterize the complex pharmacokinetics of TPPU and TCPU and gain better understanding on their target occupancy, population pharmacokinetics anal. using a nonlinear mixed-effect modeling approach was performed in the current study.  The final model was a novel simultaneous TMDD interaction model, in which TPPU and TCPU compete for sEH, with TCPU binding to an addnl. unknown target pool with larger capacity that we refer to as a refractory pool.  The total amt. of sEH enzyme in mice was predicted to be 16.2 nmol, which is consistent with the exptl. value of 10 nmol.  The dissoc. rate consts. of TPPU and TCPU were predicted to be 2.24 and 2.67 h-1, resp., which is close to the values obtained from in vitro expts.  Our simulation result predicted that 90% of the sEH will be occupied shortly after a low dose of 0.3 mg/kg TPPU administration, with ≥40% of sEH remaining to be bound with TPPU for at least 7 days.  Further efficacy expts. are warranted to confirm the predicted target occupancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWtWrrihlRU7Vg90H21EOLACvtfcHk0lh3KHVOgZz2jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFWksbrN&md5=60f6c9eea253aa78ddd8dcaf820f8b43</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fjpet.120.265330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.120.265330%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DN.%26aulast%3DHammock%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DAn%26aufirst%3DG.%26atitle%3DSimultaneous%2520target-mediated%2520drug%2520disposition%2520%2528TMDD%2529%2520model%2520for%2520two%2520small-molecule%2520compounds%2520competing%2520for%2520their%2520pharmacological%2520target%253A%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2020%26volume%3D374%26issue%3D1%26spage%3D223%26epage%3D232%26doi%3D10.1124%2Fjpet.120.265330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39a','cit39b'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Samuel Obeng, Takato Hiranita, Francisco León, Lance R. McMahon, <span class="NLM_string-name hlFld-ContribAuthor">Christopher R. McCurdy</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6523-6548. <a href="https://doi.org/10.1021/acs.jmedchem.1c00028" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00028%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BApproaches%25252C%252BDrug%252BCandidates%25252C%252Band%252BTargets%252Bin%252BPain%252BDrug%252BDiscovery%26aulast%3DObeng%26aufirst%3DSamuel%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D07012021%26date%3D06052021%26volume%3D64%26issue%3D10%26spage%3D6523%26epage%3D6548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sandra Codony, Carla Calvó-Tusell, Elena Valverde, Sílvia Osuna, Christophe Morisseau, M. Isabel Loza, José Brea, Concepción Pérez, María Isabel Rodríguez-Franco, Javier Pizarro-Delgado, Rubén Corpas, Christian Griñán-Ferré, Mercè Pallàs, Coral Sanfeliu, Manuel Vázquez-Carrera, Bruce D. Hammock, Ferran Feixas, <span class="NLM_string-name hlFld-ContribAuthor">Santiago Vázquez</span>. </span><span class="cited-content_cbyCitation_article-title">From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5429-5446. <a href="https://doi.org/10.1021/acs.jmedchem.0c01601" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01601%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFrom%252Bthe%252BDesign%252Bto%252Bthe%252BIn%252BVivo%252BEvaluation%252Bof%252BBenzohomoadamantane-Derived%252BSoluble%252BEpoxide%252BHydrolase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BPancreatitis%26aulast%3DCodony%26aufirst%3DSandra%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D14092020%26date%3D04052021%26volume%3D64%26issue%3D9%26spage%3D5429%26epage%3D5446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elham  Rezaee</span>, <span class="hlFld-ContribAuthor ">Hamid Reza  Shadzad</span>, <span class="hlFld-ContribAuthor ">Maryam  Nazari</span>, <span class="hlFld-ContribAuthor ">Sayyed Abbas  Tabatabai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of some 1,2,3-triazole derivatives as novel amide-based inhibitors of soluble epoxide hydrolase. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>19 </em><a href="https://doi.org/10.1007/s00044-021-02752-3" title="DOI URL">https://doi.org/10.1007/s00044-021-02752-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-021-02752-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-021-02752-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bsome%252B1%25252C2%25252C3-triazole%252Bderivatives%252Bas%252Bnovel%252Bamide-based%252Binhibitors%252Bof%252Bsoluble%252Bepoxide%252Bhydrolase%26aulast%3DRezaee%26aufirst%3DElham%26date%3D2021%26date%3D2021%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Yu  Zhao</span>, <span class="hlFld-ContribAuthor ">Juan-Juan  Yan</span>, <span class="hlFld-ContribAuthor ">Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Chao  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Feng</span>, <span class="hlFld-ContribAuthor ">Xia  Lv</span>, <span class="hlFld-ContribAuthor ">Xiao-Kui  Huo</span>, <span class="hlFld-ContribAuthor ">Cheng-Peng  Sun</span>, <span class="hlFld-ContribAuthor ">Li-Xia  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao-Chi  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Natural soluble epoxide hydrolase inhibitors from Inula britanica and their potential interactions with soluble epoxide hydrolase: Insight from inhibition kinetics and molecular dynamics. </span><span class="cited-content_cbyCitation_journal-name">Chemico-Biological Interactions</span><span> <strong>2021,</strong> <em>345 </em>, 109571. <a href="https://doi.org/10.1016/j.cbi.2021.109571" title="DOI URL">https://doi.org/10.1016/j.cbi.2021.109571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbi.2021.109571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbi.2021.109571%26sid%3Dliteratum%253Aachs%26jtitle%3DChemico-Biological%2520Interactions%26atitle%3DNatural%252Bsoluble%252Bepoxide%252Bhydrolase%252Binhibitors%252Bfrom%252BInula%252Bbritanica%252Band%252Btheir%252Bpotential%252Binteractions%252Bwith%252Bsoluble%252Bepoxide%252Bhydrolase%25253A%252BInsight%252Bfrom%252Binhibition%252Bkinetics%252Band%252Bmolecular%252Bdynamics%26aulast%3DZhao%26aufirst%3DWen-Yu%26date%3D2021%26volume%3D345%26spage%3D109571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. V.  Burmistrov</span>, <span class="hlFld-ContribAuthor ">D. S.  Karlov</span>, <span class="hlFld-ContribAuthor ">G. M.  Butov</span>, <span class="hlFld-ContribAuthor ">I. A.  Novakov</span>. </span><span class="cited-content_cbyCitation_article-title">Prospects for the inhibition of the phosphatase domain of human soluble epoxide hydrolase (sEH-P). </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Bulletin</span><span> <strong>2021,</strong> <em>70 </em>
                                    (6)
                                     , 1067-1074. <a href="https://doi.org/10.1007/s11172-021-3185-4" title="DOI URL">https://doi.org/10.1007/s11172-021-3185-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11172-021-3185-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11172-021-3185-4%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Bulletin%26atitle%3DProspects%252Bfor%252Bthe%252Binhibition%252Bof%252Bthe%252Bphosphatase%252Bdomain%252Bof%252Bhuman%252Bsoluble%252Bepoxide%252Bhydrolase%252B%252528sEH-P%252529%26aulast%3DBurmistrov%26aufirst%3DV.%2BV.%26date%3D2021%26date%3D2021%26volume%3D70%26issue%3D6%26spage%3D1067%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seung  Baek</span>, <span class="hlFld-ContribAuthor ">Bruce  Hammock</span>, <span class="hlFld-ContribAuthor ">In-Koo  Hwang</span>, <span class="hlFld-ContribAuthor ">Qing  Li</span>, <span class="hlFld-ContribAuthor ">Naima  Moustaid-Moussa</span>, <span class="hlFld-ContribAuthor ">Yeonhwa  Park</span>, <span class="hlFld-ContribAuthor ">Stephen  Safe</span>, <span class="hlFld-ContribAuthor ">Nanjoo  Suh</span>, <span class="hlFld-ContribAuthor ">Sun-Shin  Yi</span>, <span class="hlFld-ContribAuthor ">Darryl  Zeldin</span>, <span class="hlFld-ContribAuthor ">Qixin  Zhong</span>, <span class="hlFld-ContribAuthor ">Jennifer  Bradbury</span>, <span class="hlFld-ContribAuthor ">Matthew  Edin</span>, <span class="hlFld-ContribAuthor ">Joan  Graves</span>, <span class="hlFld-ContribAuthor ">Hyo-Young  Jung</span>, <span class="hlFld-ContribAuthor ">Young-Hyun  Jung</span>, <span class="hlFld-ContribAuthor ">Mi-Bo  Kim</span>, <span class="hlFld-ContribAuthor ">Woosuk  Kim</span>, <span class="hlFld-ContribAuthor ">Jaehak  Lee</span>, <span class="hlFld-ContribAuthor ">Hong  Li</span>, <span class="hlFld-ContribAuthor ">Jong-Seok  Moon</span>, <span class="hlFld-ContribAuthor ">Ik-Dong  Yoo</span>, <span class="hlFld-ContribAuthor ">Yiren  Yue</span>, <span class="hlFld-ContribAuthor ">Ji-Young  Lee</span>, <span class="hlFld-ContribAuthor ">Ho-Jae  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Natural Products in the Prevention of Metabolic Diseases: Lessons Learned from the 20th KAST Frontier Scientists Workshop. </span><span class="cited-content_cbyCitation_journal-name">Nutrients</span><span> <strong>2021,</strong> <em>13 </em>
                                    (6)
                                     , 1881. <a href="https://doi.org/10.3390/nu13061881" title="DOI URL">https://doi.org/10.3390/nu13061881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/nu13061881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fnu13061881%26sid%3Dliteratum%253Aachs%26jtitle%3DNutrients%26atitle%3DNatural%252BProducts%252Bin%252Bthe%252BPrevention%252Bof%252BMetabolic%252BDiseases%25253A%252BLessons%252BLearned%252Bfrom%252Bthe%252B20th%252BKAST%252BFrontier%252BScientists%252BWorkshop%26aulast%3DBaek%26aufirst%3DSeung%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D6%26spage%3D1881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">EC5026, an Analgesic Without the Addictive Potential of Opioids. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2021,</strong>,, 0568. <a href="https://doi.org/10.1055/s-0040-1719802" title="DOI URL">https://doi.org/10.1055/s-0040-1719802</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1719802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1719802%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DEC5026%25252C%252Ban%252BAnalgesic%252BWithout%252Bthe%252BAddictive%252BPotential%252Bof%252BOpioids%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D05%26spage%3D0568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of early stage sEHI. A commonly used four-letter abbreviation and a University of California (UC) number are provided. Our lead compound in this series was DCU. The presence of an adamantyl group made the sEHI more potent and easier to detect by LC-MS in blood. They also tended to mimic EpFA, which were the presumptive substrates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of late stage sEH inhibitors. A commonly used four-letter abbreviation and University of California numbers are provided.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical properties impact ease of formulation. Generally, the more potent the compound the more facile the formulation. There are relatively routine procedures to formulate high melting or poorly water-soluble materials, but high melting poorly soluble crystals are a challenge. This problem was addressed by synthesis to increase potency on the human target enzyme, increase water solubility, and reduce the stability of the crystal structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Roles of EETs and sEH in the arachidonic acid cascade. Similar products arise from other polyunsaturated fatty acids. EETs are epoxides of arachidonic acid, and DHETs are the corresponding diols.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) The crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OD0">4OD0</a>) of human sEH bound with TPPU (cyan, stick) showed that Tyr383 and Tyr466 formed tight hydrogen bonding with the carbonyl oxygen of the urea and Asp336 formed a tight hydrogen bonding with the urea hydrogens. (B) The crystal structure revived the long hydrophobic binding channel at the C-terminus domain of human sEH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) In a chronic constriction injury model of neuropathy in male SD rats, EC5026 blocked pain measured with a von Frey assay (mechanical withdrawal thresholds). The efficacy of EC5026 was superior to pregabalin at 10–20 fold lower doses over the time course represented as area under the response curve (AUC) over 6 h post dose. The AUC was calculated with the trapezoidal method for each animal and the average of the group reported ± SEM (<i>n</i> = 6–8/group). Kruskal–Wallis one way analysis of variance on ranks, <i>H</i> = 21.011 with 3 degrees of freedom with Dunn’s Method post hoc. EC5026 vs PEG 300 (<i>p</i> ≤ 0.001), EC5026 vs pregabalin (30 mg/kg) (<i>p</i> = 0.039). (B) The same effective dose of 3 mg/kg EC5026 was able to block withdrawal pain in morphine dependent rats (male SD rats, <i>n</i> = 4/group). Rats were made morphine tolerant with twice daily 10 mg/kg subcutaneous injections of morphine for 10 days. Morphine was stopped and after 18 h of withdrawal the rats were assessed and administered EC5026 or vehicle by oral gavage and tested at 30 min and 1 h post treatment. Painful withdrawal baseline scores (von Frey assay) were normalized to zero (zero is the painful state). EC5026 relieved opioid withdrawal pain compared to vehicle controls. For both graphs scores are calculated as the percent improvement over the painful baseline: the score per time point/painful baseline score *100 calculated for each animal and averaged ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) <i>C</i><sub>max</sub> and (B) area under the curve (AUC) of EC5026 after single oral dose administration in humans. Following single oral administration of EC5026 in healthy male and female subjects, plasma concentrations peaked rapidly with <i>T</i><sub>max</sub> observed at 1.25 h across all dose groups and declined slowly through the end of sampling (14 days, data not shown). Plasma concentrations following 0.5 mg EC5026 were below the limit of quantification for all subjects at all time. Linear exposure was observed in the highest concentration measured at a specific time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of metabolites of EC5026 identified from human blood in Phase 1a clinical trial. Amide or urea cleavage was not observed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Hulahalla (4-year old female thoroughbred), shown above, before (left) and after (right) a five-day treatment of once daily <i>t</i>-TUCB at 0.1 mg/kg. Hulahalla presented with acute laminitis and was treated with standard of care for 3 days with little effect. Her condition became extremely painful, and given the lack of response to the medications and worsening of the condition, humane euthanasia was being considered as the last resort to relieve pain and suffering. At this point, daily <i>t</i>-TUCB was administered in addition to her standard of care treatment. Over the course of the five-day treatment, her pain level decreased, and no signs of adverse effects were observed both from clinical exams and evaluation of blood work. Hulahalla continued to do well, and laminitis has not reoccurred.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/medium/jm0c01886_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0010.jpeg" id="rightTab-GRAPHIC-d7e1219-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Scale-up Non-GMP Synthesis of EC5026</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-4/acs.jmedchem.0c01886/20210421/images/large/jm0c01886_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01886&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) triphosgene, <i>tert</i>-butyl 4-amino-piperidine-1-carboxylate, Et<sub>3</sub>N, DCM, −78 °C to rt, overnight; (b) 4 N HCl in MeOH, rt, overnight; (c) <b>7</b>, Jones reagent, acetone, 0 °C to rt, 2.4 h; (d) EDCI, Et<sub>3</sub>N, DCM, rt, overnight.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61647" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61647" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodani, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">The 2014 Bernard B. Brodie Award Lecture Epoxide Hydrolases: Drug metabolism to therapeutics for chronic pain</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">802</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.063339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1124%2Fdmd.115.063339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=25762541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2MXms1artrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=788-802&issue=5&author=S.+D.+Kodaniauthor=B.+D.+Hammock&title=The+2014+Bernard+B.+Brodie+Award+Lecture+Epoxide+Hydrolases%3A+Drug+metabolism+to+therapeutics+for+chronic+pain&doi=10.1124%2Fdmd.115.063339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain</span></div><div class="casAuthors">Kodani, Sean D.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">788-802</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Dr.  Bernard Brodie's legacy is built on fundamental discoveries in pharmacol. and drug metab. that were then translated to the clinic to improve patient care.  Similarly, the development of a novel class of therapeutics termed the sol. epoxide hydrolase (sEH) inhibitors was originally spurred by fundamental research exploring the biochem. and physiol. of the sEH.  Here, we present an overview of the history and current state of research on epoxide hydrolases, specifically focusing on sEHs.  In doing so, we start with the translational project studying the metab. of the insect juvenile hormone mimic R-20458 [(E)-6,7-epoxy-1-(4-ethylphenoxy)-3,7-dimethyl-2-octene], which led to the identification of the mammalian sEH.  Further investigation of this enzyme and its substrates, including the epoxyeicosatrienoic acids, led to insight into mechanisms of inflammation, chronic and neuropathic pain, angiogenesis, and other physiol. processes.  This basic knowledge in turn led to the development of potent inhibitors of the sEH that are promising therapeutics for pain, hypertension, chronic obstructive pulmonary disorder, arthritis, and other disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnfbbEZsuMs7Vg90H21EOLACvtfcHk0lhaTymL2dU39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXms1artrs%253D&md5=128ca0de985be1c5e20b75ecd080fc75</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.063339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.063339%26sid%3Dliteratum%253Aachs%26aulast%3DKodani%26aufirst%3DS.%2BD.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DThe%25202014%2520Bernard%2520B.%2520Brodie%2520Award%2520Lecture%2520Epoxide%2520Hydrolases%253A%2520Drug%2520metabolism%2520to%2520therapeutics%2520for%2520chronic%2520pain%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26issue%3D5%26spage%3D788%26epage%3D802%26doi%3D10.1124%2Fdmd.115.063339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S. S.</span>; <span class="NLM_string-name">Hammock, B. D.</span>; <span class="NLM_string-name">Yamamoto, I.</span>; <span class="NLM_string-name">Casida, J. E.</span></span> <span> </span><span class="NLM_article-title">Preliminary Chromatographic Studies on the Metabolites and Photodecomposition Products of the Juvenoid 1-(4′-ethylphenoxy-6,7-epoxy-3,7- dimethyl-2-octene</span>. In  <i>Insect Juvenile Hormones: Chemistry and Action</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menn, J. J.</span>, <span class="NLM_string-name">Beroza, M.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1972</span>; pp  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">189</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2FB978-0-12-490950-2.50013-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1972&pages=177-189&author=S.+S.+Gill&author=B.+D.+Hammock&author=I.+Yamamoto&author=J.+E.+Casidaauthor=J.+J.+Menn&author=M.+Beroza&title=Insect+Juvenile+Hormones%3A+Chemistry+and+Action"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-490950-2.50013-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-490950-2.50013-9%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DS.%2BS.%26atitle%3DPreliminary%2520Chromatographic%2520Studies%2520on%2520the%2520Metabolites%2520and%2520Photodecomposition%2520Products%2520of%2520the%2520Juvenoid%25201-%25284%25E2%2580%25B2-ethylphenoxy-6%252C7-epoxy-3%252C7-%2520dimethyl-2-octene%26btitle%3DInsect%2520Juvenile%2520Hormones%253A%2520Chemistry%2520and%2520Action%26aulast%3DMenn%26aufirst%3DJ.%2BJ.%26pub%3DAcademic%2520Press%26date%3D1972%26spage%3D177%26epage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casida, J. E.</span></span> <span> </span><span class="NLM_article-title">Mammalian metabolism and environmental degradation of the juvenoid 1-(4’- ethylphenoxy)-3,7-dimethyl-6,7-epoxy-trans-2-octene and related compounds</span>. <i>J. Agric. Food Chem.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">386</span>– <span class="NLM_lpage">395</span>, <span class="refDoi"> DOI: 10.1021/jf60193a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jf60193a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADyaE2c3lslartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1974&pages=386-395&issue=3&author=S.+S.+Gillauthor=B.+D.+Hammockauthor=J.+E.+Casida&title=Mammalian+metabolism+and+environmental+degradation+of+the+juvenoid+1-%284%E2%80%99-+ethylphenoxy%29-3%2C7-dimethyl-6%2C7-epoxy-trans-2-octene+and+related+compounds&doi=10.1021%2Fjf60193a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian metabolism and environmental degradation of the juvenoid 1-(4'-ethylphenoxy)-3,7-dimethyl-6,7-epoxy-trans-2-octene and related compounds</span></div><div class="casAuthors">Gill S S; Hammock B D; Casida J E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of agricultural and food chemistry</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">386-95</span>
        ISSN:<span class="NLM_cas:issn">0021-8561</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdeZUfMt0x_tHxxy173TfNfW6udTcc2eZjIDXduYHrRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE2c3lslartw%253D%253D&md5=1ec657a025cad465c8cb128adcc888de</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1021%2Fjf60193a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjf60193a058%26sid%3Dliteratum%253Aachs%26aulast%3DGill%26aufirst%3DS.%2BS.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DCasida%26aufirst%3DJ.%2BE.%26atitle%3DMammalian%2520metabolism%2520and%2520environmental%2520degradation%2520of%2520the%2520juvenoid%25201-%25284%25E2%2580%2599-%2520ethylphenoxy%2529-3%252C7-dimethyl-6%252C7-epoxy-trans-2-octene%2520and%2520related%2520compounds%26jtitle%3DJ.%2520Agric.%2520Food%2520Chem.%26date%3D1974%26volume%3D22%26issue%3D3%26spage%3D386%26epage%3D395%26doi%3D10.1021%2Fjf60193a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span>; <span class="NLM_string-name">Gill, S. S.</span>; <span class="NLM_string-name">Mumby, S. M.</span>; <span class="NLM_string-name">Ota, K.</span></span> <span> </span><span class="NLM_article-title">Comparison of Epoxide Hydrases in the Soluble and Microsomal Fractions of Mammalian Liver</span>. In:  <i>Molecular Basis of Environmental Toxicity</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, R. S.</span></span>, Eds.; <span class="NLM_publisher-name">Ann Arbor Science Publishers</span>: <span class="NLM_publisher-loc">Ann Arbor, MI</span>, <span class="NLM_year">1980</span>; pp  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">272</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1980&pages=229-272&author=B.+D.+Hammock&author=S.+S.+Gill&author=S.+M.+Mumby&author=K.+Otaauthor=R.+S.+Bhatnagar&title=Molecular+Basis+of+Environmental+Toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DComparison%2520of%2520Epoxide%2520Hydrases%2520in%2520the%2520Soluble%2520and%2520Microsomal%2520Fractions%2520of%2520Mammalian%2520Liver%26btitle%3DMolecular%2520Basis%2520of%2520Environmental%2520Toxicity%26aulast%3DBhatnagar%26aufirst%3DR.%2BS.%26pub%3DAnn%2520Arbor%2520Science%2520Publishers%26date%3D1980%26spage%3D229%26epage%3D272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spector, A. A.</span></span> <span> </span><span class="NLM_article-title">Arachidonic acid cytochrome P450 epoxygenase pathway</span>. <i>J. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">S52</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1194/jlr.R800038-JLR200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1194%2Fjlr.R800038-JLR200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=18952572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BD1MzltFGjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2009&pages=S52-56&author=A.+A.+Spector&title=Arachidonic+acid+cytochrome+P450+epoxygenase+pathway&doi=10.1194%2Fjlr.R800038-JLR200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Arachidonic acid cytochrome P450 epoxygenase pathway</span></div><div class="casAuthors">Spector Arthur A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of lipid research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">50 Suppl</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">S52-6</span>
        ISSN:<span class="NLM_cas:issn">0022-2275</span>.
    </div><div class="casAbstract">Cytochrome P450 (CYP) epoxygenases convert arachidonic acid to four epoxyeicosatrienoic acid (EET) regioisomers, 5,6-, 8,9-, 11,12-, and 14,15-EET, that function as autacrine and paracrine mediators.  EETs produce vascular relaxation by activating smooth muscle large-conductance Ca2+-activated K+ channels (BKCa).  In addition, they have anti-inflammatory effects on blood vessels and in the kidney, promote angiogenesis, and protect ischemic myocardium and brain.  CYP epoxygenases also convert eicosapentaenoic acid to vasoactive epoxy-derivatives, and endocannabinoids containing 11,12- and 14,15-EET are formed.  Many EET actions appear to be initiated by EET binding to a membrane receptor that activates ion channels and intracellular signal transduction pathways.  However, EETs also are taken up by cells, are incorporated into phospholipids, and bind to cytosolic proteins and nuclear receptors, suggesting that some functions may occur through direct interaction of the EET with intracellular effector systems.  Soluble epoxide hydrolase (sEH) converts EETs to dihydroxyeicosatrienoic acids (DHETs).  Because this attenuates many of the functional effects of EETs, sEH inhibition is being evaluated as a mechanism for increasing and prolonging the beneficial actions of EETs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRlmbUW5992b5oR8RchjrrfW6udTcc2eZjIDXduYHrRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MzltFGjtg%253D%253D&md5=95173f3b316afa04d960b93b6eb6d3db</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1194%2Fjlr.R800038-JLR200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1194%252Fjlr.R800038-JLR200%26sid%3Dliteratum%253Aachs%26aulast%3DSpector%26aufirst%3DA.%2BA.%26atitle%3DArachidonic%2520acid%2520cytochrome%2520P450%2520epoxygenase%2520pathway%26jtitle%3DJ.%2520Lipid%2520Res.%26date%3D2009%26volume%3D50%26spage%3DS52%26epage%3D56%26doi%3D10.1194%2Fjlr.R800038-JLR200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1146/annurev.pharmtox.45.120403.095920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1146%2Fannurev.pharmtox.45.120403.095920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=15822179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVWjt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2005&pages=311-333&author=C.+Morisseauauthor=B.+D.+Hammock&title=Epoxide+hydrolases%3A+mechanisms%2C+inhibitor+designs%2C+and+biological+roles&doi=10.1146%2Fannurev.pharmtox.45.120403.095920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles</span></div><div class="casAuthors">Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-333, 3 plates</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Organisms are exposed to epoxide-contg. compds. from both exogenous and endogenous sources.  In mammals, the hydration of these compds. by various epoxide hydrolases (EHs) can not only regulate their genotoxicity but also, for lipid-derived epoxides, their endogenous roles as chem. mediators.  Recent findings suggest that the EHs as a family represent novel drug discovery targets for regulation of blood pressure, inflammation, cancer progression, and the onset of several other diseases.  Knowledge of the EH reaction mechanism provides a solid foundation for the rational design of inhibitors, and this review summarizes the current understanding of the catalytic mechanism of EHs.  Although the overall EH reaction mechanism is now known, the mol. basis of substrate selectivity, possible allosteric regulation, and many fine details of the catalytic mechanism remain to be solved.  Finally, recent development in the design of EH inhibitors and the biol. roles of EHs are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgu-XChp4zKbVg90H21EOLACvtfcHk0lhaGcTTBoSgVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVWjt7k%253D&md5=faf96336e9373dd089c5eae29804f1bb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.45.120403.095920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.45.120403.095920%26sid%3Dliteratum%253Aachs%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DEpoxide%2520hydrolases%253A%2520mechanisms%252C%2520inhibitor%2520designs%252C%2520and%2520biological%2520roles%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2005%26volume%3D45%26spage%3D311%26epage%3D333%26doi%3D10.1146%2Fannurev.pharmtox.45.120403.095920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">115735</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bmc.2020.115735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=33007552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVCjsr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115735&issue=22&author=K.+S.+S.+Leeauthor=J.+C.+Ngauthor=J.+Yangauthor=S.+H.+Hwangauthor=C.+Morisseauauthor=K.+Wagnerauthor=B.+D.+Hammock&title=Preparation+and+evaluation+of+soluble+epoxide+hydrolase+inhibitors+with+improved+physical+properties+and+potencies+for+treating+diabetic+neuropathic+pain&doi=10.1016%2Fj.bmc.2020.115735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Ng, Jen C.; Yang, Jun; Hwang, Sung-Hee; Morisseau, Christophe; Wagner, Karen; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">115735</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH), a novel therapeutic target for neuropathic pain, is a largely cytosolic enzyme that degrades epoxy-fatty acids (EpFAs), an important class of lipid signaling mols.  Many inhibitors of sEH have been reported, and to date, the 1,3-disubstituted urea has the highest affinity reported for the sEH among the central pharmacophores evaluated.  An earlier somewhat water sol. sEH inhibitor taken to the clinic for blood pressure control had mediocre potency (both affinity and kinetics) and a short in vivo half-life.  We undertook a study to overcome these difficulties, but the sEH inhibitors carrying a 1,3-disubstituted urea often suffer poor phys. properties that hinder their formulation.  In this report, we described new strategies to improve the phys. properties of sEH inhibitors with a 1,3-disubstituted urea while maintaining their potency and drug-target residence time (a complementary in vitro parameter) against sEH.  To our surprise, we identified two structural modifications that substantially improve the potency and phys. properties of sEH inhibitors carrying a 1,3-disubstituted urea pharmacophore.  Such improvements will greatly facilitate the movement of sEH inhibitors to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrX3Srm06vvLVg90H21EOLACvtfcHk0lhaGcTTBoSgVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVCjsr%252FE&md5=abddbd9b05827074a7b93b3bcd58fde2</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115735%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DNg%26aufirst%3DJ.%2BC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DPreparation%2520and%2520evaluation%2520of%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%2520with%2520improved%2520physical%2520properties%2520and%2520potencies%2520for%2520treating%2520diabetic%2520neuropathic%2520pain%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26issue%3D22%26spage%3D115735%26doi%3D10.1016%2Fj.bmc.2020.115735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beetham, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borhan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Molecular and biochemical evidence for the involvement of the Asp333-His523 pair in the catalytic mechanism of soluble epoxide hydrolase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">7968</span>– <span class="NLM_lpage">7974</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.14.7968</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1074%2Fjbc.270.14.7968" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=7713895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADyaK2MXltVShtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=7968-7974&issue=14&author=F.+Pinotauthor=D.+F.+Grantauthor=J.+K.+Beethamauthor=A.+G.+Parkerauthor=B.+Borhanauthor=S.+Landtauthor=A.+D.+Jonesauthor=B.+D.+Hammock&title=Molecular+and+biochemical+evidence+for+the+involvement+of+the+Asp333-His523+pair+in+the+catalytic+mechanism+of+soluble+epoxide+hydrolase&doi=10.1074%2Fjbc.270.14.7968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and biochemical evidence for the involvement of the Asp-333-His-523 pair in the catalytic mechanism of soluble epoxide hydrolase</span></div><div class="casAuthors">Pinot, Franck; Grant, David F.; Beetham, Jeffrey K.; Parker, Anthony G.; Borhan, Babak; Landt, Steve; Jones, Arthur D.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7968-74</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">To investigate the involvement of amino acids in the catalytic mechanism of the sol. epoxide hydrolase, different mutants of the murine enzyme were produced using the baculovirus expression system.  The results are consistent with the involvement of Asp-333 and His-523 in a catalytic mechanism similar to that of other α/β hydrolase fold enzymes.  Mutation of His-263 to asparagine led to the loss of approx. half the specific activity compared to wild-type enzyme.  When His-332 was replaced by asparagine, 96.7% of the specific activity was lost and mutation of the conserved His-523 to glutamine led to a more dramatic loss of 99.9% of the specific activity.  No activity was detectable after the replacement of Asp-333 by serine.  However, more than 20% of the wild-type activity was retained in an Asp-333 → Asn mutant produced in Spodoptera frugiperda cells.  The authors purified, by affinity chromatog., the wild-type and the Asp-333 → Asn mutant enzymes produced in Trichoplusia ni cells.  The authors labeled these enzymes by incubating them with the epoxide contg. radiolabeled substrate juvenile hormone III (JH III).  The purified Asp-333 → Asn mutant bound 6% of the substrate compared to the wild-type sol. epoxide hydrolase.  The mutant also showed 8% of the specific activity of the wild-type.  Preincubation of the purified Asp-333 → Asn mutant at 37° (pH 8), however, led to a complete recovery of activity and to a change of isoelec. point (pI), both of which are consistent with hydrolysis of Asn-333 to aspartic acid.  This intramol. hydrolysis of asparagine to aspartic acid may explain the activity obsd. in this mutant.  Wild-type enzyme that had been radiolabeled with the substrate was digested with trypsin.  Using reverse phase-high pressure liq. chromatog., the authors isolated four radiolabeled peptides of similar polarity.  These peptides were not radiolabeled if the enzyme was preincubated with a selective competitive inhibitor of sol. epoxide hydrolase 4-fluorochalcone oxide.  This strongly suggested that these peptides contained a catalytic amino acid.  Each peptide was characterized with N-terminal amino acid sequencing and electrospray mass spectrometry.  All four radiolabeled peptides contained overlapping sequences.  The only aspartic acid present in all four peptides and conserved in all epoxide hydrolases was Asp-333.  These peptides resulted from cleavage as different trypsin sites and the mass of each was consistent with the covalent linkage of Asp-333 to the substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr8f5a-BiDnLVg90H21EOLACvtfcHk0lhaGcTTBoSgVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltVShtLg%253D&md5=037a6bfb1933d5d1c5a744a5ee210db8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.14.7968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.14.7968%26sid%3Dliteratum%253Aachs%26aulast%3DPinot%26aufirst%3DF.%26aulast%3DGrant%26aufirst%3DD.%2BF.%26aulast%3DBeetham%26aufirst%3DJ.%2BK.%26aulast%3DParker%26aufirst%3DA.%2BG.%26aulast%3DBorhan%26aufirst%3DB.%26aulast%3DLandt%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DA.%2BD.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DMolecular%2520and%2520biochemical%2520evidence%2520for%2520the%2520involvement%2520of%2520the%2520Asp333-His523%2520pair%2520in%2520the%2520catalytic%2520mechanism%2520of%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26issue%3D14%26spage%3D7968%26epage%3D7974%26doi%3D10.1074%2Fjbc.270.14.7968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrow, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowdy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Potent urea and carbamate inhibitors of soluble epoxide hydrolases</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">8849</span>– <span class="NLM_lpage">8854</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.16.8849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1073%2Fpnas.96.16.8849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10430859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADyaK1MXltVeqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=8849-8854&issue=16&author=C.+Morisseauauthor=M.+H.+Goodrowauthor=D.+Dowdyauthor=J.+Zhengauthor=J.+F.+Greeneauthor=J.+R.+Sanbornauthor=B.+D.+Hammock&title=Potent+urea+and+carbamate+inhibitors+of+soluble+epoxide+hydrolases&doi=10.1073%2Fpnas.96.16.8849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Potent urea and carbamate inhibitors of soluble epoxide hydrolases</span></div><div class="casAuthors">Morisseau, Christophe; Goodrow, Marvin H.; Dowdy, Deanna; Zheng, Jiang; Greene, Jessica F.; Sanborn, James R.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">8849-8854</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The sol. epoxide hydrolase (sEH) plays a significant role in the biosynthesis of inflammation mediators as well as xenobiotic transformations.  Herein, the authors report the discovery of substituted ureas and carbamates as potent inhibitors of sEH.  Some of these selective, competitive tight-binding inhibitors with nanomolar Ki values interacted stoichiometrically with the homogeneous recombinant murine and human sEHs.  These inhibitors enhance cytotoxicity of trans-stilbene oxide, which is active as the epoxide, but reduce cytotoxicity of leukotoxin, which is activated by epoxide hydrolase to its toxic diol.  They also reduce toxicity of leukotoxin in vivo in mice and prevent symptoms suggestive of acute respiratory distress syndrome.  These potent inhibitors may be valuable tools for testing hypotheses of involvement of diol and epoxide lipids in chem. mediation in vitro or in vivo systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobOIwuI01SYLVg90H21EOLACvtfcHk0lj1HH-u4OAxRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVeqsL8%253D&md5=eeff85f27c1a33e2da6fb7f8f2ae91de</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.16.8849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.16.8849%26sid%3Dliteratum%253Aachs%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DGoodrow%26aufirst%3DM.%2BH.%26aulast%3DDowdy%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DGreene%26aufirst%3DJ.%2BF.%26aulast%3DSanborn%26aufirst%3DJ.%2BR.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DPotent%2520urea%2520and%2520carbamate%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26issue%3D16%26spage%3D8849%26epage%3D8854%26doi%3D10.1073%2Fpnas.96.16.8849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olearczyk, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imig, J. D.</span></span> <span> </span><span class="NLM_article-title">Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>318</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1307</span>– <span class="NLM_lpage">1314</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.103556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1124%2Fjpet.106.103556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=16772540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XovFygtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2006&pages=1307-1314&issue=3&author=J.+J.+Olearczykauthor=M.+B.+Fieldauthor=I.-H.+Kimauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=J.+D.+Imig&title=Substituted+adamantyl-urea+inhibitors+of+the+soluble+epoxide+hydrolase+dilate+mesenteric+resistance+vessels&doi=10.1124%2Fjpet.106.103556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels</span></div><div class="casAuthors">Olearczyk, Jeffrey J.; Field, Mary B.; Kim, In-Hae; Morisseau, Christophe; Hammock, Bruce D.; Imig, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1307-1314</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The epoxyeicosatrienoic acids (EETs) have been identified as endothelium-derived hyperpolarizing factors.  Metab. of the EETs to the dihydroxyeicosatrienoic acids is catalyzed by sol. epoxide hydrolase (sEH).  Administration of urea-based sEH inhibitors provides protection from hypertension-induced renal injury at least in part by lowering blood pressure.  Here, we investigated the hypothesis that a mechanism by which sEH inhibitors elicit their cardiovascular protective effects is via their action on the vasculature.  Mesenteric resistance arteries were isolated from Sprague-Dawley rats, pressurized, and constricted with the thromboxane A2 agonist U46619 (9,11-dideoxy-11,9-epoxymethano-prostaglandin F2α).  Mesenteric arteries were then incubated with increasing concns. of the sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA).  AUDA resulted in a concn.-dependent relaxation of mesenteric arteries, with 10 μM resulting in a 48±7% relaxation.  Chain-shortened analogs of AUDA had an attenuated vasodilatory response.  Interestingly, at 10 μM, the sEH inhibitors 1-cyclohexyl-3-dodecylurea, 12-(3-cyclohexyl-ureido)dodecanoic acid, and 950 [adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea] were significantly less active, resulting in a 25±8%, 10±9%, and -8±3% relaxation, resp.  Treatment of mesenteric arteries with tetraethyl-ammonium, iberiotoxin, ouabain, or glibenclamide did not alter AUDA-induced relaxation.  The AUDA-induced relaxation was completely inhibited when constricted with KCl.  In sep. expts., denuding mesenteric resistance vessels did not alter AUDA-induced relaxation.  Taken together, these data demonstrate that adamantyl-urea inhibitors have unique dilator actions on vascular smooth muscle compared with other sEH inhibitors and that these dilator actions depend on the adamantyl group and carbon chain length.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8pVo1uopB3rVg90H21EOLACvtfcHk0lj1HH-u4OAxRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovFygtL4%253D&md5=27971d1365be872385e45ea04d3cb3ec</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.103556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.103556%26sid%3Dliteratum%253Aachs%26aulast%3DOlearczyk%26aufirst%3DJ.%2BJ.%26aulast%3DField%26aufirst%3DM.%2BB.%26aulast%3DKim%26aufirst%3DI.-H.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DImig%26aufirst%3DJ.%2BD.%26atitle%3DSubstituted%2520adamantyl-urea%2520inhibitors%2520of%2520the%2520soluble%2520epoxide%2520hydrolase%2520dilate%2520mesenteric%2520resistance%2520vessels%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D318%26issue%3D3%26spage%3D1307%26epage%3D1314%26doi%3D10.1124%2Fjpet.106.103556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lango, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bcp.2015.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=26494425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2015&pages=718-731&issue=4&author=J.+Y.+Liuauthor=H.+J.+Tsaiauthor=C.+Morisseauauthor=J.+Langoauthor=S.+H.+Hwangauthor=T.+Watanabeauthor=I.+H.+Kimauthor=B.+D.+Hammock&title=In+vitro+and+in+vivo+metabolism+of+N-adamantyl+substituted+urea-based+soluble+epoxide+hydrolase+inhibitors&doi=10.1016%2Fj.bcp.2015.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors</span></div><div class="casAuthors">Liu, Jun-Yan; Tsai, Hsing-Ju; Morisseau, Christophe; Lango, Jozsef; Hwang, Sung Hee; Watanabe, Takaho; Kim, In-Hae; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">718-731</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">N,N'-disubstituted urea-based sol. epoxide hydrolase (sEH) inhibitors are promising therapeutics for hypertension, inflammation, and pain in multiple animal models.  The drug absorption and pharmacol. efficacy of these inhibitors have been reported extensively.  However, the drug metab. of these inhibitors is not well described.  Here we reported the metabolic profile and assocd. biochem. studies of an N-adamantyl urea-based sEH inhibitor 1-adamantan-1-yl-3-(5-(2-(2-ethoxyethoxy)ethoxy)pentyl)urea (AEPU) in vitro and in vivo.  The metabolites of AEPU were identified by interpretation of liq. chromatog.-mass spectrometry (LC-MS), liq. chromatog.-tandem mass spectrometry (LC-MS/MS) and/or NMR.  In vitro, AEPU had three major positions for phase I metab. including oxidns. on the adamantyl moiety, urea nitrogen atoms, and cleavage of the polyethylene glycol chain.  In a rodent model, the metabolites from the hydroxylation on the adamantyl group and nitrogen atom were existed in blood while the metabolites from cleavage of polyethylene glycol chain were not found in urine.  The major metabolite found in rodent urine was 3-(3-adamantyl-ureido)-propanoic acid, a presumably from cleavage and oxidn. of the polyethylene glycol moiety.  All the metabolites found were active but less potent than AEPU at inhibiting human sEH.  Furthermore, cytochrome P 450 (CYP) 3A4 was found to be a major enzyme mediating AEPU metab.  In conclusion, the metab. of AEPU resulted from oxidn. by CYP could be shared with other N-adamantyl-urea-based compds.  These findings suggest possible therapeutic roles for AEPU and new strategies for drug design in this series of possible drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoamH_ZDSrfurVg90H21EOLACvtfcHk0liU1gsIEt7B2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12qsb7M&md5=dd67c79fac41ef5bfb3bc1c3b494c266</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DTsai%26aufirst%3DH.%2BJ.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLango%26aufirst%3DJ.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DI.%2BH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520metabolism%2520of%2520N-adamantyl%2520substituted%2520urea-based%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D98%26issue%3D4%26spage%3D718%26epage%3D731%26doi%3D10.1016%2Fj.bcp.2015.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imig, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capdevila, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">694</span>, <span class="refDoi"> DOI: 10.1161/hy0202.103788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1161%2Fhy0202.103788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=11882632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD38Xhs1WqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2002&pages=690-694&issue=2&author=J.+D.+Imigauthor=X.+Zhaoauthor=J.+H.+Capdevilaauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+inhibition+lowers+arterial+blood+pressure+in+angiotensin+II+hypertension&doi=10.1161%2Fhy0202.103788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension</span></div><div class="casAuthors">Imig, John D.; Zhao, Xueying; Capdevila, Jorge H.; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">690-694</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Epoxyeicosatrienoic acids (EETs) have antihypertensive properties and play a part in the maintenance of renal microvascular function.  A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conversion of biol. active EETs to dihydroxyeicosatrienoic acids (DHETs) that are void of effects on the preglomerular vasculature.  We hypothesized that inhibition of sol. epoxide hydrolase (sEH) would lower blood pressure in angiotensin II (Ang II) hypertension.  Rat renal cortical tissue was harvested and urine collected 2 wk following implantation of an osmotic minipump contg. Ang II (60 ng/min).  Renal cortical sEH protein expression was significantly higher in Ang II hypertension compared with normotensive animals.  Likewise, urinary 14,15-DHET levels were significantly increased in hypertensive compared with normotensive animals and averaged 8.1±1.3 and 2.7±1.1 ng/d; resp.  In addnl. expts., the sEH inhibitor N-cyclohexyl-N-dodecyl urea (NCND; 3 mg/d) or vehicle (corn oil, 0.5 mL) was administered daily by i.p. injection starting on day 10.  Administration of NCND for 4 days lowered systolic blood pressure by 30 mm Hg in Ang II hypertensive animals, whereas the corn oil vehicle had no effect on blood pressure in normotensive or Ang II hypertensive animals.  Measurement of blood pressure by indwelling arterial catheters in conscious animals with free movement in their cages confirmed that NCND had antihypertensive properties.  Arterial blood pressure averaged 119±5 mm Hg in normotensive, 170±3 mm Hg in hypertensive and 149±10 mm Hg in NCND-treated, Ang II-infused animals.  Administration of the potential metabolite of NCND, N-cyclohexylformamide to Ang II hypertensive rats did not lower the systolic blood pressure.  These studies demonstrate that increased sEH expression in the Ang II hypertensive kidney leads to increased EET hydration.  Moreover, sEH plays a role in the regulation of blood pressure, and inhibition of sEH during Ang II hypertension is antihypertensive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou360SDFrqPrVg90H21EOLACvtfcHk0liU1gsIEt7B2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xhs1WqurY%253D&md5=859488f03618128f22a259863526f658</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1161%2Fhy0202.103788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fhy0202.103788%26sid%3Dliteratum%253Aachs%26aulast%3DImig%26aufirst%3DJ.%2BD.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DCapdevila%26aufirst%3DJ.%2BH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520inhibition%2520lowers%2520arterial%2520blood%2520pressure%2520in%2520angiotensin%2520II%2520hypertension%26jtitle%3DHypertension%26date%3D2002%26volume%3D39%26issue%3D2%26spage%3D690%26epage%3D694%26doi%3D10.1161%2Fhy0202.103788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">High-throughput pharmacokinetic method: cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis</span>. <i>Anal. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1016/j.aca.2005.11.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.aca.2005.11.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=16636700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFyhsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2006&pages=37-44&author=T.+Watanabeauthor=D.+Schulzauthor=C.+Morisseauauthor=B.+D.+Hammock&title=High-throughput+pharmacokinetic+method%3A+cassette+dosing+in+mice+associated+with+minuscule+serial+bleedings+and+LC%2FMS%2FMS+analysis&doi=10.1016%2Fj.aca.2005.11.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis</span></div><div class="casAuthors">Watanabe, Takaho; Schulz, Daniela; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Analytica Chimica Acta</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-44</span>CODEN:
                <span class="NLM_cas:coden">ACACAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2670</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A method for pharmacokinetic studies using cassette dosing assocd. with serial bleeding in mice is described.  PK profiles of four sol. epoxide hydrolase inhibitors were detd. following oral, s.c. or i.p. administration individually or in cassette dosing.  Parent analyses were performed on only 5 μL of whole blood from serial bleeds (up to 10 per animal), by LC/MS/MS.  An accuracy (88-100%) and precision (<10% RSD) were obsd., leading to reliable datum points for PK calcn.  PK profiles, T max, C max and half-life values after cassette dosing were si similar to the individual PK results.  This method dramatically increases speed of data collection while dramatically reducing cost and animal usage.  The results presented here clearly indicate that this proposed method could be applicable to high-throughput PK studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEleltRqF1pbVg90H21EOLACvtfcHk0liU1gsIEt7B2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFyhsrw%253D&md5=af8f278fc2c7de69a655416067a99437</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.aca.2005.11.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.aca.2005.11.049%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DSchulz%26aufirst%3DD.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DHigh-throughput%2520pharmacokinetic%2520method%253A%2520cassette%2520dosing%2520in%2520mice%2520associated%2520with%2520minuscule%2520serial%2520bleedings%2520and%2520LC%252FMS%252FMS%2520analysis%26jtitle%3DAnal.%2520Chim.%2520Acta%26date%3D2006%26volume%3D559%26spage%3D37%26epage%3D44%26doi%3D10.1016%2Fj.aca.2005.11.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2110</span>– <span class="NLM_lpage">2122</span>, <span class="refDoi"> DOI: 10.1021/jm030514j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030514j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2qtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2110-2122&author=I.+Kimauthor=C.+Morisseauauthor=T.+Watanabeauthor=B.+D.+Hammock&title=Design%2C+synthesis%2C+and+biological+activity+of+1%2C3-disubstituted+ureas+as+potent+inhibitors+of+the+soluble+epoxide+hydrolase+of+increased+water+solubility&doi=10.1021%2Fjm030514j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Activity of 1,3-Disubstituted Ureas as Potent Inhibitors of the Soluble Epoxide Hydrolase of Increased Water Solubility</span></div><div class="casAuthors">Kim, In-Hae; Morisseau, Christophe; Watanabe, Takaho; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2110-2122</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The sol. epoxide hydrolase (sEH) is involved in the metab. of endogenous chem. mediators that play an important role in blood pressure regulation and inflammation.  1,3-Disubstituted ureas are potent inhibitors of sEH that are active both in vitro and in vivo.  However, their poor soly. in either water or lipid reduces their in vivo efficacy and makes them difficult to formulate.  To improve these phys. properties, the effect of incorporating polar functional groups into one of the alkyl chains was evaluated on their inhibitor potencies, water soly., octanol/water partition coeffs. (log P), and m.ps.  No loss of inhibition potency was obsd. when a polar functional group was incorporated at least five atoms (∼7.5 Å) from the central urea carbonyl.  In addn., the presence of a polar group at least 11 atoms away from the urea carbonyl group for the mouse and human sEHs, resp., did not alter the inhibitor potency.  The resulting compds. have better water soly. and generally lower log P values and m.ps. than nonfunctionalized lipophilic ureas.  These properties will make the compds. more bioavailable and more sol. in either water- or oil-based formulations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMDG4_y35pKLVg90H21EOLACvtfcHk0lhyKXd4jEWMpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2qtrs%253D&md5=d80753310c34a3374ad7e6c61e721e19</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm030514j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030514j%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DI.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520activity%2520of%25201%252C3-disubstituted%2520ureas%2520as%2520potent%2520inhibitors%2520of%2520the%2520soluble%2520epoxide%2520hydrolase%2520of%2520increased%2520water%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2110%26epage%3D2122%26doi%3D10.1021%2Fjm030514j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.1021/jm201468j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201468j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ajtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1789-1808&issue=5&author=H.+Shenauthor=B.+D.+Hammock&title=Discovery+of+inhibitors+of+soluble+epoxide+hydrolase%3A+a+target+with+multiple+potential+therapeutic+indications&doi=10.1021%2Fjm201468j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Inhibitors of Soluble Epoxide Hydrolase: A Target with Multiple Potential Therapeutic Indications</span></div><div class="casAuthors">Shen, Hong C.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1789-1808</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The inhibition of sol. epoxide hydrolase (sEH) by small mols. has been shown to increase the levels of fatty acid epoxides such as epoxyeicosatrienoic acids (EETs), and decrease the levels of the corresponding fatty acid diols including dihydroxyeicosatrienoic acids (DHETs).  Due to numerous beneficial effects of EETs, the elevation of their levels, as a result of sEH inhibition, may eventually lead to new therapeutic approaches for multiple diseases.  Specifically, it has been shown, largely in rodent models, that sEH inhibitors can be used to treat heart failure, hypertension, diabetes, stroke, dyslipidemia, inflammatory and neuropathic pain, immunol. disorders, eye diseases, neurol. diseases, and other indications.  Medicinal chem. strategies, key biol. data of benchmark compds., and possible paths for sEH inhibitors to reach the clinic will be reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBjFZ7QGkOVbVg90H21EOLACvtfcHk0lhyKXd4jEWMpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ajtrzK&md5=1a2ba726f26b7e207df467f67685cf2d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm201468j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201468j%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%253A%2520a%2520target%2520with%2520multiple%2520potential%2520therapeutic%2520indications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D5%26spage%3D1789%26epage%3D1808%26doi%3D10.1021%2Fjm201468j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Podolin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognese, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, E.,  3rd.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umbrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweitzer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galop, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belyanskaya, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israel, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurali, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnette, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booth-Genthe, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, J. F.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor</span>. <i>Prostaglandins Other Lipid Mediators</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104–105</i></span>,  <span class="NLM_fpage">25</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.prostaglandins.2013.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.prostaglandins.2013.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23434473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFCgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104%E2%80%93105&publication_year=2013&pages=25-31&author=P.+L.+Podolinauthor=B.+J.+Bologneseauthor=J.+F.+Foleyauthor=E.+Longauthor=B.+Peckauthor=S.+Umbrechtauthor=X.+Zhangauthor=P.+Zhuauthor=B.+Schwartzauthor=W.+Xieauthor=C.+Quinnauthor=H.+Qiauthor=S.+Sweitzerauthor=S.+Chenauthor=M.+Galopauthor=Y.+Dingauthor=S.+L.+Belyanskayaauthor=D.+I.+Israelauthor=B.+A.+Morganauthor=D.+J.+Behmauthor=J.+P.+Marinoauthor=E.+Kuraliauthor=M.+S.+Barnetteauthor=R.+J.+Mayerauthor=C.+L.+Booth-Gentheauthor=J.+F.+Callahan&title=In+vitro+and+in+vivo+characterization+of+a+novel+soluble+epoxide+hydrolase+inhibitor&doi=10.1016%2Fj.prostaglandins.2013.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor</span></div><div class="casAuthors">Podolin, Patricia L.; Bolognese, Brian J.; Foley, Joseph F.; Long, Edward; Peck, Brian; Umbrecht, Sandra; Zhang, Xiaojun; Zhu, Penny; Schwartz, Benjamin; Xie, Wensheng; Quinn, Chad; Qi, Hongwei; Sweitzer, Sharon; Chen, Stephanie; Galop, Marc; Ding, Yun; Belyanskaya, Svetlana L.; Israel, David I.; Morgan, Barry A.; Behm, David J.; Marino, Joseph P.; Kurali, Edit; Barnette, Mary S.; Mayer, Ruth J.; Booth-Genthe, Catherine L.; Callahan, James F.</div><div class="citationInfo"><span class="NLM_cas:title">Prostaglandins and Other Lipid Mediators</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104-105</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25-31</span>CODEN:
                <span class="NLM_cas:coden">POLMFL</span>;
        ISSN:<span class="NLM_cas:issn">1098-8823</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH, EPHX2) metabolizes eicosanoid epoxides, including epoxyeicosatrienoic acids (EETs) to the corresponding dihydroxyeicosatrienoic acids (DHETs), and leukotoxin (LTX) to leukotoxin diol (LTX diol).  EETs, endothelium-derived hyperpolarizing factors, exhibit potentially beneficial properties, including anti-inflammatory effects and vasodilation.  A novel, potent, selective inhibitor of recombinant human, rat and mouse sEH, GSK2256294A, exhibited potent cell-based activity, a concn.-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET in human, rat and mouse whole blood in vitro, and a dose-dependent increase in the LTX/LTX diol ratio in rat plasma following oral administration.  Mice receiving 10 days of cigarette smoke exposure concomitant with oral administration of GSK2256294A exhibited significant, dose-dependent redns. in pulmonary leukocytes and keratinocyte chemoattractant (KC, CXCL1) levels.  Mice receiving oral administration of GSK2256294A following 10 days of cigarette smoke exposure exhibited significant redns. in pulmonary leukocytes compared to vehicle-treated mice.  These data indicate that GSK2256294A attenuates cigarette smoke-induced inflammation by both inhibiting its initiation and/or maintenance and promoting its resoln.  Collectively, these data indicate that GSK2256294A would be an appropriate agent to evaluate the role of sEH in clin. studies, for example in diseases where cigarette smoke is a risk factor, such as chronic obstructive pulmonary disease (COPD) and cardiovascular disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeXL0W8Yob67Vg90H21EOLACvtfcHk0lhyKXd4jEWMpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFCgu7s%253D&md5=e7842bc2d88795ef4a7fae1b0988454b</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2Fj.prostaglandins.2013.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prostaglandins.2013.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DPodolin%26aufirst%3DP.%2BL.%26aulast%3DBolognese%26aufirst%3DB.%2BJ.%26aulast%3DFoley%26aufirst%3DJ.%2BF.%26aulast%3DLong%26aufirst%3DE.%26aulast%3DPeck%26aufirst%3DB.%26aulast%3DUmbrecht%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DQuinn%26aufirst%3DC.%26aulast%3DQi%26aufirst%3DH.%26aulast%3DSweitzer%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DGalop%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DBelyanskaya%26aufirst%3DS.%2BL.%26aulast%3DIsrael%26aufirst%3DD.%2BI.%26aulast%3DMorgan%26aufirst%3DB.%2BA.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DMarino%26aufirst%3DJ.%2BP.%26aulast%3DKurali%26aufirst%3DE.%26aulast%3DBarnette%26aufirst%3DM.%2BS.%26aulast%3DMayer%26aufirst%3DR.%2BJ.%26aulast%3DBooth-Genthe%26aufirst%3DC.%2BL.%26aulast%3DCallahan%26aufirst%3DJ.%2BF.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520a%2520novel%2520soluble%2520epoxide%2520hydrolase%2520inhibitor%26jtitle%3DProstaglandins%2520Other%2520Lipid%2520Mediators%26date%3D2013%26volume%3D104%25E2%2580%2593105%26spage%3D25%26epage%3D31%26doi%3D10.1016%2Fj.prostaglandins.2013.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boardley, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newby, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">cheriyan, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">971</span>– <span class="NLM_lpage">979</span>, <span class="refDoi"> DOI: 10.1111/bcp.12855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1111%2Fbcp.12855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=26620151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtF2ls7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2016&pages=971-979&author=A.+L.+Lazaarauthor=L.+Yangauthor=R.+L.+Boardleyauthor=N.+S.+Goyalauthor=J.+Robertsonauthor=S.+J.+Baldwinauthor=D.+E.+Newbyauthor=I.+B.+Wilkinsonauthor=R.+Tal-Singerauthor=R.+J.+Mayerauthor=J.+cheriyan&title=Pharmacokinetics%2C+pharmacodynamics+and+adverse+event+profile+of+GSK2256294%2C+a+novel+soluble+epoxide+hydrolase+inhibitor&doi=10.1111%2Fbcp.12855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor</span></div><div class="casAuthors">Lazaar, Aili L.; Yang, Lucy; Boardley, Rebecca L.; Goyal, Navin S.; Robertson, Jonathan; Baldwin, Sandra J.; Newby, David E.; Wilkinson, Ian B.; Tal-Singer, Ruth; Mayer, Ruth J.; Cheriyan, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">971-979</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Endothelial-derived epoxyeicosatrienoic acids may regulate vascular tone and are metabolized by sol. epoxide hydrolase enzymes (sEH).  GSK2256294 is a potent and selective sEH inhibitor that was tested in two phase I studies.  Single escalating doses of GSK2256294 2-20 mg or placebo were administered in a randomized crossover design to healthy male subjects or obese smokers.  Once daily doses of 6 or 18 mg or placebo were administered for 14 days to obese smokers.  Data were collected on safety, pharmacokinetics, sEH enzyme inhibition and blood biomarkers.  Single doses of GSK2256294 10 mg were also administered to healthy younger males or healthy elderly males and females with and without food.  Data on safety, pharmacokinetics and biliary metabolites were collected.  Results : GSK2256294 was well-tolerated with no serious adverse events (AEs) attributable to the drug.  The most frequent AEs were headache and contact dermatitis.  Plasma concns. of GSK2256294 increased with single doses, with a half-life averaging 25-43 h.  There was no significant effect of age, food or gender on pharmacokinetic parameters.  Inhibition of sEH enzyme activity was dose-dependent, from an av. of 41.9% on 2 mg (95% confidence interval [CI] -51.8, 77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 h.  There were no significant changes in serum VEGF or plasma fibrinogen.  GSK2256294 was well-tolerated and demonstrated sustained inhibition of sEH enzyme activity.  These data support further investigation in patients with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound healing or COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr37PHmVvZ8A7Vg90H21EOLACvtfcHk0liClBB2WLOZUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtF2ls7w%253D&md5=085db35368f6acb60aef7aa05d4aaa1c</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1111%2Fbcp.12855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.12855%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DBoardley%26aufirst%3DR.%2BL.%26aulast%3DGoyal%26aufirst%3DN.%2BS.%26aulast%3DRobertson%26aufirst%3DJ.%26aulast%3DBaldwin%26aufirst%3DS.%2BJ.%26aulast%3DNewby%26aufirst%3DD.%2BE.%26aulast%3DWilkinson%26aufirst%3DI.%2BB.%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DMayer%26aufirst%3DR.%2BJ.%26aulast%3Dcheriyan%26aufirst%3DJ.%26atitle%3DPharmacokinetics%252C%2520pharmacodynamics%2520and%2520adverse%2520event%2520profile%2520of%2520GSK2256294%252C%2520a%2520novel%2520soluble%2520epoxide%2520hydrolase%2520inhibitor%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2016%26volume%3D81%26spage%3D971%26epage%3D979%26doi%3D10.1111%2Fbcp.12855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">5212</span>– <span class="NLM_lpage">5216</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.07.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bmcl.2006.07.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=16870439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XoslCnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=5212-5216&author=P.+D.+Jonesauthor=H.-J.+Tsaiauthor=Z.+N.+Doauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Synthesis+and+SAR+of+conformationally+restricted+inhibitors+of+soluble+epoxide+hydrolase&doi=10.1016%2Fj.bmcl.2006.07.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase</span></div><div class="casAuthors">Jones, Paul D.; Tsai, Hsing-Ju; Do, Zung N.; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5212-5216</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of conformationally restricted inhibitors of human sol. epoxide hydrolase (sEH) was synthesized.  Inhibition potency of the described compds. was studied against recombinant sEH.  N-(1-Acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea (I) was found to be a potent inhibitor that was also orally bioavailable in canines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI-6I7WMkpm7Vg90H21EOLACvtfcHk0liClBB2WLOZUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XoslCnur0%253D&md5=d18b1510f26ea62837a63e93556d20a0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.07.009%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%2BD.%26aulast%3DTsai%26aufirst%3DH.-J.%26aulast%3DDo%26aufirst%3DZ.%2BN.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520conformationally%2520restricted%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D5212%26epage%3D5216%26doi%3D10.1016%2Fj.bmcl.2006.07.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Orally bioavailable potent soluble epoxide hydrolase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">3825</span>– <span class="NLM_lpage">3840</span>, <span class="refDoi"> DOI: 10.1021/jm070270t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070270t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2sXns1Cksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=3825-3840&issue=16&author=S.+H.+Hwangauthor=H.+J.+Tsaiauthor=J.-Y.+Liuauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Orally+bioavailable+potent+soluble+epoxide+hydrolase+inhibitors&doi=10.1021%2Fjm070270t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Bioavailable Potent Soluble Epoxide Hydrolase Inhibitors</span></div><div class="casAuthors">Hwang, Sung Hee; Tsai, Hsing-Ju; Liu, Jun-Yan; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3825-3840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of N,N'-disubstituted ureas having a conformationally restricted cis- or trans-1,4-cyclohexane α to the urea were prepd. and tested as sol. epoxide hydrolase (sEH) inhibitors.  This series of compds. showed low nanomolar to picomolar activities against recombinant human sEH.  Both isomers showed similar potencies, but the trans isomers were more metabolically stable in human hepatic microsomes.  Furthermore, these new potent inhibitors show a greater metabolic stability in vivo than previously described sEH inhibitors.  Trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid (I, t-AUCB, IC50 = 1.3 ± 0.05 nM) had excellent oral bioavailability (98%, n = 2) and blood area under the curve in dogs and was effective in vivo to treat hypotension in lipopolysaccharide challenged murine models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVS4Wx8hrt_bVg90H21EOLACvtfcHk0liKa8kNz28u9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXns1Cksbg%253D&md5=ad2116c2671dc36d35b44ff93d55863d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm070270t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070270t%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DTsai%26aufirst%3DH.%2BJ.%26aulast%3DLiu%26aufirst%3DJ.-Y.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DOrally%2520bioavailable%2520potent%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26issue%3D16%26spage%3D3825%26epage%3D3840%26doi%3D10.1021%2Fjm070270t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rose, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure – activity relationships, pharmacokinetics, and reduction of inflammatory pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">7067</span>– <span class="NLM_lpage">7075</span>, <span class="refDoi"> DOI: 10.1021/jm100691c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100691c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWlsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7067-7075&issue=19&author=T.+E.+Roseauthor=C.+Morisseauauthor=J.-Y.+Liuauthor=B.+Inceogluauthor=P.+D.+Jonesauthor=J.+R.+Sanbornauthor=B.+D.+Hammock&title=1-Aryl-3-%281-acylpiperidin-4-yl%29urea+inhibitors+of+human+and+murine+soluble+epoxide+hydrolase%3A+structure+%E2%80%93+activity+relationships%2C+pharmacokinetics%2C+and+reduction+of+inflammatory+pain&doi=10.1021%2Fjm100691c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">1-Aryl-3-(1-acylpiperidin-4-yl)urea Inhibitors of Human and Murine Soluble Epoxide Hydrolase: Structure-Activity Relationships, Pharmacokinetics, and Reduction of Inflammatory Pain</span></div><div class="casAuthors">Rose, Tristan E.; Morisseau, Christophe; Liu, Jun-Yan; Inceoglu, Bora; Jones, Paul D.; Sanborn, James R.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7067-7075</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine sol. epoxide hydrolase (sEH).  Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors.  For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea showed a 7-fold increase in potency, a 65-fold increase in Cmax, and a 3300-fold increase in AUC over its adamantane analog 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea.  This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mech. withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokUmpG9nURobVg90H21EOLACvtfcHk0liKa8kNz28u9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWlsb%252FL&md5=bc2b151553d732942c1ac7e2e963d524</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm100691c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100691c%26sid%3Dliteratum%253Aachs%26aulast%3DRose%26aufirst%3DT.%2BE.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DJ.-Y.%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DP.%2BD.%26aulast%3DSanborn%26aufirst%3DJ.%2BR.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3D1-Aryl-3-%25281-acylpiperidin-4-yl%2529urea%2520inhibitors%2520of%2520human%2520and%2520murine%2520soluble%2520epoxide%2520hydrolase%253A%2520structure%2520%25E2%2580%2593%2520activity%2520relationships%252C%2520pharmacokinetics%252C%2520and%2520reduction%2520of%2520inflammatory%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D19%26spage%3D7067%26epage%3D7075%26doi%3D10.1021%2Fjm100691c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anandan, S.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aavula, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cases, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincelette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszczuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitcomb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gless, R.</span></span> <span> </span><span class="NLM_article-title">1-(1-Acethyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">983</span>– <span class="NLM_lpage">988</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bmcl.2010.12.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=21211973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=983-988&issue=3&author=S.-K.+Anandanauthor=H.+K.+Webbauthor=D.+Chenauthor=Y.-X.+J.+Wangauthor=B.+R.+Aavulaauthor=S.+Casesauthor=Y.+Chengauthor=Z.+N.+Doauthor=U.+Mehraauthor=V.+Tranauthor=J.+Vinceletteauthor=J.+Waszczukauthor=K.+Whiteauthor=K.+R.+Wongauthor=L.-N.+Zhangauthor=P.+D.+Jonesauthor=B.+D.+Hammockauthor=D.+V.+Patelauthor=R.+Whitcombauthor=D.+E.+MacIntyreauthor=J.+Sabryauthor=R.+Gless&title=1-%281-Acethyl-piperidin-4-yl%29-3-adamantan-1-yl-urea+%28AR9281%29+as+a+potent%2C+selective%2C+and+orally+available+soluble+epoxide+hydrolase+inhibitor+with+efficacy+in+rodent+models+of+hypertension+and+dysglycemia&doi=10.1016%2Fj.bmcl.2010.12.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia</span></div><div class="casAuthors">Anandan, Sampath-Kumar; Webb, Heather Kay; Chen, Dawn; Wang, Yi-Xin; Aavula, Basker R.; Cases, Sylvaine; Cheng, Ying; Do, Zung N.; Mehra, Upasana; Tran, Vinh; Vincelette, Jon; Waszczuk, Joanna; White, Kathy; Wong, Kenneth R.; Zhang, Le-Ning; Jones, Paul D.; Hammock, Bruce D.; Patel, Dinesh V.; Whitcomb, Randall; MacIntyre, D. Euan; Sabry, James; Gless, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">983-988</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective sol. epoxide hydrolase inhibitor, was recently tested in a phase 2a clin. setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients.  In a mouse model of diet induced obesity, AR9281 attenuated the enhanced glucose excursion following an i.p. glucose tolerance test.  AR9281 also attenuated the increase in blood pressure in angiotensin-II-induced hypertension in rats.  These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the obsd. pharmacol. in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1h613kO4ASLVg90H21EOLACvtfcHk0lj9N_cUU74PZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVSjsA%253D%253D&md5=6731b9816864dcb005436896b526e8a1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.042%26sid%3Dliteratum%253Aachs%26aulast%3DAnandan%26aufirst%3DS.-K.%26aulast%3DWebb%26aufirst%3DH.%2BK.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.-X.%2BJ.%26aulast%3DAavula%26aufirst%3DB.%2BR.%26aulast%3DCases%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DDo%26aufirst%3DZ.%2BN.%26aulast%3DMehra%26aufirst%3DU.%26aulast%3DTran%26aufirst%3DV.%26aulast%3DVincelette%26aufirst%3DJ.%26aulast%3DWaszczuk%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DK.%2BR.%26aulast%3DZhang%26aufirst%3DL.-N.%26aulast%3DJones%26aufirst%3DP.%2BD.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DPatel%26aufirst%3DD.%2BV.%26aulast%3DWhitcomb%26aufirst%3DR.%26aulast%3DMacIntyre%26aufirst%3DD.%2BE.%26aulast%3DSabry%26aufirst%3DJ.%26aulast%3DGless%26aufirst%3DR.%26atitle%3D1-%25281-Acethyl-piperidin-4-yl%2529-3-adamantan-1-yl-urea%2520%2528AR9281%2529%2520as%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520soluble%2520epoxide%2520hydrolase%2520inhibitor%2520with%2520efficacy%2520in%2520rodent%2520models%2520of%2520hypertension%2520and%2520dysglycemia%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D3%26spage%3D983%26epage%3D988%26doi%3D10.1016%2Fj.bmcl.2010.12.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakhomova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mara, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newcomer, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeldin, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7016</span>– <span class="NLM_lpage">7030</span>, <span class="refDoi"> DOI: 10.1021/jm500694p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500694p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Git77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7016-7030&issue=16&author=K.+S.+S.+Leeauthor=J.-Y.+Liuauthor=K.+M.+Wagnerauthor=S.+Pakhomovaauthor=H.+Dongauthor=C.+Morisseauauthor=S.+H.+Fuauthor=J.+Yangauthor=P.+Wangauthor=A.+Uluauthor=C.+A.+Mateauthor=L.+V.+Nguyenauthor=S.+H.+Hwangauthor=M.+L.+Edinauthor=A.+A.+Maraauthor=H.+Wulffauthor=M.+E.+Newcomerauthor=D.+C.+Zeldinauthor=B.+D.+Hammock&title=Optimized+inhibitors+of+soluble+epoxide+hydrolase+improve+in+vitro+target+residence+time+and+in+vivo+efficacy&doi=10.1021%2Fjm500694p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Liu, Jun-Yan; Wagner, Karen M.; Pakhomova, Svetlana; Dong, Hua; Morisseau, Christophe; Fu, Samuel H.; Yang, Jun; Wang, Peng; Ulu, Arzu; Mate, Christina A.; Nguyen, Long V.; Hwang, Sung Hee; Edin, Matthew L.; Mara, Alexandria A.; Wulff, Heike; Newcomer, Marcia E.; Zeldin, Darryl C.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7016-7030</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Diabetes is affecting the life of millions of people.  A large proportion of diabetic patients suffer from severe complications such as neuropathic pain, and current treatments for these complications have deleterious side effects.  Thus, alternate therapeutic strategies are needed.  Recently, the elevation of epoxy-fatty acids through inhibition of sol. epoxide hydrolase (sEH) was shown to reduce diabetic neuropathic pain in rodents.  In this report, the authors describe a series of newly synthesized sEH inhibitors I [R1 = 4-CF3C6H4, 4-CF3OC6H4; (CF3)2CFC6H4, etc.; R2 = MeCO, MeCH2CO, MeCH2CH2CO, etc.] with at least 5-fold higher potency and doubled residence time inside both the human and rodent sEH enzyme than previously reported inhibitors.  These inhibitors also have better phys. properties and optimized pharmacokinetic profiles.  The optimized inhibitor selected from this new series displayed improved efficacy of almost 10-fold in relieving pain perception in diabetic neuropathic rats as compared to the approved drug, gabapentin, and previously published sEH inhibitors.  Therefore, these new sEH inhibitors could be an attractive alternative to treat diabetic neuropathy in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_j6x9O0dsd7Vg90H21EOLACvtfcHk0ljg0nWQq9L_4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git77K&md5=1f57ad6909389ac8d101fb548b64c2e2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm500694p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500694p%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DLiu%26aufirst%3DJ.-Y.%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DPakhomova%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DS.%2BH.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DUlu%26aufirst%3DA.%26aulast%3DMate%26aufirst%3DC.%2BA.%26aulast%3DNguyen%26aufirst%3DL.%2BV.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DEdin%26aufirst%3DM.%2BL.%26aulast%3DMara%26aufirst%3DA.%2BA.%26aulast%3DWulff%26aufirst%3DH.%26aulast%3DNewcomer%26aufirst%3DM.%2BE.%26aulast%3DZeldin%26aufirst%3DD.%2BC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DOptimized%2520inhibitors%2520of%2520soluble%2520epoxide%2520hydrolase%2520improve%2520in%2520vitro%2520target%2520residence%2520time%2520and%2520in%2520vivo%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D16%26spage%3D7016%26epage%3D7030%26doi%3D10.1021%2Fjm500694p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiserich, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase is a therapeutic target for acute inflammation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span> (<span class="NLM_issue">28</span>),  <span class="NLM_fpage">9772</span>– <span class="NLM_lpage">9777</span>, <span class="refDoi"> DOI: 10.1073/pnas.0503279102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1073%2Fpnas.0503279102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=15994227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=9772-9777&issue=28&author=K.+R.+Schmelzerauthor=L.+Kubalaauthor=J.+W.+Newmanauthor=I.-H.+Kimauthor=J.+P.+Eiserichauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+is+a+therapeutic+target+for+acute+inflammation&doi=10.1073%2Fpnas.0503279102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase is a therapeutic target for acute inflammation</span></div><div class="casAuthors">Schmelzer, Kara R.; Kubala, Lukas; Newman, John W.; Kim, In-Hae; Eiserich, Jason P.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">9772-9777</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">As of 2004, >73 million people were prescribed antiinflammatory medication.  Despite the extensive no. of current products, many people still suffer from their diseases or the pharmacol. properties (side effects) of the medications.  Therefore, developing therapeutic strategies to treat inflammation remains an important endeavor.  Here, we demonstrate that the sol. epoxide hydrolase (sEH) is a key pharmacol. target for treating acute systemic inflammation.  Lipopolysaccharide-induced mortality, systemic hypotension, and histol. evaluated tissue injury were substantially diminished by administration of urea-based, small-mol. inhibitors of sEH to C57BL/6 mice.  Moreover, sEH inhibitors decreased plasma levels of proinflammatory cytokines and nitric oxide metabolites while promoting the formation of lipoxins, thus supporting inflammatory resoln.  These data suggest that sEH inhibitors have therapeutic efficacy in the treatment and management of acute inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-XGKhNB1YLrVg90H21EOLACvtfcHk0ljg0nWQq9L_4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFartb0%253D&md5=4abeedd569a3d36e20e06bfcc94b6a98</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0503279102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0503279102%26sid%3Dliteratum%253Aachs%26aulast%3DSchmelzer%26aufirst%3DK.%2BR.%26aulast%3DKubala%26aufirst%3DL.%26aulast%3DNewman%26aufirst%3DJ.%2BW.%26aulast%3DKim%26aufirst%3DI.-H.%26aulast%3DEiserich%26aufirst%3DJ.%2BP.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520is%2520a%2520therapeutic%2520target%2520for%2520acute%2520inflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26issue%3D28%26spage%3D9772%26epage%3D9777%26doi%3D10.1073%2Fpnas.0503279102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McReynolds, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase regulation of lipid mediators limits pain</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">916</span>, <span class="refDoi"> DOI: 10.1007/s13311-020-00916-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1007%2Fs13311-020-00916-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32875445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslOgsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2020&pages=900-916&author=K.+M.+Wagnerauthor=A.+Gomesauthor=C.+B.+McReynoldsauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+regulation+of+lipid+mediators+limits+pain&doi=10.1007%2Fs13311-020-00916-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain</span></div><div class="casAuthors">Wagner, Karen M.; Gomes, Aldrin; McReynolds, Cindy B.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">900-916</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review of the role of lipids in pain signaling is well established and built on decades of knowledge about the pain and inflammation produced by prostaglandin and leukotriene metabolites of cyclooxygenase and lipoxygenase metab., resp.  The analgesic properties of other lipid metabolites are more recently coming to light.  Lipid metabolites have been obsd. to act directly at ion channels and G protein-coupled receptors on nociceptive neurons as well as act indirectly at cellular membranes.  Cytochrome P 450 metab. of specifically long-chain fatty acids forms epoxide metabolites, the epoxy-fatty acids (EpFA).  The biol. role of these metabolites has been found to mediate analgesia in several types of pain pathol.  EpFA act through a variety of direct and indirect mechanisms to limit pain and inflammation including nuclear receptor agonism, limiting endoplasmic reticulum stress and blocking mitochondrial dysfunction.  Small mol. inhibitors of the sol. epoxide hydrolase can stabilize the EpFA in vivo, and this approach has demonstrated relief in preclin. modeled pain pathol.  Moreover, the ability to block neuroinflammation extends the potential benefit of targeting sol. epoxide hydrolase to maintain EpFA for neuroprotection in neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqry9A9-sTpnLVg90H21EOLACvtfcHk0ljg0nWQq9L_4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslOgsbvL&md5=06d2bf8a4a484dbeeb6a8375b8b196b5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs13311-020-00916-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-020-00916-4%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DGomes%26aufirst%3DA.%26aulast%3DMcReynolds%26aufirst%3DC.%2BB.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520regulation%2520of%2520lipid%2520mediators%2520limits%2520pain%26jtitle%3DNeurotherapeutics%26date%3D2020%26volume%3D17%26spage%3D900%26epage%3D916%26doi%3D10.1007%2Fs13311-020-00916-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goswami, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rand, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2017.05.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.lfs.2017.05.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=28522175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXot1ent70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2017&pages=114-122&author=S.+K.+Goswamiauthor=A.+A.+Randauthor=D.+Wanauthor=J.+Yangauthor=B.+Inceogluauthor=M.+Thomasauthor=C.+Morisseauauthor=G.-Y.+Yangauthor=B.+D.+Hammock&title=Pharmacological+inhibition+of+soluble+epoxide+hydrolase+or+genetic+deletion+reduces+diclofenac-induced+gastric+ulcers&doi=10.1016%2Fj.lfs.2017.05.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers</span></div><div class="casAuthors">Goswami, Sumanta Kumar; Rand, Amelia Ann; Wan, Debin; Yang, Jun; Inceoglu, Bora; Thomas, Melany; Morisseau, Christophe; Yang, Guang-Yu; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114-122</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This research was conducted to evaluate the hypothesis that gastric ulcers caused by the NSAID diclofenac sodium (DCF) can be prevented by the sol. epoxide hydrolase inhibitor TPPU.  Mice were administered a single dose of 10, 30 or 100 mg/kg of DCF.  Once an ulcerative dose of DCF was chosen, mice were pretreated with TPPU for 7 days at 0.1 mg/kg to evaluate anti-ulcer effects of the sEH inhibitor on anatomy, histopathol., pH, inflammatory markers and epithelial apoptosis of stomachs.  Diclofenac caused ulceration of the stomach at a dose of 100 mg/kg and a time post dose of 6 h.  Ulcers generated under these conditions were assocd. with a significant increase in the levels of TNF-α and IL-6 in serum and increased apoptosis compared to control mice.  Pretreatment with TPPU resulted in a decrease of ulceration in mice treated with DCF with a significant decrease in the level of apoptosis, TNF-α and IL-6 in the serum in comparison to diclofenac-treated mice.  TPPU did not affect the pH of the stomach, whereas omeprazole elevated the pH of the stomach as expected.  A similar anti-ulcer effect was obsd. in sEH gene knockout mice treated with DCF.  The sEH inhibitor TPPU decreases the NSAID-induced stomach ulcers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg06JOt8-OBLVg90H21EOLACvtfcHk0lj4CUyJF53IKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXot1ent70%253D&md5=1fe89e4a2979476c1cb0d8c5c71ab869</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2017.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2017.05.018%26sid%3Dliteratum%253Aachs%26aulast%3DGoswami%26aufirst%3DS.%2BK.%26aulast%3DRand%26aufirst%3DA.%2BA.%26aulast%3DWan%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DG.-Y.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DPharmacological%2520inhibition%2520of%2520soluble%2520epoxide%2520hydrolase%2520or%2520genetic%2520deletion%2520reduces%2520diclofenac-induced%2520gastric%2520ulcers%26jtitle%3DLife%2520Sci.%26date%3D2017%26volume%3D180%26spage%3D114%26epage%3D122%26doi%3D10.1016%2Fj.lfs.2017.05.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wecksler, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Rationally designed multitarget agents against inflammation and pain</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1783</span>– <span class="NLM_lpage">1799</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.2174%2F0929867311320130013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23410172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1783-1799&issue=13&author=S.+H.+Hwangauthor=A.+T.+Weckslerauthor=K.+Wagnerauthor=B.+D.+Hammock&title=Rationally+designed+multitarget+agents+against+inflammation+and+pain&doi=10.2174%2F0929867311320130013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally designed multitarget agents against inflammation and pain</span></div><div class="casAuthors">Hwang, S. H.; Wecksler, A. T.; Wagner, K.; Hammock, B. D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1783-1799</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Arachidonic acid (ARA) undergoes enzyme-mediated oxidative metab., resulting in the formation of a no. of biol. active metabolites.  For over a century, these biochem. transformations have been the target of numerous pharmacol. drugs for inflammation and pain.  In particular, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) selective inhibitors (coxibs) are widely used in the treatment of inflammation and pain.  However, gastrointestinal (GI) and cardiovascular adverse effects of NSAIDs and coxibs, and recent findings demonstrating that there are significant risks from the disruption of oxylipin levels when pharmacol. inhibiting a single ARA cascade metabolic pathway, have led to studies involving the simultaneous inhibition of multiple pathways in ARA cascade.  These studies suggest that multitarget inhibition represents a new and valuable option to enhance efficacy or reduce side-effects in the treatment of inflammation and pain.  This review focuses on the crosstalk within the three pathways of the ARA cascade (cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P 450 (CYP450)), and summarizes the current and future approaches of multitarget inhibitors for the treatment of eicosanoid driven inflammation and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ-JRx21Y2i7Vg90H21EOLACvtfcHk0lj4CUyJF53IKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jurg%253D&md5=5ab2b5313e700cac5b7a009b2e0fd943</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130013%26sid%3Dliteratum%253Aachs%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DWecksler%26aufirst%3DA.%2BT.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DRationally%2520designed%2520multitarget%2520agents%2520against%2520inflammation%2520and%2520pain%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26issue%3D13%26spage%3D1783%26epage%3D1799%26doi%3D10.2174%2F0929867311320130013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodani, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Drug-target residence time affects in vivo target occupancy through multiple pathways</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1614</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.9b00770</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.9b00770" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yntrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=1614-1624&author=K.+S.+S.+Leeauthor=J.+Yangauthor=J.+Niuauthor=C.+J.+Ngauthor=K.+M.+Wagnerauthor=H.+Dongauthor=S.+D.+Kodaniauthor=D.+Wanauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Drug-target+residence+time+affects+in+vivo+target+occupancy+through+multiple+pathways&doi=10.1021%2Facscentsci.9b00770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-Target Residence Time Affects in Vivo Target Occupancy through Multiple Pathways</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Yang, Jun; Niu, Jun; Ng, Connie J.; Wagner, Karen M.; Dong, Hua; Kodani, Sean D.; Wan, Debin; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1614-1624</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The drug discovery and development process is greatly hampered by difficulties in translating in vitro potency to in vivo efficacy.  Recent studies suggest that the long-neglected drug-target residence time parameter complements classical drug affinity parameters (KI, Kd, IC50, or EC50) and is a better predictor of in vivo efficacy.  Compds. with a long drug-target residence time are often more efficacious in vivo.  The impact, however, of the drug-target residence time on in vivo efficacy remains controversial due to difficulties in exptl. detg. the in vivo target occupancy during drug treatment.  To tackle this problem, an in vivo displacement assay was developed using sol. epoxide hydrolase as a biol. model.  In this report, we exptl. demonstrated that drug-target residence time affects the duration of in vivo drug-target binding.  In addn., the drug-target residence time plays an important role in modulating the rate of drug metab. which also affects the efficacy of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrobn6bpYZnn7Vg90H21EOLACvtfcHk0lj4CUyJF53IKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yntrzF&md5=442c2eb0a430cdfda3109692b2e7e55b</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.9b00770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.9b00770%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DC.%2BJ.%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DKodani%26aufirst%3DS.%2BD.%26aulast%3DWan%26aufirst%3DD.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520affects%2520in%2520vivo%2520target%2520occupancy%2520through%2520multiple%2520pathways%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2019%26volume%3D5%26spage%3D1614%26epage%3D1624%26doi%3D10.1021%2Facscentsci.9b00770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsume, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudie, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langguth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span> <span> </span><span class="NLM_article-title">The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2014.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.ejps.2014.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=24486482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivF2ms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=152-163&author=Y.+Tsumeauthor=D.+M.+Mudieauthor=P.+Langguthauthor=G.+E.+Amidonauthor=G.+L.+Amidon&title=The+biopharmaceutics+classification+system%3A+subclasses+for+in+vivo+predictive+dissolution+%28IPD%29+methodology+and+IVIVC&doi=10.1016%2Fj.ejps.2014.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC</span></div><div class="casAuthors">Tsume, Yasuhiro; Mudie, Deanna M.; Langguth, Peter; Amidon, Greg E.; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">152-163</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) has found widespread utility in drug discovery, product development and drug product regulatory sciences.  The classification scheme captures the two most significant factors influencing oral drug absorption; soly. and intestinal permeability, and it has proven to be a very useful and a widely accepted starting point for drug product development and drug product regulation.  The mechanistic base of the BCS approach has, no doubt, contributed to its wide spread acceptance and utility.  Nevertheless, underneath the simplicity of BCS are many detailed complexities, both in vitro and in vivo which must be evaluated and investigated for any given drug and drug product.  In this manuscript we propose a simple extension of the BCS classes to include sub-specification of acid (a), base (b) and neutral (c) for classes II and IV.  Sub-classification for Classes I and III (high soly. drugs as currently defined) is generally not needed except perhaps in border line soly. cases.  It is well known that the , pKa phys. property of a drug (API) has a significant impact on the aq. soly. dissoln. of drug from the drug product both in vitro and in vivo for BCS Class II and IV acids and bases, and is the basis, we propose for a sub-classification extension of the original BCS classification.This BCS sub-classification is particularly important for in vivo predictive dissoln. methodol. development due to the complex and variable in vivo environment in the gastrointestinal tract, with its changing pH, buffer capacity, luminal vol., surfactant luminal conditions, permeability profile along the gastrointestinal tract and variable transit and fasted and fed states.  We believe this sub-classification is a step toward developing a more science-based mechanistic in vivo predictive dissoln. (IPD) methodol.  Such a dissoln. methodol. can be used by development scientists to assess the likelihood of a formulation and dosage form functioning as desired in humans, can be optimized along with parallel human pharmacokinetic studies to set a dissoln. methodol. for Quality by Design (QbD) and in vitro-in vivo correlations (IVIVC) and ultimately can be used as a basis for a dissoln. std. that will ensure continued in vivo product performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRBzV9OFo_8rVg90H21EOLACvtfcHk0liSI2nO5IvTyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivF2ms7g%253D&md5=3f60c8bda03d0eae4505d6608ec2e3bd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2014.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2014.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DTsume%26aufirst%3DY.%26aulast%3DMudie%26aufirst%3DD.%2BM.%26aulast%3DLangguth%26aufirst%3DP.%26aulast%3DAmidon%26aufirst%3DG.%2BE.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DThe%2520biopharmaceutics%2520classification%2520system%253A%2520subclasses%2520for%2520in%2520vivo%2520predictive%2520dissolution%2520%2528IPD%2529%2520methodology%2520and%2520IVIVC%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2014%26volume%3D57%26spage%3D152%26epage%3D163%26doi%3D10.1016%2Fj.ejps.2014.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Repka, M. A.</span>; <span class="NLM_string-name">Gerding, T. G.</span></span> Polyethylene Glycol Ointment for Apthous Ulcers. U.S. Patent <span class="NLM_patent">5,112,620</span>, May 12, <span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Repka%2C+M.+A.%3B+Gerding%2C+T.+G.+Polyethylene+Glycol+Ointment+for+Apthous+Ulcers.+U.S.+Patent+5%2C112%2C620%2C+May+12%2C+1992."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRepka%26aufirst%3DM.%2BA.%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McReynolds, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.pharmthera.2017.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=28642117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyntLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2017&pages=62-76&author=K.+M.+Wagnerauthor=C.+B.+McReynoldsauthor=W.+K.+Schmidtauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+as+a+therapeutic+target+for+pain%2C+inflammatory+and+neurodegenerative+diseases&doi=10.1016%2Fj.pharmthera.2017.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases</span></div><div class="casAuthors">Wagner, Karen M.; McReynolds, Cindy B.; Schmidt, William K.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">62-76</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Eicosanoids are biol. active lipid signaling mols. derived from polyunsatd. fatty acids.  Many of the actions of eicosanoid metabolites formed by cyclooxygenase and lipoxygenase enzymes have been characterized, however, the epoxy-fatty acids (EpFAs) formed by cytochrome P 450 enzymes are newly described by comparison.  The EpFA metabolites modulate a diverse set of physiol. functions that include inflammation and nociception among others.  Regulation of EpFAs occurs primarily via release, biosynthesis and enzymic transformation by the sol. epoxide hydrolase (sEH).  Targeting sEH with small mol. inhibitors has enabled observation of the biol. activity of the EpFAs in vivo in animal models, greatly contributing to the overall understanding of their role in the inflammatory response.  Their role in modulating inflammation has been demonstrated in disease models including cardiovascular pathol. and inflammatory pain, but extends to neuroinflammation and neuroinflammatory disease.  Moreover, while EpFAs demonstrate activity against inflammatory pain, interestingly, this action extends to blocking chronic neuropathic pain as well.  This review outlines the role of modulating sEH and the biol. action of EpFAs in models of pain and inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYpflNfJFI-LVg90H21EOLACvtfcHk0liSI2nO5IvTyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyntLzN&md5=cce7ef34908084360e85c153a0c428ee</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DMcReynolds%26aufirst%3DC.%2BB.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520as%2520a%2520therapeutic%2520target%2520for%2520pain%252C%2520inflammatory%2520and%2520neurodegenerative%2520diseases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D180%26spage%3D62%26epage%3D76%26doi%3D10.1016%2Fj.pharmthera.2017.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">4716</span>– <span class="NLM_lpage">4723</span>, <span class="refDoi"> DOI: 10.1021/bi036189j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi036189j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Ols7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=4716-4723&author=G.+A.+Gomezauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=D.+W.+Christianson&title=Structure+of+human+epoxide+hydrolase+reveals+mechanistic+inferences+on+bifunctional+catalysis+in+epoxide+and+phosphate+ester+hydrolysis&doi=10.1021%2Fbi036189j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis</span></div><div class="casAuthors">Gomez, German A.; Morisseau, Christophe; Hammock, Bruce D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4716-4723</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The x-ray crystal structure of human sol. epoxide hydrolase (sEH) was detd. at 2.6 Å resoln., revealing a domain-swapped quaternary structure identical to that obsd. for the murine enzyme.  As with the murine enzyme, the epoxide hydrolytic mechanism of the human enzyme proceeded through an alkyl-enzyme intermediate with Asp-333 in the C-terminal domain.  The structure of human sEH complexed with the inhibitor, N-cyclohexyl-N'-(iodophenyl)urea (CIU), at 2.35 Å resoln. was also detd.  Tyr-381 and Tyr-465 donated H-bonds to the alkylurea carbonyl group of CIU, consistent with the proposed roles of these residues as proton donors in the 1st step of catalysis.  The N-terminal domain of mammalian sEH contained a 15 Å deep cleft, but its biol. function was unclear.  Recent expts. demonstrated that the N-terminal domain of human sEH catalyzes the metal-dependent hydrolysis of phosphate esters.  The binding of Mg2+-HPO42- to the N-terminal domain of human sEH in its CIU complex revealed structural features relevant to those of the enzyme-substrate complex in the phosphatase reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRgQ3Rx-U2trVg90H21EOLACvtfcHk0liSI2nO5IvTyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Ols7g%253D&md5=c6cc1850d50daf2d1690c4024cb8d7bb</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fbi036189j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi036189j%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DG.%2BA.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructure%2520of%2520human%2520epoxide%2520hydrolase%2520reveals%2520mechanistic%2520inferences%2520on%2520bifunctional%2520catalysis%2520in%2520epoxide%2520and%2520phosphate%2520ester%2520hydrolysis%26jtitle%3DBiochemistry%26date%3D2004%26volume%3D43%26spage%3D4716%26epage%3D4723%26doi%3D10.1021%2Fbi036189j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1110/ps.051720206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1110%2Fps.051720206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=16322563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XktlSrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=58-64&author=G.+A.+Gomezauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=D.+W.+Christianson&title=Human+soluble+epoxide+hydrolase%3A+structural+basis+of+inhibition+by+4-%283-cyclohexylureido%29-carboxylic+acids&doi=10.1110%2Fps.051720206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Human soluble epoxide hydrolase: Structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids</span></div><div class="casAuthors">Gomez, German A.; Morisseau, Christophe; Hammock, Bruce D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-64</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">0961-8368</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">X-ray crystal structures of human sol. epoxide hydrolase (sEH) complexed with four different dialkylurea inhibitors bearing pendant carboxylate "tails" of varying length have been detd. at 2.3-3.0 Å resoln.  Similarities among inhibitor binding modes reinforce the proposed roles of Y381 and/or Y465 as general acids that protonate the epoxide ring of the substrate in concert with nucleophilic attack of D333 at the electrophilic epoxide carbon.  Addnl., the binding of these inhibitors allows us to model the binding mode of the endogenous substrate 14,15-epoxyeicosatrienoic acid.  Contrasts among inhibitor binding modes include opposite orientations of inhibitor binding in the active-site hydrophobic tunnel.  Alternative binding orientations obsd. for this series of inhibitors to human sEH, as well as the binding of certain dialkylurea inhibitors to human sEH and murine sEH, complicate the structure-based design of human sEH inhibitors with potential pharmaceutical applications in the treatment of hypertension.  Thus, with regard to the optimization of inhibitor designs targeting human sEH, it is crit. that human sEH and not murine sEH be utilized for inhibitor screening, and it is crit. that structures of human sEH-inhibitor complexes be detd. to verify inhibitor binding orientations that correlate with measured affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCrqO7mSzRPrVg90H21EOLACvtfcHk0liSI2nO5IvTyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktlSrsQ%253D%253D&md5=b16bb0c99a177acc885cbbb789374f2b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1110%2Fps.051720206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1110%252Fps.051720206%26sid%3Dliteratum%253Aachs%26aulast%3DGomez%26aufirst%3DG.%2BA.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHuman%2520soluble%2520epoxide%2520hydrolase%253A%2520structural%2520basis%2520of%2520inhibition%2520by%25204-%25283-cyclohexylureido%2529-carboxylic%2520acids%26jtitle%3DProtein%2520Sci.%26date%3D2006%26volume%3D15%26spage%3D58%26epage%3D64%26doi%3D10.1110%2Fps.051720206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henriksen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andaya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>613</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2016.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.abb.2016.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=27983948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVagsr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=613&publication_year=2017&pages=1-11&author=K.+S.+Leeauthor=N.+M.+Henriksenauthor=C.+J.+Ngauthor=J.+Yangauthor=W.+Jiaauthor=C.+Morisseauauthor=A.+Andayaauthor=M.+K.+Gilsonauthor=B.+D.+Hammock&title=Probing+the+orientation+of+inhibitor+and+epoxy-eicosatrienoic+acid+binding+in+the+active+site+of+soluble+epoxide+hydrolase&doi=10.1016%2Fj.abb.2016.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Probing the orientation of inhibitor and epoxy-eicosatrienoic acid binding in the active site of soluble epoxide hydrolase</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Henriksen, Niel M.; Ng, Connie J.; Yang, Jun; Jia, Weitao; Morisseau, Christophe; Andaya, Armann; Gilson, Michael K.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">613</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH) is an important therapeutic target of many diseases, such as chronic obstructive pulmonary disease (COPD) and diabetic neuropathic pain.  It acts by hydrolyzing and thus regulating specific bioactive long chain polyunsatd. fatty acid epoxides (lcPUFA), like epoxyeicosatrienoic acids (EETs).  To better predict which epoxides could be hydrolyzed by sEH, one needs to dissect the important factors and structural requirements that govern the binding of the substrates to sEH.  This knowledge allows further exploration of the physiol. role played by sEH.  Unfortunately, a crystal structure of sEH with a substrate bound has not yet been reported.  In this report, new photoaffinity mimics of a sEH inhibitor and EET regioisomers were prepd. and used in combination with peptide sequencing and computational modeling, to identify the binding orientation of different regioisomers and enantiomers of EETs into the catalytic cavity of sEH.  Results indicate that the stereochem. of the epoxide plays a crucial role in dictating the binding orientation of the substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ1ih65m797bVg90H21EOLACvtfcHk0liOn2yA7ddy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVagsr7J&md5=cbcbfa84e051c25c57d95a56774fd710</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2016.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2016.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DHenriksen%26aufirst%3DN.%2BM.%26aulast%3DNg%26aufirst%3DC.%2BJ.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DW.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DAndaya%26aufirst%3DA.%26aulast%3DGilson%26aufirst%3DM.%2BK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DProbing%2520the%2520orientation%2520of%2520inhibitor%2520and%2520epoxy-eicosatrienoic%2520acid%2520binding%2520in%2520the%2520active%2520site%2520of%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2017%26volume%3D613%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.abb.2016.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burmistrov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitushkin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernigora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasskazova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butov, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">127430</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.bmcl.2020.127430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32736212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVyis77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127430&issue=18&author=V.+Burmistrovauthor=C.+Morisseauauthor=D.+Karlovauthor=D.+Pitushkinauthor=A.+Vernigoraauthor=E.+Rasskazovaauthor=G.+M.+Butovauthor=B.+D.+Hammock&title=Bioisosteric+substitution+of+adamantane+with+bicyclic+lipophilic+groups+improves+water+solubility+of+human+soluble+epoxide+hydrolase+inhibitors&doi=10.1016%2Fj.bmcl.2020.127430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric substitution of adamantane with bicyclic lipophilic groups improves water solubility of human soluble epoxide hydrolase inhibitors</span></div><div class="casAuthors">Burmistrov, Vladimir; Morisseau, Christophe; Karlov, Dmitry; Pitushkin, Dmitry; Vernigora, Andrey; Rasskazova, Elena; Butov, Gennady M.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">127430</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of inhibitors of the sol. epoxide hydrolase (sEH) contg. lipophilic groups of natural origin (camphanyl, norcamphanyl, furan-2-yl) were developed.  Inhibitory potency ranging from 0.4 nM to 2.16 μM were obtained.  While having the same level of inhibitory activity bicyclic ureas are up to 10-fold more sol. than the corresponding ureas contg. adamantyl or 4-trifluoromethoxyphenyl substituents.  This makes them easier to formulate, more bioavailable and thus more promising as therapeutic sEH inhibitors.  Endo/exo-form of compd. 2b derived from L-camphor is 14-fold more potent than the corresponding analog derived from D-camphor (IC50 = 3.7 nM vs. 50.6 nM) indicating enantiomeric preference.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO4jRQU49uprVg90H21EOLACvtfcHk0liOn2yA7ddy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVyis77P&md5=381b64d2afdd43659a8f0a2bec833d2b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127430%26sid%3Dliteratum%253Aachs%26aulast%3DBurmistrov%26aufirst%3DV.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DKarlov%26aufirst%3DD.%26aulast%3DPitushkin%26aufirst%3DD.%26aulast%3DVernigora%26aufirst%3DA.%26aulast%3DRasskazova%26aufirst%3DE.%26aulast%3DButov%26aufirst%3DG.%2BM.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DBioisosteric%2520substitution%2520of%2520adamantane%2520with%2520bicyclic%2520lipophilic%2520groups%2520improves%2520water%2520solubility%2520of%2520human%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26issue%3D18%26spage%3D127430%26doi%3D10.1016%2Fj.bmcl.2020.127430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Förster resonance energy transfer (FRET) competitive displacement assay for human soluble epoxide hydrolase</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>434</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2012.11.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.ab.2012.11.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23219719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVGjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2013&pages=259-268&issue=2&author=K.+S.+S.+Leeauthor=C.+Morisseauauthor=J.+Yangauthor=P.+Wangauthor=S.+H.+Hwangauthor=B.+D.+Hammock&title=F%C3%B6rster+resonance+energy+transfer+%28FRET%29+competitive+displacement+assay+for+human+soluble+epoxide+hydrolase&doi=10.1016%2Fj.ab.2012.11.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Foerster resonance energy transfer competitive displacement assay for human soluble epoxide hydrolase</span></div><div class="casAuthors">Lee, Kin Sing Stephen; Morisseau, Christophe; Yang, Jun; Wang, Peng; Hwang, Sung Hee; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-268</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sol. epoxide hydrolase (sEH), responsible for the hydrolysis of various fatty acid epoxides to their corresponding 1,2-diols, is becoming an attractive pharmaceutical target.  These fatty acid epoxides, particularly epoxyeicosatrienoic acids (EETs), play an important role in human homeostatic and inflammation processes.  Therefore, inhibition of human sEH, which stabilizes EETs in vivo, brings several beneficial effects to human health.  Although there are several catalytic assays available to det. the potency of sEH inhibitors, measuring the in vitro inhibition const. (Ki) for these inhibitors using catalytic assay is laborious.  In addn., koff, which has been recently suggested to correlate better with the in vivo potency of inhibitors, has never been measured for sEH inhibitors.  To better measure the potency of sEH inhibitors, a reporting ligand, 1-(adamantan-1-yl)-3-(1-(2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetyl) piperidin-4-yl)urea (ACPU), was designed and synthesized.  With ACPU, we have developed a Foerster resonance energy transfer (FRET)-based competitive displacement assay using intrinsic tryptophan fluorescence from sEH.  In addn., the resulting assay allows us to measure the Ki values of very potent compds. to the picomolar level and to obtain relative koff values of the inhibitors.  This assay provides addnl. data to evaluate the potency of sEH inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBfo3H10EZfbVg90H21EOLACvtfcHk0liOn2yA7ddy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVGjtL4%253D&md5=8776c1bc83265e6b6b3f66e963c88e5b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2012.11.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2012.11.015%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DF%25C3%25B6rster%2520resonance%2520energy%2520transfer%2520%2528FRET%2529%2520competitive%2520displacement%2520assay%2520for%2520human%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DAnal.%2520Biochem.%26date%3D2013%26volume%3D434%26issue%3D2%26spage%3D259%26epage%3D268%26doi%3D10.1016%2Fj.ab.2012.11.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Measurement of soluble epoxide hydrolase (sEH) activity</span>. <i>Curr. Protoc. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">4.23.1</span>– <span class="NLM_lpage">4.23.18</span>, <span class="refDoi"> DOI: 10.1002/0471140856.tx0423s33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1002%2F0471140856.tx0423s33" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2007&pages=4.23.1-4.23.18&author=C.+Morisseauauthor=B.+D.+Hammock&title=Measurement+of+soluble+epoxide+hydrolase+%28sEH%29+activity&doi=10.1002%2F0471140856.tx0423s33"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2F0471140856.tx0423s33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471140856.tx0423s33%26sid%3Dliteratum%253Aachs%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DMeasurement%2520of%2520soluble%2520epoxide%2520hydrolase%2520%2528sEH%2529%2520activity%26jtitle%3DCurr.%2520Protoc.%2520Toxicol.%26date%3D2007%26volume%3D33%26spage%3D4.23.1%26epage%3D4.23.18%26doi%3D10.1002%2F0471140856.tx0423s33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jinks, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmelzer, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">18901</span>– <span class="NLM_lpage">18906</span>, <span class="refDoi"> DOI: 10.1073/pnas.0809765105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1073%2Fpnas.0809765105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=19028872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2rtLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=18901-18906&issue=48&author=B.+Inceogluauthor=S.+L.+Jinksauthor=A.+Uluauthor=C.+M.+Hegedusauthor=K.+Georgiauthor=K.+R.+Schmelzerauthor=K.+Wagnerauthor=P.+D.+Jonesauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+and+epoxyeicosatrienoic+acids+modulate+two+distinct+analgesic+pathways&doi=10.1073%2Fpnas.0809765105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways</span></div><div class="casAuthors">Inceoglu, Bora; Jinks, Steven L.; Ulu, Arzu; Hegedus, Christine M.; Georgi, Katrin; Schmelzer, Kara R.; Wagner, Karen; Jones, Paul D.; Morisseau, Christophe; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">18901-18906</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">During inflammation, a large amt. of arachidonic acid (AA) is released into the cellular milieu and cyclooxygenase enzymes convert this AA to prostaglandins that in turn sensitize pain pathways.  However, AA is also converted to natural epoxyeicosatrienoic acids (EETs) by cytochrome P 450 enzymes.  EET levels are typically regulated by sol. epoxide hydrolase (sEH), the major enzyme degrading EETs.  Here we demonstrate that EETs or inhibition of sEH lead to antihyperalgesia by at least 2 spinal mechanisms, first by repressing the induction of the COX2 gene and second by rapidly up-regulating an acute neurosteroid-producing gene, StARD1, which requires the synchronized presence of elevated cAMP and EET levels.  The analgesic activities of neurosteroids are well known; however, here we describe a clear course toward augmenting the levels of these mols.  Redirecting the flow of pronociceptive intracellular cAMP toward up-regulation of StARD1 mRNA by concomitantly elevating EETs is a novel path to accomplish pain relief in both inflammatory and neuropathic pain states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwtxbwVAXe-7Vg90H21EOLACvtfcHk0ljkOeFWgyJZNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2rtLrI&md5=d0cd74a5a3de8c9aeb90bda6dfda8b0e</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0809765105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0809765105%26sid%3Dliteratum%253Aachs%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DJinks%26aufirst%3DS.%2BL.%26aulast%3DUlu%26aufirst%3DA.%26aulast%3DHegedus%26aufirst%3DC.%2BM.%26aulast%3DGeorgi%26aufirst%3DK.%26aulast%3DSchmelzer%26aufirst%3DK.%2BR.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DP.%2BD.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520and%2520epoxyeicosatrienoic%2520acids%2520modulate%2520two%2520distinct%2520analgesic%2520pathways%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D48%26spage%3D18901%26epage%3D18906%26doi%3D10.1073%2Fpnas.0809765105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bettaieb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AbouBechara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chahed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haj, F. G.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">14189</span>– <span class="NLM_lpage">114199</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.458414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1074%2Fjbc.M113.458414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23576437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVGksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=14189-114199&issue=20&author=A.+Bettaiebauthor=N.+Nagataauthor=D.+AbouBecharaauthor=S.+Chahedauthor=C.+Morisseauauthor=B.+D.+Hammockauthor=F.+G.+Haj&title=Soluble+epoxide+hydrolase+deficiency+or+inhibition+attenuates+diet-induced+endoplasmic+reticulum+stress+in+liver+and+adipose+tissue&doi=10.1074%2Fjbc.M113.458414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue</span></div><div class="casAuthors">Bettaieb, Ahmed; Nagata, Naoto; Abou Bechara, Daniel; Chahed, Samah; Morisseau, Christophe; Hammock, Bruce D.; Haj, Fawaz G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">14189-14199</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has beneficial effects in cardiovascular, inflammatory, and metabolic diseases in murine models.  Mice with targeted deletion or pharmacol. inhibition of sEH exhibit improved insulin signaling in liver and adipose tissue.  Herein, we assessed the role of sEH in regulating endoplasmic reticulum (ER) stress in liver and adipose tissue.  We report that sEH expression was increased in the livers and adipose tissue of mice fed a high fat diet, the adipose tissue of overweight humans, and palmitate-treated cells.  Importantly, sEH deficiency or inhibition in mice attenuated chronic high fat diet-induced ER stress in liver and adipose tissue.  Similarly, pharmacol. inhibition of sEH in HepG2 cells and 3T3-L1 adipocytes mitigated chem.-induced ER stress and activation of JNK, p38, and cell death.  In addn., insulin signaling was enhanced in HepG2 cells treated with sEH substrates and attenuated in cells treated with sEH products.  In summary, these findings demonstrate that sEH is a physiol. modulator of ER stress and a potential target for mitigating complications assocd. with obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJbIQBLHGVjbVg90H21EOLACvtfcHk0ljkOeFWgyJZNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVGksL4%253D&md5=17bcaac765ee90fa89f1efcd96b5648a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.458414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.458414%26sid%3Dliteratum%253Aachs%26aulast%3DBettaieb%26aufirst%3DA.%26aulast%3DNagata%26aufirst%3DN.%26aulast%3DAbouBechara%26aufirst%3DD.%26aulast%3DChahed%26aufirst%3DS.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DHaj%26aufirst%3DF.%2BG.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520deficiency%2520or%2520inhibition%2520attenuates%2520diet-induced%2520endoplasmic%2520reticulum%2520stress%2520in%2520liver%2520and%2520adipose%2520tissue%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D20%26spage%3D14189%26epage%3D114199%26doi%3D10.1074%2Fjbc.M113.458414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiamvimonvat, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">The soluble epoxide hydrolase as a pharmaceutical target for hypertension</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1097/FJC.0b013e3181506445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1097%2FFJC.0b013e3181506445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=17878749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCktbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=225-237&author=N.+Chiamvimonvatauthor=C.-M.+Hoauthor=H.-J.+Tsaiauthor=B.+D.+Hammock&title=The+soluble+epoxide+hydrolase+as+a+pharmaceutical+target+for+hypertension&doi=10.1097%2FFJC.0b013e3181506445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The Soluble Epoxide Hydrolase as a Pharmaceutical Target for Hypertension</span></div><div class="casAuthors">Chiamvimonvat, Nipavan; Ho, Chin-Min; Tsai, Hsing-Ju; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-237</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  The sol. epoxide hydrolase appears to be a promising target for the development of antihypertensive therapies based on a previously unexplored mechanism of action.  Epoxide hydrolases are enzymes that add water to three membered cyclic ethers known as epoxides.  The sol. epoxide hydrolase in mammalian systems (sEH) is a member of the α/β-hydrolase fold family of enzymes and it shows a high degree of selectivity for epoxides of fatty acids.  The regioisomeric epoxides of arachidonic acid or epoxyeicosanoids (EETs) are particularly good substrates.  These EETs appear to be major components of the endothelium-derived hyperpolarizing factors (EDHFs).  As such, EETs cause vasodilation and reduce blood pressure.  The EETs also are strongly anti-inflammatory and analgesic.  By inhibiting sEH, the increase in circulating EETs leads to a redn. in blood pressure in a no. of animal models.  Potent transition state mimic inhibitors have been developed for the sEH.  Some of these sEH inhibitors (sEHIs) show nanomolar to picomolar potency and good pharmacokinetic properties.  Because of their unique mode of action they show promise in treating hypertension while reducing problems with end organ failure, vascular inflammation and diabetes.  Indeed, the anti-inflammatory properties of the sEHI may make them particularly suitable for treating hypertension in patients with other concomitant metabolic syndromes.  They are more potent on a molar basis than most nonsteroidal anti-inflammatory drugs (NSAIDs) in reducing PGE2 in inflammation models, they strongly synergize with NSAIDs, and appear to ameliorate apparently unfavorable eicosanoid profiles assocd. with some cyclo-oxygenase-2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxCeaJbKdxrrVg90H21EOLACvtfcHk0lg7K97ILYt1kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCktbjJ&md5=7ee1c71bf0db07c05eafba50b4096a09</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1097%2FFJC.0b013e3181506445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFJC.0b013e3181506445%26sid%3Dliteratum%253Aachs%26aulast%3DChiamvimonvat%26aufirst%3DN.%26aulast%3DHo%26aufirst%3DC.-M.%26aulast%3DTsai%26aufirst%3DH.-J.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DThe%2520soluble%2520epoxide%2520hydrolase%2520as%2520a%2520pharmaceutical%2520target%2520for%2520hypertension%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D2007%26volume%3D50%26spage%3D225%26epage%3D237%26doi%3D10.1097%2FFJC.0b013e3181506445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeyev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuteja, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, R. K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singapuri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiamvimonvat, N.</span></span> <span> </span><span class="NLM_article-title">Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">18733</span>– <span class="NLM_lpage">18738</span>, <span class="refDoi"> DOI: 10.1073/pnas.0609158103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1073%2Fpnas.0609158103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=17130447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlahtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=18733-18738&author=D.+Xuauthor=N.+Liauthor=Y.+Heauthor=V.+Timofeyevauthor=L.+Luauthor=H.-J.+Tsaiauthor=I.-H.+Kimauthor=D.+Tutejaauthor=R.+K.+P.+Mateoauthor=A.+Singapuriauthor=B.+Davisauthor=R.+Lowauthor=B.+D.+Hammockauthor=N.+Chiamvimonvat&title=Prevention+and+reversal+of+cardiac+hypertrophy+by+soluble+epoxide+hydrolase+inhibitors&doi=10.1073%2Fpnas.0609158103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors</span></div><div class="casAuthors">Xu, Danyan; Li, Ning; He, Yuxia; Timofeyev, Valeriy; Lu, Ling; Tsai, Hsing-Ju; Kim, In-Hae; Tuteja, Dipika; Mateo, Robertino Karlo P.; Singapuri, Anil; Davis, Benjamin B.; Low, Reginald; Hammock, Bruce D.; Chiamvimonvat, Nipavan</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">18733-18738</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sustained cardiac hypertrophy represents one of the most common causes leading to cardiac failure.  There is emerging evidence to implicate the involvement of NF-κB in the development of cardiac hypertrophy.  However, several crit. questions remain unanswered.  The authors tested the use of sol. epoxide hydrolase (sEH) inhibitors as a means to enhance the biol. activities of epoxyeicosatrienoic acids (EETs) to treat cardiac hypertrophy.  SEH catalyzes the conversion of EETs to form the corresponding dihydroxyeicosatrienoic acids.  Previous data have suggested that EETs may inhibit the activation of NF-KB-mediated gene transcription.  The authors directly demonstrate the beneficial effects of several potent sEH inhibitors (sEHIs) in cardiac hypertrophy.  Specifically, the authors show that sEHIs can prevent the development of cardiac hypertrophy using a murine model of pressure-induced cardiac hypertrophy.  In addn., sEHIs reverse the preestablished cardiac hypertrophy caused by chronic pressure overload.  The authors further demonstrate that these compds. potently block the NF-κB activation in cardiac myocytes.  Moreover, by using in vivo electrophysiol. recordings, our study shows a beneficial effect of the compds. in the prevention of cardiac arrhythmias that occur in assocn. with cardiac hypertrophy.  The authors conclude that the use of sEHIs to increase the level of the endogenous lipid epoxides such as EETs may represent a viable and completely unexplored avenue to reduce cardiac hypertrophy by blocking NF-κB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpt96mXNMo7Vg90H21EOLACvtfcHk0lg7K97ILYt1kA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlahtLrN&md5=1c323e41ece67fb2f5708632e4284b0d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0609158103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0609158103%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DTimofeyev%26aufirst%3DV.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DTsai%26aufirst%3DH.-J.%26aulast%3DKim%26aufirst%3DI.-H.%26aulast%3DTuteja%26aufirst%3DD.%26aulast%3DMateo%26aufirst%3DR.%2BK.%2BP.%26aulast%3DSingapuri%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DB.%26aulast%3DLow%26aufirst%3DR.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DChiamvimonvat%26aufirst%3DN.%26atitle%3DPrevention%2520and%2520reversal%2520of%2520cardiac%2520hypertrophy%2520by%2520soluble%2520epoxide%2520hydrolase%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D18733%26epage%3D18738%26doi%3D10.1073%2Fpnas.0609158103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comerota, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Propson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span> <span> </span><span class="NLM_article-title">An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">573</span>),  <span class="NLM_fpage">eabb1206</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.abb1206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1126%2Fscitranslmed.abb1206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=33298560" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eabb1206&issue=573&author=A.+Ghoshauthor=M.+M.+Comerotaauthor=D.+Wanauthor=F.+Chenauthor=N.+E.+Propsonauthor=S.+H.+Hwangauthor=B.+D.+Hammockauthor=H.+Zheng&title=An+epoxide+hydrolase+inhibitor+reduces+neuroinflammation+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1126%2Fscitranslmed.abb1206"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.abb1206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.abb1206%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DComerota%26aufirst%3DM.%2BM.%26aulast%3DWan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DPropson%26aufirst%3DN.%2BE.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DZheng%26aufirst%3DH.%26atitle%3DAn%2520epoxide%2520hydrolase%2520inhibitor%2520reduces%2520neuroinflammation%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26issue%3D573%26spage%3Deabb1206%26doi%3D10.1126%2Fscitranslmed.abb1206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Karmakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashidian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, C.</span></span> <span> </span><span class="NLM_article-title">Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial</span>. <i>J. Neuroeng. Rehabil.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">125</span>, <span class="refDoi"> DOI: 10.1186/1743-0003-11-125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1186%2F1743-0003-11-125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=25139539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252Fjtlajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=125&author=S.+Karmakarauthor=H.+Rashidianauthor=C.+Chanauthor=C.+Liuauthor=C.+Toth&title=Investigating+the+role+of+neuropathic+pain+relief+in+decreasing+gait+variability+in+diabetes+mellitus+patients+with+neuropathic+pain%3A+a+randomized%2C+double-blind+crossover+trial&doi=10.1186%2F1743-0003-11-125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial</span></div><div class="casAuthors">Karmakar Surshen; Rashidian Houman; Chan Cynthia; Liu CaiXia; Toth Cory</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroengineering and rehabilitation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">125</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Subjects with diabetes mellitus (DM) develop gait dysfunction contributing to falls, reluctance to perform activities and injuries.  Neuropathic pain (NeP) related to diabetic peripheral neuropathy (DPN) is associated with increased gait variability that may contribute to gait dysfunction.  We used a portable device (GaitMeter®) and related gait and balance measures to measure gait parameters in painful DPN (PDPN) subjects prior to and during analgesia.  Our hypothesis was that PDPN subjects would have decreased gait step variability when receiving pharmacological relief of NeP.  METHODS:  DPN subjects with at least moderate NeP were assessed in a randomized, double-blind crossover study of pregabalin versus placebo.  The outcome measure was variability in step length and step velocity.  Testing for Timed Get-Up-and-Go Test, Tinetti Mobility Scales, Sway Testing, a Physiological Profile Approach, and fall-related surveys were also performed.  DPN severity was quantified using the Utah Early Neuropathy Score.  RESULTS:  PDPN subjects developed increased, rather than decreased, step length and step velocity variability during pregabalin treatment.  There were no significant differences between cohorts for other physiological gait and balance testing.  Non-significant NeP relief occurred in the pregabalin phase of study as compared with placebo.  There was a negative relationship for step length with pain severity.  CONCLUSION:  Analgesia did not decrease gait variability in PDPN patients, and in fact, increased gait variability was seen during pregabalin treatment.  Other important relationships of gait dysfunction with PDPN should be sought.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJ5_69URqBZresJRIHUP1ofW6udTcc2eZTfjw8ns1bjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252Fjtlajtg%253D%253D&md5=0270d6568677ecac497d04281de8b189</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1186%2F1743-0003-11-125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1743-0003-11-125%26sid%3Dliteratum%253Aachs%26aulast%3DKarmakar%26aufirst%3DS.%26aulast%3DRashidian%26aufirst%3DH.%26aulast%3DChan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DToth%26aufirst%3DC.%26atitle%3DInvestigating%2520the%2520role%2520of%2520neuropathic%2520pain%2520relief%2520in%2520decreasing%2520gait%2520variability%2520in%2520diabetes%2520mellitus%2520patients%2520with%2520neuropathic%2520pain%253A%2520a%2520randomized%252C%2520double-blind%2520crossover%2520trial%26jtitle%3DJ.%2520Neuroeng.%2520Rehabil.%26date%3D2014%26volume%3D11%26spage%3D125%26doi%3D10.1186%2F1743-0003-11-125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kharasch, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kheterpal, S.</span></span> <span> </span><span class="NLM_article-title">Perioperative Gabapentinoids: Deflating the Bubble</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>133</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">254</span>, <span class="refDoi"> DOI: 10.1097/ALN.0000000000003394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1097%2FALN.0000000000003394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32667153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BB38jis12ksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2020&pages=251-254&issue=2&author=E.+D.+Kharaschauthor=J.+D.+Clarkauthor=S.+Kheterpal&title=Perioperative+Gabapentinoids%3A+Deflating+the+Bubble&doi=10.1097%2FALN.0000000000003394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Perioperative Gabapentinoids: Deflating the Bubble</span></div><div class="casAuthors">Kharasch Evan D; Clark J David; Kheterpal Sachin</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-254</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbA4WdK1-lWEBuFdjgVNKSfW6udTcc2eZTfjw8ns1bjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38jis12ksA%253D%253D&md5=6997691200c75c5ad56e59c3c5052eda</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1097%2FALN.0000000000003394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0000000000003394%26sid%3Dliteratum%253Aachs%26aulast%3DKharasch%26aufirst%3DE.%2BD.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DKheterpal%26aufirst%3DS.%26atitle%3DPerioperative%2520Gabapentinoids%253A%2520Deflating%2520the%2520Bubble%26jtitle%3DAnesthesiology%26date%3D2020%26volume%3D133%26issue%3D2%26spage%3D251%26epage%3D254%26doi%3D10.1097%2FALN.0000000000003394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patil, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Said, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. C.</span></span> <span> </span><span class="NLM_article-title">Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population</span>. <i>Clin. J. Pain.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1097/AJP.0000000000000124</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1097%2FAJP.0000000000000124" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=25853725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BC2MjisVWntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2015&pages=414-424&issue=5&author=P.+R.+Patilauthor=J.+Wolfeauthor=Q.+Saidauthor=J.+Thomasauthor=B.+C.+Martin&title=Opioid+use+in+the+management+of+diabetic+peripheral+neuropathy+%28DPN%29+in+a+large+commercially+insured+population&doi=10.1097%2FAJP.0000000000000124"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population</span></div><div class="casAuthors">Patil Pravinkumar R; Wolfe Jonathan; Said Qayyim; Thomas Jeremy; Martin Bradley C</div><div class="citationInfo"><span class="NLM_cas:title">The Clinical journal of pain</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">414-24</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine the proportion of diabetic peripheral neuropathy (DPN) patients receiving pharmacologic DPN treatments and specifically to identify the rates and factors associated with opioid use and first-line opioid use.  METHODS:  A 10% sample of IMS-LifeLink claims data from 1998 through 2008 was used.  The study population consisted of diabetic patients who met DPN criteria using a validated DPN algorithm.  Multivariable logistic regression controlling for demographics, comorbidities, and other clinical characteristics was used to identify factors associated with any DPN pharmacologic treatment, any opioid use, and first-line opioid treatment.  Sensitivity analyses were conducted to explore variations in exclusion criteria as well as opioid use definitions.  RESULTS:  A total of 666 DPN patients met inclusion criteria and pharmacologic treatment was received by 288 patients (43.24%) and of those, 154 (53.47%) had DPN-related opioid use and 96 (33.33%) received opioid as first-line treatment.  Persons with diabetic complications were more likely to use opioids (odds ratio=4.53; 95% confidence interval, 1.09-18.92).  Food and Drug Administration-approved DPN agents duloxetine 1.04% (n=3) and pregabalin 5.56% (n=16) had much lower rates of use.  DPN-related drug use and DPN-related opioid usage increased as we used less restrictive samples in sensitivity analyses.  CONCLUSIONS:  Opioids were the most frequently prescribed first-line agents for DPN.  More than 50% of DPN patients remained untreated with pharmacologic agents 1 year after a DPN diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRejOMaiBELaVZoq0fPSOTvfW6udTcc2eYnBNDxrY07Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjisVWntQ%253D%253D&md5=b67345d11c3830e6a51cb4efb8556c89</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2FAJP.0000000000000124&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FAJP.0000000000000124%26sid%3Dliteratum%253Aachs%26aulast%3DPatil%26aufirst%3DP.%2BR.%26aulast%3DWolfe%26aufirst%3DJ.%26aulast%3DSaid%26aufirst%3DQ.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DB.%2BC.%26atitle%3DOpioid%2520use%2520in%2520the%2520management%2520of%2520diabetic%2520peripheral%2520neuropathy%2520%2528DPN%2529%2520in%2520a%2520large%2520commercially%2520insured%2520population%26jtitle%3DClin.%2520J.%2520Pain.%26date%3D2015%26volume%3D31%26issue%3D5%26spage%3D414%26epage%3D424%26doi%3D10.1097%2FAJP.0000000000000124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">914</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2014.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.jpain.2014.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=24924124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGltrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=907-914&issue=9&author=K.+Wagnerauthor=J.+Yangauthor=B.+Inceogluauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+inhibition+is+antinociceptive+in+a+mouse+model+of+diabetic+neuropathy&doi=10.1016%2Fj.jpain.2014.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble Epoxide Hydrolase Inhibition Is Antinociceptive in a Mouse Model of Diabetic Neuropathy</span></div><div class="casAuthors">Wagner, Karen; Yang, Jun; Inceoglu, Bora; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">907-914</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Neuropathic pain is currently an insufficiently treated clin. condition.  There remains a crit. need for efficacious therapies without severe side effects to treat the uniquely persistent and tonic pain of neuropathy.  Inhibitors of the sol. epoxide hydrolase (sEH) enzyme that stabilize endogenous epoxy fatty acids have demonstrated antihyperalgesia in clin. chronic inflammatory pain and modeled neuropathic pain.  Recently, the conditioned place preference assay has been used to evaluate the tonic nature of neuropathy in several animal models.  The current expts. use the conditioned place preference assay alongside withdrawal thresholds to investigate the antihyperalgesic efficacy of sEH inhibitors in a murine model of diabetic neuropathy.  Here, the sEH inhibitor trans-4-[4-(3-trifluoromethoxyphenyl-1-ureido)-cyclohexyloxy]-benzoic acid (t-TUCB) at 10 mg/kg induced a robust place preference in diabetic neuropathic mice representative of pain relief.  Importantly, this effect was absent both in control mice and in sEH-knockout mice at the same dose, indicating that t-TUCB is not pos. reinforcing or rewarding.  When compared to gabapentin, t-TUCB elicited a similar degree of withdrawal threshold improvement without the same degree of spontaneous locomotion decline in neuropathic mice.  Overall, these expts. show that inhibiting the sEH enzyme attenuates chronic pain and offers an alternative to current side-effect-limited therapies to meet this clin. need.These expts. demonstrate antihyperalgesia in a murine chronic pain model mediated by inhibiting the sEH enzyme.  The results of this study indicate that inhibiting the sEH is a promising alternative for blocking chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcdA-epFDZyLVg90H21EOLACvtfcHk0lgLUq2G6S0UHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGltrzM&md5=fa282d9b07810ca941454259e5532cb9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2014.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2014.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520inhibition%2520is%2520antinociceptive%2520in%2520a%2520mouse%2520model%2520of%2520diabetic%2520neuropathy%26jtitle%3DJ.%2520Pain%26date%3D2014%26volume%3D15%26issue%3D9%26spage%3D907%26epage%3D914%26doi%3D10.1016%2Fj.jpain.2014.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backonja, M. M.</span></span> <span> </span><span class="NLM_article-title">Combination drug therapy for chronic pain: a call for more clinical studies</span>. <i>J. Pain</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/j.jpain.2010.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.jpain.2010.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=20851058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=157-166&issue=2&author=J.+Maoauthor=M.+S.+Goldauthor=M.+M.+Backonja&title=Combination+drug+therapy+for+chronic+pain%3A+a+call+for+more+clinical+studies&doi=10.1016%2Fj.jpain.2010.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Drug Therapy for Chronic Pain: A Call for More Clinical Studies</span></div><div class="casAuthors">Mao, Jianren; Gold, Michael S.; Backonja, Miroslav</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">JPOAB5</span>;
        ISSN:<span class="NLM_cas:issn">1526-5900</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chronic pain is a debilitating clin. condition assocd. with a variety of disease entities including diabetic neuropathy, postherpetic neuralgia, low back pathol., fibromyalgia, and neurol. disorders.  For many general practitioners and specialists, managing chronic pain has become a daunting challenge.  As a modality of multidisciplinary chronic pain management, medications are often prescribed in combinations, an approach referred to as combination drug therapy (CDT).  However, many medications for pain therapy, including antidepressants and opioid analgesics, have significant side effects that can compd. when used in combination and impact the effectiveness of CDT.  To date, clin. practice of CDT for chronic pain has been based largely on clin. experiences.  In this article, we will focus on (1) the scientific basis and rationales for CDT, (2) current clin. data on CDT, and (3) the need for more clin. studies to establish a framework for the use of CDT.  Perspective: More preclin., clin., and translational studies are needed to improve the efficacy of combination drug therapy that is an integral part of a comprehensive approach to the management of chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjDPNs-xJvEbVg90H21EOLACvtfcHk0lgLUq2G6S0UHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhslOns7Y%253D&md5=955711ac2946dd44adc0e8b96b6ee423</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.jpain.2010.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpain.2010.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DGold%26aufirst%3DM.%2BS.%26aulast%3DBackonja%26aufirst%3DM.%2BM.%26atitle%3DCombination%2520drug%2520therapy%2520for%2520chronic%2520pain%253A%2520a%2520call%2520for%2520more%2520clinical%2520studies%26jtitle%3DJ.%2520Pain%26date%3D2011%26volume%3D12%26issue%3D2%26spage%3D157%26epage%3D166%26doi%3D10.1016%2Fj.jpain.2010.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edin, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielenberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benny, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaponis, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergilio, J.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietramaggiori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer-Pietramaggiori, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lih, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomer, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwendener, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falck, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthati, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingber, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaipainen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amore, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeldin, D. C.</span></span> <span> </span><span class="NLM_article-title">Epoxyeicosanoids stimulate mutiorgan metastasis and tumor dormancy escape in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>122</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1172/JCI58128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1172%2FJCI58128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=22182838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFCltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2012&pages=178-191&issue=1&author=D.+Panigrahyauthor=M.+L.+Edinauthor=C.+R.+Leeauthor=S.+Huangauthor=D.+R.+Bielenbergauthor=C.+E.+Butterfieldauthor=C.+M.+Barnesauthor=A.+Mammotoauthor=T.+Mammotoauthor=A.+Luriaauthor=O.+Bennyauthor=D.+M.+Chaponisauthor=A.+C.+Dudleyauthor=E.+R.+Greeneauthor=J.-A.+Vergilioauthor=G.+Pietramaggioriauthor=S.+S.+Scherer-Pietramaggioriauthor=S.+M.+Shortauthor=M.+Sethauthor=F.+B.+Lihauthor=K.+B.+Tomerauthor=J.+Yangauthor=R.+A.+Schwendenerauthor=B.+D.+Hammockauthor=J.+R.+Falckauthor=V.+L.+Manthatiauthor=D.+E.+Ingberauthor=A.+Kaipainenauthor=P.+A.+D%E2%80%99Amoreauthor=M.+W.+Kieranauthor=D.+C.+Zeldin&title=Epoxyeicosanoids+stimulate+mutiorgan+metastasis+and+tumor+dormancy+escape+in+mice&doi=10.1172%2FJCI58128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice</span></div><div class="casAuthors">Panigrahy, Dipak; Edin, Matthew L.; Lee, Craig R.; Huang, Sui; Bielenberg, Diane R.; Butterfield, Catherine E.; Barnes, Carmen M.; Mammoto, Akiko; Mammoto, Tadanori; Luria, Ayala; Benny, Ofra; Chaponis, Deviney M.; Dudley, Andrew C.; Greene, Emily R.; Vergilio, Jo-Anne; Pietramaggiori, Giorgio; Scherer-Pietramaggiori, Sandra S.; Short, Sarah M.; Seth, Meetu; Lih, Fred B.; Tomer, Kenneth B.; Yang, Jun; Schwendener, Reto A.; Hammock, Bruce D.; Falck, John R.; Manthati, Vijaya L.; Ingber, Donald E.; Kaipainen, Arja; D'Amore, Patricia A.; Kieran, Mark W.; Zeldin, Darryl C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-191</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Epoxyeicosatrienoic acids (EETs) are small mols. produced by cytochrome P 450 epoxygenases.  They are lipid mediators that act as autocrine or paracrine factors to regulate inflammation and vascular tone.  As a result, drugs that raise EET levels are in clin. trials for the treatment of hypertension and many other diseases.  However, despite their pleiotropic effects on cells, little is known about the role of these epoxyeicosanoids in cancer.  Here, using genetic and pharmacol. manipulation of endogenous EET levels, we demonstrate that EETs are crit. for primary tumor growth and metastasis in a variety of mouse models of cancer.  Remarkably, we found that EETs stimulated extensive multiorgan metastasis and escape from tumor dormancy in several tumor models.  This systemic metastasis was not caused by excessive primary tumor growth but depended on endothelium-derived EETs at the site of metastasis.  Administration of synthetic EETs recapitulated these results, while EET antagonists suppressed tumor growth and metastasis, demonstrating in vivo that pharmacol. modulation of EETs can affect cancer growth.  Furthermore, inhibitors of sol. epoxide hydrolase (sEH), the enzyme that metabolizes EETs, elevated endogenous EET levels and promoted primary tumor growth and metastasis.  Thus, our data indicate a central role for EETs in tumorigenesis, offering a mechanistic link between lipid signaling and cancer and emphasizing the crit. importance of considering possible effects of EET-modulating drugs on cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAwAKcpa92frVg90H21EOLACvtfcHk0lhyUuAopg-bcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFCltQ%253D%253D&md5=856c7a0ae6b8db3e747f8bfcbe11a8f0</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1172%2FJCI58128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI58128%26sid%3Dliteratum%253Aachs%26aulast%3DPanigrahy%26aufirst%3DD.%26aulast%3DEdin%26aufirst%3DM.%2BL.%26aulast%3DLee%26aufirst%3DC.%2BR.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DBielenberg%26aufirst%3DD.%2BR.%26aulast%3DButterfield%26aufirst%3DC.%2BE.%26aulast%3DBarnes%26aufirst%3DC.%2BM.%26aulast%3DMammoto%26aufirst%3DA.%26aulast%3DMammoto%26aufirst%3DT.%26aulast%3DLuria%26aufirst%3DA.%26aulast%3DBenny%26aufirst%3DO.%26aulast%3DChaponis%26aufirst%3DD.%2BM.%26aulast%3DDudley%26aufirst%3DA.%2BC.%26aulast%3DGreene%26aufirst%3DE.%2BR.%26aulast%3DVergilio%26aufirst%3DJ.-A.%26aulast%3DPietramaggiori%26aufirst%3DG.%26aulast%3DScherer-Pietramaggiori%26aufirst%3DS.%2BS.%26aulast%3DShort%26aufirst%3DS.%2BM.%26aulast%3DSeth%26aufirst%3DM.%26aulast%3DLih%26aufirst%3DF.%2BB.%26aulast%3DTomer%26aufirst%3DK.%2BB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSchwendener%26aufirst%3DR.%2BA.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DFalck%26aufirst%3DJ.%2BR.%26aulast%3DManthati%26aufirst%3DV.%2BL.%26aulast%3DIngber%26aufirst%3DD.%2BE.%26aulast%3DKaipainen%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Amore%26aufirst%3DP.%2BA.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DZeldin%26aufirst%3DD.%2BC.%26atitle%3DEpoxyeicosanoids%2520stimulate%2520mutiorgan%2520metastasis%2520and%2520tumor%2520dormancy%2520escape%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D122%26issue%3D1%26spage%3D178%26epage%3D191%26doi%3D10.1172%2FJCI58128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McReynolds, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnych, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blocher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title"><i>In vitro</i> and <i>in vivo</i> metabolism of a potent inhibitor of soluble epoxide hydrolase, 1-(1-propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">464</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.3389%2Ffphar.2019.00464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=31143115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGksLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=464&author=D.+Wanauthor=J.+Yangauthor=C.+B.+McReynoldsauthor=B.+Barnychauthor=K.+M.+Wagnerauthor=C.+Morisseauauthor=S.+H.+Hwangauthor=J.+Sunauthor=R.+Blocherauthor=B.+D.+Hammock&title=In+vitro+and+in+vivo+metabolism+of+a+potent+inhibitor+of+soluble+epoxide+hydrolase%2C+1-%281-propionylpiperidin-4-yl%29-3-%284-%28trifluoromethoxy%29phenyl%29urea&doi=10.3389%2Ffphar.2019.00464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo metabolism of a potent inhibitor of soluble epoxide hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea</span></div><div class="casAuthors">Wan, Debin; Yang, Jun; McReynolds, Cindy B.; Barnych, Bogdan; Wagner, Karen M.; Morisseau, Christophe; Hwang, Sung Hee; Sun, Jia; Blocher, Rene; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">464</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (TPPU) is a potent sol. epoxide hydrolase inhibitor that is used extensively in research for modulating inflammation and protecting against hypertension, neuropathic pain, and neurodegeneration.  Herein, we describe the identification of TPPU metabolites using LC-MS/MS.  Four metabolites of TPPU (M1-M4) were identified from rat urine by a sensitive and specific LC-MS/MS method with double precursor ion scans.  Metabolites M1 and M2 were formed from hydroxylation on a propionyl group of TPPU; M3 was formed by amide hydrolysis of the 1-propionylpiperdinyl group on TPPU; and M4 was formed by further oxidn. of the hydroxylated metabolite M2.  M1, M2, and M3 were generated in liver S9 fractions from all species, and higher amts. of M3 were generated in monkey S9 fractions compared to other species.  In addn., rat and human S9 metab. showed the highest species similarity based on the quantities of each metabolite.  The presence of all four metabolites were confirmed in vivo in rats over 72-h post single oral dose of TPPU.  All four metabolites were potent inhibitors of human sEH but were less potent than the parent TPPU.  In conclusion, TPPU is metabolized via oxidn. and amide hydrolysis without apparent breakdown of the urea.  Our findings increase the confidence in the ability to translate preclin. PK of TPPU in rats to humans and facilitates the potential clin. development of TPPU and other sEH inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVf1dfQAbZ47Vg90H21EOLACvtfcHk0lhyUuAopg-bcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGksLbF&md5=1f98a0e3d72191d2f19994d4d9cdf831</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00464%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMcReynolds%26aufirst%3DC.%2BB.%26aulast%3DBarnych%26aufirst%3DB.%26aulast%3DWagner%26aufirst%3DK.%2BM.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DBlocher%26aufirst%3DR.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520metabolism%2520of%2520a%2520potent%2520inhibitor%2520of%2520soluble%2520epoxide%2520hydrolase%252C%25201-%25281-propionylpiperidin-4-yl%2529-3-%25284-%2528trifluoromethoxy%2529phenyl%2529urea%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D464%26doi%3D10.3389%2Ffphar.2019.00464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schebb, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inceoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Investigation of human exposure to triclocarban after showering and preliminary evaluation of its biological effects</span>. <i>Environ. Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3115</span>, <span class="refDoi"> DOI: 10.1021/es103650m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/es103650m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVSgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2011&pages=3109-3115&issue=7&author=N.+H.+Schebbauthor=B.+Inceogluauthor=K.+C.+Ahnauthor=C.+Morisseauauthor=S.+J.+Geeauthor=B.+D.+Hammock&title=Investigation+of+human+exposure+to+triclocarban+after+showering+and+preliminary+evaluation+of+its+biological+effects&doi=10.1021%2Fes103650m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of Human Exposure to Triclocarban after Showering and Preliminary Evaluation of Its Biological Effects</span></div><div class="casAuthors">Schebb, Nils Helge; Inceoglu, Bora; Ahn, Ki Chang; Morisseau, Christophe; Gee, Shirley J.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Environmental Science & Technology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3109-3115</span>CODEN:
                <span class="NLM_cas:coden">ESTHAG</span>;
        ISSN:<span class="NLM_cas:issn">0013-936X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The antibacterial soap additive triclocarban (TCC) is widely used in personal care products.  TCC has a high environmental persistence.  We developed and validated a sensitive online solid-phase extn.-LC-MS/MS method to rapidly analyze TCC and its major metabolites in urine and other biol. samples to assess human exposure.  We measured human urine concns. 0-72 h after showering with a com. bar soap contg. 0.6% TCC.  The major route of renal elimination was excretion as N-glucuronides.  The absorption was estd. at 0.6% of the 70 ± 15 mg of TCC in the soap used.  The TCC-N-glucuronide urine concn. varied widely among the subjects, and continuous daily use of the soap led to steady state levels of excretion.  In order to assess potential biol. effects arising from this exposure, we screened TCC for the inhibition of human enzymes in vitro.  We demonstrate that TCC is a potent inhibitor of the enzyme sol. epoxide hydrolase (sEH), whereas TCC's major metabolites lack strong inhibitory activity.  Topical administration of TCC at similar levels to rats in a preliminary in vivo study, however, failed to alter plasma biomarkers of sEH activity.  Overall the anal. strategy described here revealed that use of TCC soap causes exposure levels that warrant further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoHOcjmXd8d7Vg90H21EOLACvtfcHk0lisrwM7U1IayA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVSgtbo%253D&md5=802ca941b7bbfd6ed8485f1414109d45</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fes103650m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fes103650m%26sid%3Dliteratum%253Aachs%26aulast%3DSchebb%26aufirst%3DN.%2BH.%26aulast%3DInceoglu%26aufirst%3DB.%26aulast%3DAhn%26aufirst%3DK.%2BC.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DGee%26aufirst%3DS.%2BJ.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DInvestigation%2520of%2520human%2520exposure%2520to%2520triclocarban%2520after%2520showering%2520and%2520preliminary%2520evaluation%2520of%2520its%2520biological%2520effects%26jtitle%3DEnviron.%2520Sci.%2520Technol.%26date%3D2011%26volume%3D45%26issue%3D7%26spage%3D3109%26epage%3D3115%26doi%3D10.1021%2Fes103650m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulciner, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhasin, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielenberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwowarski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishbein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler-Ferran, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staffa, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhatme, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieran, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhasin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukhatme, V. P.</span></span> <span> </span><span class="NLM_article-title">2019. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>129</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2964</span>– <span class="NLM_lpage">2979</span>, <span class="refDoi"> DOI: 10.1172/JCI127282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1172%2FJCI127282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=31205032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BB3M3ntlemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2019&pages=2964-2979&issue=7&author=D.+Panigrahyauthor=A.+Gartungauthor=J.+Yangauthor=H.+Yangauthor=M.+M.+Gilliganauthor=M.+L.+Sulcinerauthor=S.+S.+Bhasinauthor=D.+R.+Bielenbergauthor=J.+Changauthor=B.+A.+Schmidtauthor=J.+Piwowarskiauthor=A.+Fishbeinauthor=D.+Soler-Ferranauthor=M.+A.+Sparksauthor=S.+J.+Staffaauthor=V.+Sukhatmeauthor=B.+D.+Hammockauthor=M.+W.+Kieranauthor=S.+Huangauthor=M.+Bhasinauthor=C.+N.+Serhanauthor=V.+P.+Sukhatme&title=2019.+Preoperative+stimulation+of+resolution+and+inflammation+blockade+eradicates+micrometastases&doi=10.1172%2FJCI127282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases</span></div><div class="casAuthors">Panigrahy Dipak; Gartung Allison; Yang Haixia; Gilligan Molly M; Sulciner Megan L; Chang Jaimie; Piwowarski Julia; Fishbein Anna; Soler-Ferran Dulce; Panigrahy Dipak; Gartung Allison; Yang Haixia; Gilligan Molly M; Sulciner Megan L; Chang Jaimie; Piwowarski Julia; Fishbein Anna; Soler-Ferran Dulce; Panigrahy Dipak; Gartung Allison; Yang Haixia; Gilligan Molly M; Sulciner Megan L; Chang Jaimie; Piwowarski Julia; Fishbein Anna; Soler-Ferran Dulce; Sukhatme Vikas P; Yang Jun; Hammock Bruce D; Bhasin Swati S; Bhasin Manoj; Sukhatme Vikas P; Bielenberg Diane R; Schmidt Birgitta A; Sparks Matthew A; Staffa Steven J; Sukhatme Vidula; Kieran Mark W; Kieran Mark W; Huang Sui; Serhan Charles N; Sukhatme Vikas P</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2964-2979</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer therapy is a double-edged sword, as surgery and chemotherapy can induce an inflammatory/immunosuppressive injury response that promotes dormancy escape and tumor recurrence.  We hypothesized that these events could be altered by early blockade of the inflammatory cascade and/or by accelerating the resolution of inflammation.  Preoperative, but not postoperative, administration of the nonsteroidal antiinflammatory drug ketorolac and/or resolvins, a family of specialized proresolving autacoid mediators, eliminated micrometastases in multiple tumor-resection models, resulting in long-term survival.  Ketorolac unleashed anticancer T cell immunity that was augmented by immune checkpoint blockade, negated by adjuvant chemotherapy, and dependent on inhibition of the COX-1/thromboxane A2 (TXA2) pathway.  Preoperative stimulation of inflammation resolution via resolvins (RvD2, RvD3, and RvD4) inhibited metastases and induced T cell responses.  Ketorolac and resolvins exhibited synergistic antitumor activity and prevented surgery- or chemotherapy-induced dormancy escape.  Thus, simultaneously blocking the ensuing proinflammatory response and activating endogenous resolution programs before surgery may eliminate micrometastases and reduce tumor recurrence.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR94q3w7H_kvENoizSOkG_FfW6udTcc2ebugE5MP571tLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3ntlemtA%253D%253D&md5=f52a90d982a135491f4ba64799b4ca2d</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1172%2FJCI127282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI127282%26sid%3Dliteratum%253Aachs%26aulast%3DPanigrahy%26aufirst%3DD.%26aulast%3DGartung%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DGilligan%26aufirst%3DM.%2BM.%26aulast%3DSulciner%26aufirst%3DM.%2BL.%26aulast%3DBhasin%26aufirst%3DS.%2BS.%26aulast%3DBielenberg%26aufirst%3DD.%2BR.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DB.%2BA.%26aulast%3DPiwowarski%26aufirst%3DJ.%26aulast%3DFishbein%26aufirst%3DA.%26aulast%3DSoler-Ferran%26aufirst%3DD.%26aulast%3DSparks%26aufirst%3DM.%2BA.%26aulast%3DStaffa%26aufirst%3DS.%2BJ.%26aulast%3DSukhatme%26aufirst%3DV.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DKieran%26aufirst%3DM.%2BW.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DBhasin%26aufirst%3DM.%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26aulast%3DSukhatme%26aufirst%3DV.%2BP.%26atitle%3D2019.%2520Preoperative%2520stimulation%2520of%2520resolution%2520and%2520inflammation%2520blockade%2520eradicates%2520micrometastases%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2019%26volume%3D129%26issue%3D7%26spage%3D2964%26epage%3D2979%26doi%3D10.1172%2FJCI127282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panigrahy, D.</span></span> <span> </span><span class="NLM_article-title">Eicosanoids: the overlooked storm in COVID-19?</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1782</span>– <span class="NLM_lpage">1788</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2020.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.ajpath.2020.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32650004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWqtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=1782-1788&issue=9&author=B.+D.+Hammockauthor=W.+Wangauthor=M.+M.+Gilliganauthor=D.+Panigrahy&title=Eicosanoids%3A+the+overlooked+storm+in+COVID-19%3F&doi=10.1016%2Fj.ajpath.2020.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Eicosanoids</span></div><div class="casAuthors">Hammock, Bruce D.; Wang, Weicang; Gilligan, Molly M.; Panigrahy, Dipak</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1782-1788</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Coronavirus infection causes tissue damage, which triggers the endoplasmic reticulum stress response and subsequent eicosanoid and cytokine storms.  Although proinflammatory eicosanoids, including prostaglandins, thromboxanes, and leukotrienes, are crit. mediators of physiol. processes, such as inflammation, fever, allergy, and pain, their roles in COVID-19 are poorly characterized.  Sol. epoxide hydrolase (sEH) inhibitors, which increase endogenous epoxyeicosatrienoic acid levels, exhibit potent anti-inflammatory activity and inhibit various pathol. processes in preclin. disease models, including pulmonary fibrosis, thrombosis, and acute respiratory distress syndrome.  Therefore, targeting eicosanoids and sEH could be a novel therapeutic approach in combating COVID-19.  In this review, we discuss the predominant role of eicosanoids in regulating the inflammatory cascade and propose the potential application of sEH inhibitors in alleviating COVID-19 symptoms.  The host-protective action of omega-3 fatty acid-derived epoxyeicosanoids and specialized proresolving mediators in regulating anti-inflammation and antiviral response is also discussed.  Future studies detg. the eicosanoid profile in COVID-19 patients or preclin. models are pivotal in providing novel insights into coronavirus-host interaction and inflammation modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtsUL0nMdG8bVg90H21EOLACvtfcHk0ljgH9dDzZ_FmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWqtb3O&md5=5fa7d7375eacd897cb1f0a67a9821821</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2020.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2020.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DGilligan%26aufirst%3DM.%2BM.%26aulast%3DPanigrahy%26aufirst%3DD.%26atitle%3DEicosanoids%253A%2520the%2520overlooked%2520storm%2520in%2520COVID-19%253F%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2020%26volume%3D190%26issue%3D9%26spage%3D1782%26epage%3D1788%26doi%3D10.1016%2Fj.ajpath.2020.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Increased expression of soluble epoxide hydrolase in the brain and liver from patients with major psychiatric disorders: A role of brain - liver axis</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2020.03.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1016%2Fj.jad.2020.03.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32339103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnt1Wmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=2020&pages=131-134&author=J.+Zhangauthor=Y.+Tanauthor=L.+Changauthor=B.+D.+Hammockauthor=K.+Hashimoto&title=Increased+expression+of+soluble+epoxide+hydrolase+in+the+brain+and+liver+from+patients+with+major+psychiatric+disorders%3A+A+role+of+brain+-+liver+axis&doi=10.1016%2Fj.jad.2020.03.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of soluble epoxide hydrolase in the brain and liver from patients with major psychiatric disorders: A role of brain - liver axis</span></div><div class="casAuthors">Zhang, Jiancheng; Tan, Yunfei; Chang, Lijia; Hammock, Bruce D.; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">131-134</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Sol. epoxide hydrolase (sEH) in the metab. of polyunsatd. fatty acids might play a role in the pathogenesis of major psychiatric disorders.  Here we studied whether expression of sEH protein is altered in the postmortem samples (parietal cortex, and liver) from patients with major psychiatric disorders.  Protein expression of sEH in the parietal cortex and liver from control, major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ) groups was measured.  Levels of sEH in the parietal cortex and liver from MDD, BD, and SZ groups were significantly higher than the control group.  Interestingly, there was a pos. correlation between sEH protein in the parietal cortex and sEH protein the liver in all groups.  The small no. in each group may limit our interpretation.  This study shows that the increased expression of sEH in the brain and liver might play a role in the pathogenesis of major psychiatric disorders, suggesting a role of brain - liver axis in major psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_UW8wP5n0W7Vg90H21EOLACvtfcHk0liayHWRpY1aWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnt1Wmsrc%253D&md5=11fe220d337c157381d80100cd0d888d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2020.03.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2020.03.070%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DIncreased%2520expression%2520of%2520soluble%2520epoxide%2520hydrolase%2520in%2520the%2520brain%2520and%2520liver%2520from%2520patients%2520with%2520major%2520psychiatric%2520disorders%253A%2520A%2520role%2520of%2520brain%2520-%2520liver%2520axis%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2020%26volume%3D270%26spage%3D131%26epage%3D134%26doi%3D10.1016%2Fj.jad.2020.03.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sole, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis</span>. <i>Vet. Anaesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">440</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1111/vaa.12030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1111%2Fvaa.12030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=23463912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1Cltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=440-448&issue=4&author=A.+Guedesauthor=C.+Morisseauauthor=A.+Soleauthor=J.+H.+Soaresauthor=A.+Uluauthor=H.+Dongauthor=B.+D.+Hammock&title=Use+of+a+soluble+epoxide+hydrolase+inhibitor+as+an+adjunctive+analgesic+in+a+horse+with+laminitis&doi=10.1111%2Fvaa.12030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis</span></div><div class="casAuthors">Guedes, Alonso G. P.; Morisseau, Christophe; Sole, Albert; Soares, Joao H. N.; Ulu, Arzu; Dong, Hua; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Veterinary Anaesthesia and Analgesia</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">440-448</span>CODEN:
                <span class="NLM_cas:coden">VANAFV</span>;
        ISSN:<span class="NLM_cas:issn">1467-2987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">History : A 4-yr old, 500 kg Thoroughbred female horse diagnosed with bilateral forelimb laminitis and cellulitis on the left forelimb became severely painful and refractory to non-steroidal anti-inflammatory therapy (flunixin meglumine on days 1, 2, 3 and 4; and phenylbutazone on days 5, 6 and 7) alone or in combination with gabapentin (days 6 and 7).  Phys. examn. : Pain scores assessed independently by three individuals with a visual analog scale (VAS; 0 = no pain and 10 = worst possible pain) were 8.5 on day 6, and it increased to 9.5 on day 7.  Non-invasive blood pressure monitoring revealed severe hypertension.  Management : As euthanasia was being considered for humane reasons, a decision was made to add an exptl. new drug, trans-4-{4-[3-(4-Trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB), which is a sol. epoxide hydrolase (sEH) inhibitor, to the treatment protocol.  Dose and frequency of administration were selected based on the drug potency against equine sEH to produce plasma concns. within the range of 30 nmol L-1 and 2.5 μmol L-1.  Pain scores decreased sharply and remarkably following t-TUCB administration and blood pressure progressively decreased to physiol. normal values.  Plasma concns. of t-TUCB, measured daily, were within the expected range, whereas phenylbutazone and gabapentin plasma levels were below the suggested efficacious concns.  Follow up : No adverse effects were detected on clin. and lab. examns. during and after t-TUCB administration.  No new episodes of laminitis have been noted up to the time of writing (120 days following treatment).  Conclusions : Inhibition of sEH with t-TUCB was assocd. with a significant improvement in pain scores in one horse with laminitis whose pain was refractory to the std. of care therapy.  No adverse effects were noticed.  Future studies evaluating the analgesic and protective effects of these compds. in painful inflammatory diseases in animals are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLqZiVpk8sCrVg90H21EOLACvtfcHk0lgjxpGjGGrzgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1Cltb4%253D&md5=073191c368edf26b1e2152fafd71334c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fvaa.12030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fvaa.12030%26sid%3Dliteratum%253Aachs%26aulast%3DGuedes%26aufirst%3DA.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DSole%26aufirst%3DA.%26aulast%3DSoares%26aufirst%3DJ.%2BH.%26aulast%3DUlu%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DUse%2520of%2520a%2520soluble%2520epoxide%2520hydrolase%2520inhibitor%2520as%2520an%2520adjunctive%2520analgesic%2520in%2520a%2520horse%2520with%2520laminitis%26jtitle%3DVet.%2520Anaesth.%2520Analg.%26date%3D2013%26volume%3D40%26issue%3D4%26spage%3D440%26epage%3D448%26doi%3D10.1111%2Fvaa.12030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuppo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis</span>. <i>Equine Vet. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">351</span>, <span class="refDoi"> DOI: 10.1111/evj.12603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1111%2Fevj.12603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=27338788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A280%3ADC%252BC2s7jt1Kltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=345-351&issue=3&author=A.+Guedesauthor=L.+Galuppoauthor=D.+Hoodauthor=S.+H.+Hwangauthor=C.+Morisseauauthor=B.+D.+Hammock&title=Soluble+epoxide+hydrolase+activity+and+pharmacologic+inhibition+in+horses+with+chronic+severe+laminitis&doi=10.1111%2Fevj.12603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis</span></div><div class="casAuthors">Guedes A; Guedes A; Galuppo L; Hood D; Hwang S H; Morisseau C; Hammock B D</div><div class="citationInfo"><span class="NLM_cas:title">Equine veterinary journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-351</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The roles of soluble epoxide hydrolase and lipid mediators in inflammatory and neuropathic pain could be relevant in laminitis pain management.  OBJECTIVES:  To determine soluble epoxide hydrolase (sEH) activity in the digital laminae, sEH inhibitor potency in vitro, and efficacy of a sEH inhibitor as an adjunct analgesic therapy in chronic laminitic horses.  STUDY DESIGN:  In vitro experiments and clinical case series.  METHODS:  sEH activity was measured in digital laminae from euthanised healthy and laminitic horses (n = 5-6/group).  Potency of 7 synthetic sEH inhibitors was determined in vitro using equine liver cytosol.  One of them (t-TUCB; 0.1 mg/kg bwt i.v. every 24 h) was selected based on potency and stability, and used as adjunct therapy in 10 horses with severe chronic laminitis (Obel grades 2, one horse; 3-4, nine horses).  Daily assessments of forelimb lifts, pain scores, physiologic and laboratory examinations were performed before (baseline) and during t-TUCB treatment.  Data are presented as mean ± s.d. and 95% confidence intervals (CI).  RESULTS:  sEH activity in the digital laminae from laminitic horses (0.9±0.6 nmol/min/mg; 95% CI 0.16-1.55 nmol/min/mg) was significantly greater (P = 0.01) than in healthy horses (0.17±0.09 nmol/min/mg; CI 0.07-0.26 nmol/min/mg). t-TUCB as an adjunct analgesic up to 10 days (4.3±3 days) in laminitic horses was associated with significant reduction in forelimb lifts (36±22%; 95% CI 9-64%) and in pain scores (18±23%; 95% CI 2-35%) compared with baseline (P = 0.04).  One horse developed gas colic and another corneal vascularisation in a blind eye during treatment.  No other significant changes were observed.  MAIN LIMITATIONS:  Absence of control group and evaluator blinding in case series.  CONCLUSIONS:  sEH activity is significantly higher in the digital laminae of actively laminitic compared with healthy horses, and use of a potent inhibitor of equine sEH as adjunct analgesic therapy appears to decrease signs of pathologic pain in laminitic horses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTUX3G0aXvxAUcLvDNbOD4DfW6udTcc2eY4ZGgPUvuafbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7jt1Kltg%253D%253D&md5=53234423e0ea1c9ce9a1585f310520e5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fevj.12603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fevj.12603%26sid%3Dliteratum%253Aachs%26aulast%3DGuedes%26aufirst%3DA.%26aulast%3DGaluppo%26aufirst%3DL.%26aulast%3DHood%26aufirst%3DD.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DSoluble%2520epoxide%2520hydrolase%2520activity%2520and%2520pharmacologic%2520inhibition%2520in%2520horses%2520with%2520chronic%2520severe%2520laminitis%26jtitle%3DEquine%2520Vet.%2520J.%26date%3D2017%26volume%3D49%26issue%3D3%26spage%3D345%26epage%3D351%26doi%3D10.1111%2Fevj.12603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McReynolds, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morisseau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B. D.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical effects of inhibiting the soluble epoxide hydrolase in canine osteoarthritis</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">533</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.3389%2Ffphar.2019.00533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=31214021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlGqsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=533&author=C.+B.+McReynoldsauthor=S.+H.+Hwangauthor=J.+Yangauthor=D.+Wanauthor=K.+Wagnerauthor=C.+Morisseauauthor=D.+Liauthor=W.+K.+Schmidtauthor=B.+D.+Hammock&title=Pharmaceutical+effects+of+inhibiting+the+soluble+epoxide+hydrolase+in+canine+osteoarthritis&doi=10.3389%2Ffphar.2019.00533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceutical effects of inhibiting the soluble epoxide hydrolase in canine osteoarthritis</span></div><div class="casAuthors">McReynolds, Cindy B.; Hwang, Sung Hee; Yang, Jun; Wan, Debin; Wagner, Karen; Morisseau, Christophe; Li, Dongyang; Schmidt, William K.; Hammock, Bruce D.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">533</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Osteoarthritis (OA) is a degenerative joint disease that causes pain and bone deterioration driven by an increase in prostaglandins (PGs) and inflammatory cytokines.  Current treatments focus on inhibiting prostaglandin prodn., a pro-inflammatory lipid metabolite, with NSAID drugs; however, other lipid signaling targets could provide safer and more effective treatment strategies.  Epoxides of polyunsatd. fatty acids (PUFAs) are anti-inflammatory lipid mediators that are rapidly metabolized by the sol. epoxide hydrolase (sEH) into corresponding vicinal diols.  Interestingly, diol levels are increased in the synovial fluid of humans with OA, warranting further research on the biol. role of this lipid pathway in the progression of OA. sEH inhibitors (sEHI) stabilize these biol. active, anti-inflammatory lipid epoxides, resulting in analgesia in both neuropathic, and inflammatory pain conditions.  Most exptl. studies testing the analgesic effects of sEH inhibitors have used exptl. rodent models, which do not completely represent the complex etiol. of painful diseases.  Here, we tested the efficacy of sEHI in aged dogs with natural arthritis to provide a better representation of the clin. manifestations of pain.  Two sEHI were administered orally, once daily for 5 days to dogs with naturally occurring arthritis to assess efficacy and pharmacokinetics.  Blinded technicians recorded the behavior of the arthritic dogs based on pre-detd. criteria to assess pain and function.  After 5 days, EC1728 significantly reduced pain at a dose of 5 mg/kg compared to vehicle controls.  Pharmacokinetic evaluation showed concns. exceeding the enzyme potency in both plasma and synovial fluid.  In vitro data showed that epoxyeicosatrienoic acid (EETs), epoxide metabolites of arachidonic acid, decreased inflammatory cytokines, IL-6 and TNF-α, and reduced cytotoxicity in canine chondrocytes challenged with IL1β to simulate an arthritic environment.  These results provide the first example of altering lipid epoxides as a therapeutic target for OA potentially acting by protecting chondrocytes from inflammatory induced cytotoxicity.  Considering the challenges and high variability of naturally occurring disease in aged dogs, these data provide initial proof of concept justification that inhibiting the sEH is a non-NSAID, non-opioid, disease altering strategy for treating OA, and warrants further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDYCxYyjkySrVg90H21EOLACvtfcHk0lh6mr33QYV6vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlGqsLg%253D&md5=60f714d2bf594d46934d6146310a922c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00533%26sid%3Dliteratum%253Aachs%26aulast%3DMcReynolds%26aufirst%3DC.%2BB.%26aulast%3DHwang%26aufirst%3DS.%2BH.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DD.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DMorisseau%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DHammock%26aufirst%3DB.%2BD.%26atitle%3DPharmaceutical%2520effects%2520of%2520inhibiting%2520the%2520soluble%2520epoxide%2520hydrolase%2520in%2520canine%2520osteoarthritis%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D533%26doi%3D10.3389%2Ffphar.2019.00533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammock, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, G.</span></span> <span> </span><span class="NLM_article-title">Simultaneous target-mediated drug disposition (TMDD) model for two small-molecule compounds competing for their pharmacological target: soluble epoxide hydrolase</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>374</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">223</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1124/jpet.120.265330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=10.1124%2Fjpet.120.265330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=32238455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFWksbrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2020&pages=223-232&issue=1&author=N.+Wuauthor=B.+Hammockauthor=K.+S.+S.+Leeauthor=G.+An&title=Simultaneous+target-mediated+drug+disposition+%28TMDD%29+model+for+two+small-molecule+compounds+competing+for+their+pharmacological+target%3A+soluble+epoxide+hydrolase&doi=10.1124%2Fjpet.120.265330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous target-mediated drug disposition model for two small-molecule compounds competing for their pharmacological target: soluble epoxide hydrolase</span></div><div class="casAuthors">Wu, Nan; Hammock, Bruce D.; Lee, Kin Sing Stephen; An, Guohua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">223-241</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">1-(1-Propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU) and 1-(4-trifluoro-methoxy-phenyl)-3-(1-cyclopropanecarbonyl-piperidin-4-yl)-urea (TCPU) are potent inhibitors of sol. epoxide hydrolase (sEH) that have much better efficacy in relieving nociceptive response than the Food and Drug Administration-approved drug gabapentin in a rodent model of diabetic neuropathy.  Expts. conducted in sEH knockout mice or with coadministration of a potent sEH displacer demonstrated that the pharmacokinetics of TPPU and TCPU were influenced by the specific binding to their pharmacol. target sEH, a phenomenon known as target-mediated drug disposition (TMDD).  To quant. characterize the complex pharmacokinetics of TPPU and TCPU and gain better understanding on their target occupancy, population pharmacokinetics anal. using a nonlinear mixed-effect modeling approach was performed in the current study.  The final model was a novel simultaneous TMDD interaction model, in which TPPU and TCPU compete for sEH, with TCPU binding to an addnl. unknown target pool with larger capacity that we refer to as a refractory pool.  The total amt. of sEH enzyme in mice was predicted to be 16.2 nmol, which is consistent with the exptl. value of 10 nmol.  The dissoc. rate consts. of TPPU and TCPU were predicted to be 2.24 and 2.67 h-1, resp., which is close to the values obtained from in vitro expts.  Our simulation result predicted that 90% of the sEH will be occupied shortly after a low dose of 0.3 mg/kg TPPU administration, with ≥40% of sEH remaining to be bound with TPPU for at least 7 days.  Further efficacy expts. are warranted to confirm the predicted target occupancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWtWrrihlRU7Vg90H21EOLACvtfcHk0lh6mr33QYV6vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFWksbrN&md5=60f6c9eea253aa78ddd8dcaf820f8b43</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1124%2Fjpet.120.265330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.120.265330%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DN.%26aulast%3DHammock%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DK.%2BS.%2BS.%26aulast%3DAn%26aufirst%3DG.%26atitle%3DSimultaneous%2520target-mediated%2520drug%2520disposition%2520%2528TMDD%2529%2520model%2520for%2520two%2520small-molecule%2520compounds%2520competing%2520for%2520their%2520pharmacological%2520target%253A%2520soluble%2520epoxide%2520hydrolase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2020%26volume%3D374%26issue%3D1%26spage%3D223%26epage%3D232%26doi%3D10.1124%2Fjpet.120.265330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OD0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4OD0','PDB','4OD0'); return false;">PDB: 4OD0</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i47"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01886">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_81262"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01886?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01886</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Data for the full characterization of EC5026; EC5026 drug product preparation; P-gp inhibition and in vitro absorption of EC5026; CYP induction and inhibition by EC5026; Tables S1–S7 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_001.pdf">jm0c01886_si_001.pdf (1.0 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01886/suppl_file/jm0c01886_si_002.csv">jm0c01886_si_002.csv (1.52 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01886&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01886" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01886" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a19cf1fe03ca0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
